

Committee for Risk Assessment
RAC

Annex 1

Background document

to the Opinion proposing harmonised classification
and labelling at EU level of

**perboric acid, sodium salt [1]; perboric acid,
sodium salt, monohydrate [2]; perboric acid
(HBO(O₂)), sodium salt, monohydrate; sodium
peroxoborate [3]; sodium perborate [4]**

**EC Number: 234-390-0 [1]; 234-390-0 [2];
239-172-9 [4]**

**CAS Number: 11138-47-9 [1]; 12040-72-1 [2];
10332-33-9 [3]; 15120-21-5 [4]**

CLH-O-0000007164-77-01/F

The background document is a compilation of information considered relevant by the dossier submitter or by RAC for the proposed classification. It includes the proposal of the dossier submitter and the conclusion of RAC. It is based on the official CLH report submitted to consultation. RAC has not changed the text of this CLH report but inserted text which is specifically marked as 'RAC evaluation'. Only the RAC text reflects the view of RAC.

Adopted

15 September 2022

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID,
SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC
ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3];
SODIUM PERBORATE [4]

CLH report

Proposal for Harmonised Classification and Labelling

**Based on Regulation (EC) No 1272/2008 (CLP Regulation),
Annex VI, Part 2**

International Chemical Identification:

**perboric acid, sodium salt [1]; perboric acid, sodium salt, monohydrate [2];
perboric acid (HBO(O₂)), sodium salt, monohydrate; sodium peroxoborate [3];
sodium perborate [4]**

EC Numbers: 234-390-0 [1]; 234-390-0 [2]; 239-172-9 [4]

CAS Numbers: 11138-47-9 [1]; 12040-72-1 [2]; 10332-33-9 [3]; 15120-21-5 [4]

Index Numbers: 005-019-00-8; 005-019-01-5; 005-017-00-7; 005-017-01-4

Contact details for dossier submitter:

Swedish Chemicals Agency
Esplanaden 3A, P.O Box 2
SE-172 13 Sundbyberg, Sweden
kemi@kemi.se
+46 8 519 41 100

Version number: 2

Date: 2021-09-24

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID,
SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC
ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3];
SODIUM PERBORATE [4]

CONTENTS

0	BACKGROUND INFORMATION	1
1	IDENTITY OF THE SUBSTANCE	2
1.1	NAME AND OTHER IDENTIFIERS OF THE SUBSTANCE	2
1.2	COMPOSITION OF THE SUBSTANCE	4
2	PROPOSED HARMONISED CLASSIFICATION AND LABELLING	5
2.1	PROPOSED HARMONISED CLASSIFICATION AND LABELLING ACCORDING TO THE CLP CRITERIA	5
3	HISTORY OF THE PREVIOUS CLASSIFICATION AND LABELLING	9
4	JUSTIFICATION THAT ACTION IS NEEDED AT COMMUNITY LEVEL	13
5	IDENTIFIED USES	13
6	DATA SOURCES	14
7	PHYSICOCHEMICAL PROPERTIES	14
8	EVALUATION OF PHYSICAL HAZARDS	15
9	TOXICOKINETICS (ABSORPTION, METABOLISM, DISTRIBUTION AND ELIMINATION)	15
9.1	PROPERTIES OF AQUEOUS SOLUTIONS OF PER(OXO)BORATES	15
9.2	TOXICOKINETIC DATA ON PER(OXO)BORATES	16
9.3	TOXICOKINETIC DATA ON BORIC ACID	17
9.4	TOXICOKINETIC DATA ON HYDROGEN PEROXIDE	18
9.5	SHORT SUMMARY AND OVERALL RELEVANCE OF THE PROVIDED TOXICOKINETIC INFORMATION ON THE PROPOSED CLASSIFICATION(S)	19
9.5.1	<i>Justification for read-across</i>	19
10	EVALUATION OF HEALTH HAZARDS	21
10.1	ACUTE TOXICITY - ORAL ROUTE	21
10.1.1	<i>Short summary and overall relevance of the provided information on acute oral toxicity</i>	23
10.1.2	<i>Comparison with the CLP criteria</i>	25
10.1.3	<i>Conclusion on classification and labelling for acute oral toxicity</i>	25
10.2	ACUTE TOXICITY - DERMAL ROUTE	26
10.2.1	<i>Short summary and overall relevance of the provided information on acute dermal toxicity</i>	26
10.2.2	<i>Comparison with the CLP criteria</i>	28
10.2.3	<i>Conclusion on classification and labelling for acute dermal toxicity</i>	28
10.3	ACUTE TOXICITY - INHALATION ROUTE	28
10.3.1	<i>Short summary and overall relevance of the provided information on acute inhalation toxicity</i>	29
10.3.2	<i>Comparison with the CLP criteria</i>	31
10.3.3	<i>Conclusion on classification and labelling for acute inhalation toxicity</i>	32
10.4	SKIN CORROSION/IRRITATION	36
10.5	SERIOUS EYE DAMAGE/EYE IRRITATION	36
10.6	RESPIRATORY SENSITISATION	36
10.7	SKIN SENSITISATION	36
10.8	GERM CELL MUTAGENICITY	36
10.9	CARCINOGENICITY	36
10.10	REPRODUCTIVE TOXICITY	37
10.10.1	<i>Adverse effects on sexual function and fertility</i>	37

**ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID,
SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC
ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3];
SODIUM PERBORATE [4]**

10.10.2	<i>Short summary and overall relevance of the provided information on adverse effects on sexual function and fertility</i>	39
10.10.2.1	Read-across data on PBS-4 from animal studies	39
10.10.2.2	Read-across data on boric acid and borate salts from animal studies.....	41
10.10.2.3	Comparison with data data on hydrogen peroxide from animal studies	41
10.10.2.4	Read-across from human data on boron compounds	43
10.10.3	<i>Comparison with the CLP criteria</i>	49
10.10.4	<i>Adverse effects on development</i>	51
10.10.5	<i>Short summary and overall relevance of the provided information on adverse effects on development</i> 54	
10.10.5.1	Read-across data on PBS-4 from animal studies	54
10.10.5.2	Human data on boron compounds	58
10.10.6	<i>Comparison with the CLP criteria</i>	62
10.10.7	<i>Adverse effects on or via lactation</i>	63
10.10.8	<i>Conclusion on classification and labelling for reproductive toxicity</i>	64
10.11	SPECIFIC TARGET ORGAN TOXICITY-SINGLE EXPOSURE	66
10.12	SPECIFIC TARGET ORGAN TOXICITY-REPEATED EXPOSURE	72
10.13	ASPIRATION HAZARD.....	72
11	EVALUATION OF ENVIRONMENTAL HAZARDS	73
12	EVALUATION OF ADDITIONAL HAZARDS	73
13	ADDITIONAL LABELLING	73
14	REFERENCES	74
15	ANNEXES	80

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID,
SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC
ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3];
SODIUM PERBORATE [4]

0 BACKGROUND INFORMATION

The present proposal for harmonised classification and labelling concerns four existing entries (**Index no. 005-017-00-7, 005-017-01-4, 005-019-00-8 and 005-019-01-5**) in Annex VI of the Regulation (EC) No 1272/2008 (CLP Regulation). The per(oxo)borates covered in this proposal have a harmonised classification as toxic to reproduction for both developmental effects and fertility effects, i.e. Repr. 1B (H360Df). They also have specific concentration limits (SCLs) (see Table 0 below) for adverse effects on sexual function and fertility and for adverse effects on the development of the offspring based on the toxicity of the boron moiety (B) using an approach proposed by BauA (1998).

Later, this approach has been challenged and the Committee for Risk Assessment (RAC) has removed SCLs derived by it for a number of substances (see for example RAC opinions on NMP¹ and on N,N-dimethylacetamide²). Moreover, in 2019, the RAC removed the SCLs calculated based on the old method and concluded on the harmonisation of GCL 0.3% w/w for boric acid and six sodium borates³ that have a harmonised classification as Repr. 1B.

The objective of the present CLH-proposal is to:

- Harmonise the per(oxo)borates included in Annex VI of the CLP Regulation, i.e. by proposing classification in Category 1B for adverse effects on fertility based on read-across of data from boric acid and borate salts that already have a harmonised classification as Repr. 1B; H360FD;
- to revise SCL:s for reproductive toxicity in accordance with the Guidance on the application of CLP criteria (2017)
- Remove of the cut-off values for particle size used for the classification of acute inhalation toxicity, discussed and adopted by the Technical Committee for Classification and Labelling (TC C&L) in 2006 (ECBI/90/06 Rev. 8)
- Revise, update and merge existing entries in terms of names and identifiers of per(oxo)borates, see table 0 below for details.

Table 0. Changes of current Annex VI entries and justifications

	Action	Justification
1.	Remove EC 231-556-4 from Annex VI entries 005-019-00-8 and 005-019-01-5	The EC number 231-556-4 is linked to a not well defined dehydrated sodium perborate (with CAS number 7632-04-4) and is therefore removed from Annex VI entries 005-019-00-8 and 005-019-01-5 / 005-018-00-2 and 005-018-01-X
2.	Split sodium perborate (EC No. 239-172-9; CAS No. 15120-21-5) from sodium peroxometaborate (EC No. 231-556-4; CAS No. 7632-04-4), in Annex VI entries 005-017-00-7 and 005-017-01-4 to create a separate entry for sodium peroxometaborate	Sodium perborate has a dimeric cyclic structure, whereas sodium peroxometaborate is not a well-defined substance, and it differs from the dimeric cyclic structures of the other sodium per(oxo)borates. In addition, sodium perborate and sodium preoxometaborate have different ATE values for acute oral and inhalation toxicity.
3a.	Merge Annex VI entries 005-019-00-8 and 005-019-01-5	The cut-off values for particle size used for the classification of acute inhalation toxicity, discussed and adopted by the Technical Committee for

¹ <https://www.echa.europa.eu/documents/10162/355b86c1-5a0f-f104-0931-8ffdce4e1cbd>

² <https://www.echa.europa.eu/documents/10162/a435d3fc-a05f-b558-3f51-9aff166f2de0>

³ <https://www.echa.europa.eu/documents/10162/584263da-199c-f86f-9b73-422a4f22f1c3>

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID,
SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC
ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3];
SODIUM PERBORATE [4]

		Classification and Labelling (TC C&L) in 2006 (ECBI/90/06 Rev. 8) was not considered justified and hence removed.
3b.	Merge Annex VI entries 005-017-00-7 and 005-017-01-4	The cut-off values for particle size used for the classification of acute inhalation toxicity, discussed and adopted by the Technical Committee for Classification and Labelling (TC C&L) in 2006 (ECBI/90/06 Rev. 8) was not considered justified and hence removed.
4.	Merge the resulting two entries into one entry, i.e. 005-019-00-8 and 005-019-01-5 + 005-017-00-7 and 005-017-01-4	Both entries refer to the same substance, i.e. “PBS-1”.


1 IDENTITY OF THE SUBSTANCE

1.1 Name and other identifiers of the substance

Table 1: Substance identity and information related to molecular and structural formula of sodium perborate (EU RAR, 2007; REACH registration (ECHA dissemination, [2020])⁴)

⁴ <https://www.echa.europa.eu/en/web/guest/registration-dossier/-/registered-dossier/13523>

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID,
SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC
ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3];
SODIUM PERBORATE [4]

Name(s) in the IUPAC nomenclature or other international chemical name(s)	Perboric acid, sodium salt [1] Perboric acid, sodium salt, monohydrate [2] Perboric acid (HBO(O₂)), sodium salt, monohydrate [3] Perboric acid (H ₃ BO ₂ (O ₂)), monosodium salt [4]
Other names (usual name, trade name, abbreviation)	PBS-1, PBSM [3] and [4] (EU RAR, 2007)
ISO common name (if available and appropriate)	-
EC number (if available and appropriate)	234-390-0 [1] & 234-390-0 [2] 239-172-9 [4]
EC name (if available and appropriate)	Perboric acid, sodium salt [1] and [2] Sodium perborate [4]
CAS number (if available)	11138-47-9 [1] 12040-72-1 [2] 10332-33-9 [3] 15120-21-5 [4]
Other identity code (if available)	-
Molecular formula	B ₂ H ₄ O ₈ Na ₂ *
Structural formula	
SMILES notation (if available)	-
Molecular weight or molecular weight range	199.6 g/mol [#]
Information on optical activity and typical ratio of (stereo) isomers (if applicable and appropriate)	-
Description of the manufacturing process and identity of the source (for UVCB substances only)	-
Degree of purity (%) (if relevant for the entry in Annex VI)	-

& Collective EC No. and CAS No. for the mono- and tetrahydrate of sodium perborate (EU RAR, 2007).

* Correct formula according to X-ray diffraction studies which reflect the dimeric structure of the substance (illustrated for [3] and [4] in EU RAR, 2007).

Molecular weight corresponding to the dimeric structure of this sodium per(oxo)borate.

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID,
SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC
ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3];
SODIUM PERBORATE [4]

1.2 Composition of the substance

Table 2: Constituents (non-confidential information)

Constituent (Name and numerical identifier)	Concentration range (% w/w minimum and maximum in multi- constituent substances)	Current CLH in Annex VI Table 3.1 (CLP)	Current self- classification and labelling (CLP)
Perboric acid, sodium salt EC No. 234-390-0 CAS No. 11138-47-9 Annex VI Index No. 005-019-00-8; 005-019-01-5	≥ 90 - ≤ 100	Ox. Sol. 3; H272 Repr. 1B; H360Df Acute Tox. 3*; H331 Acute Tox. 4*; H302 STOT SE 3; H335 Eye Dam. 1; H318 Repr. 1B; H360Df: C ≥ 9 % Repr. 1B; H360D: 6,5 % ≤ C < 9 % Eye Dam. 1; H318: C ≥ 22 % Eye Irrit. 2; H319: 14 % ≤ C < 22 %	Ox. Sol. 2; H272 Acute Tox. 4; H332

Table 3: Impurities (non-confidential information) if relevant for the classification of the substance

Impurity (Name and numerical identifier)	Concentration range (% w/w minimum and maximum)	Current CLH in Annex VI Table 3.1 (CLP)	Current self- classification and labelling (CLP)	The impurity contributes to the classification and labelling
Disodium tetraborate, anhydrous EC No. 215-540-4 CAS No. 1330-43-4 Annex VI Index No. 005-011-00-4	n.g.*	Repr. 1B; H360FD	Acute Tox. 4; H302 Acute Tox. 4; H312 Acute Tox. 1; H330 Eye Dam 1; H318 Eye Irrit. 2; H319 Repr. 1A; H360 Repr. 1B; H360Df Repr. 2; H360 Aquatic Chronic 3; H412	No

*n.g. – not given

Table 4: Additives (non-confidential information) if relevant for the classification of the substance

Additive (Name and numerical identifier)	Function	Concentration range (% w/w minimum and maximum)	Current CLH in Annex VI Table 3.1 (CLP)	Current self- classification and labelling (CLP)	The additive contributes to the classification and labelling
No data available					

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID, SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3]; SODIUM PERBORATE [4]

2 PROPOSED HARMONISED CLASSIFICATION AND LABELLING

2.1 Proposed harmonised classification and labelling according to the CLP criteria

Table 5: Proposed harmonised classification according to the CLP criteria

	Index No	International Chemical Identification	EC No.	CAS No.	Classification		Labelling			Specific Conc. Limits, M-factors	Notes
					Hazard Class and Category Code(s)	Hazard statement Code(s)	Pictogram, Signal Word Code(s)	Hazard statement Code(s)	Suppl. Hazard statement Code(s)		
Current Annex VI entries	005-019-00-8	perboric acid, sodium salt [1]; perboric acid, sodium salt, monohydrate [2]; perboric acid (HBO(O ₂)), sodium salt, monohydrate [3]; sodium peroxoborate; [containing < 0,1 % (w/w) of particles with an aerodynamic diameter of below 50 µm]	234-390-0 [1] 234-390-0 [2] 231-556-4 [3]	11138-47-9 [1] 12040-72-1 [2] 10332-33-9 [3]	Ox. Sol. 3 Repr. 1B Acute Tox. 4 * STOT SE 3 Eye Dam. 1	H272 H360Df H302 H335 H318	GHS03 GHS05 GHS08 GHS07 Dgr	H272 H360Df H302 H335 H318		Repr. 1B; H360D: 6,5 % ≤ C < 9 % Repr. 1B; H360Df: C ≥ 9 % Eye Dam. 1; H318: C ≥ 22 % Eye Irrit. 2; H319: 14 % ≤ C < 22 %	
	005-019-01-5	perboric acid, sodium salt [1]; perboric acid, sodium salt, monohydrate [2]; perboric acid	234-390-0 [1] 234-390-0 [2] 231-556-4 [3]	11138-47-9 [1] 12040-72-1 [2] 10332-33-9 [3]	Ox. Sol. 3 Repr. 1B Acute Tox. 3 * Acute Tox. 4 * STOT SE 3 Eye Dam. 1	H272 H360Df H331 H302 H335 H318	GHS03 GHS06 GHS05 GHS08 Dgr	H272 H360Df H331 H302 H335 H318		Repr. 1B; H360D: 6,5 % ≤ C < 9 % Repr. 1B; H360Df: C ≥ 9 % Eye Dam. 1; H318: C ≥ 22 %	

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID, SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3]; SODIUM PERBORATE [4]

		(HBO(O ₂)), sodium salt, monohydrate [3]; sodium peroxoborate; [containing = 0,1 % (w/w) of particles with an aerodynamic diameter of below 50 µm]								Eye Irrit. 2; H319: 14 % ≤ C < 22 %	
	005-017-00-7	sodium perborate [1]; sodium peroxometaborate [2]; sodium peroxoborate; [containing < 0,1 % (w/w) of particles with an aerodynamic diameter of below 50 µm]	239-172-9 [1] 231-556-4 [2]	15120-21-5 [1] 7632-04-4 [2]	Ox. Sol. 2 Repr. 1B Acute Tox. 4 * STOT SE 3 Eye Dam. 1	H272 H360Df H302 H335 H318	GHS03 GHS05 GHS08 GHS07 Dgr	H272 H360Df H302 H335 H318		Repr. 1B; H360Df: C ≥ 9 % Repr. 1B; H360D: 6,5 % ≤ C < 9 % Eye Dam. 1; H318: C ≥ 22 % Eye Irrit. 2; H319: 14 % ≤ C < 22 %	
	005-017-01-4	sodium perborate [1]; sodium peroxometaborate [2]; sodium peroxoborate; [containing ≥ 0,1 % (w/w) of particles with an aerodynamic diameter of below 50 µm]	239-172-9 [1] 231-556-4 [2]	15120-21-5 [1] 7632-04-4 [2]	Ox. Sol. 2 Repr. 1B Acute Tox. 3 * Acute Tox. 4 * STOT SE3 Eye Dam. 1	H272 H360Df H331 H302 H335 H318	GHS03 GHS06 GHS05 GHS08 Dgr	H272 H360Df H331 H302 H335 H318		Repr. 1B; H360Df: C ≥ 9 % Repr. 1B; H360D: 6,5 % ≤ C < 9 % Eye Dam. 1; H318: C ≥ 22 % Eye Irrit. 2; H319: 14 % ≤ C < 22 %	
Dossier submitter's proposal	Merge: 005-019-00-8 005-019-01-5 005-017-00-7 005-017-01-4	Retain: perboric acid, sodium salt [1] perboric acid, sodium salt, monohydrate [2] perboric acid	Retain: 234-390-0 [1] 234-390-0 [2] 239-172-9 [4] Remove: 231-556-4 [3]	Retain: 11138-47-9 [1] 12040-72-1 [2] 10332-33-9 [3] 15120-21-5 [4]	Modify: Repr. 1B Acute Tox. 3 Acute Tox. 4	Modify: H360FD H331 H302	Retain: GHS06 GHS08 Dgr	Modify: H360FD H331 H302		Remove: Repr. 1B; H360D: 6,5 % ≤ C < 9 % Repr. 1B; H360Df: C ≥ 9 % Add:	

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID, SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC ACID (HBO(O2)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3]; SODIUM PERBORATE [4]

		(HBO(O2)), sodium salt, monohydrate [3] sodium perborate [4] Remove: [containing < 0,1 % (w/w) of particles with an aerodynamic diameter of below 50 µm] [containing = 0,1 % (w/w) of particles with an aerodynamic diameter of below 50 µm]								Inhalation: ATE = 0.75 mg/L Oral: ATE = 890 mg/kg bw/day	
Resulting Annex VI entry if agreed by RAC and COM	TBD	perboric acid, sodium salt [1] perboric acid, sodium salt, monohydrate [2] perboric acid (HBO(O2)), sodium salt, monohydrate; sodium peroxoborate [3] sodium perborate [4]	234-390-0 [1] 234-390-0 [2] 239-172-9 [4]	11138-47-9 [1] 12040-72-1 [2] 10332-33-9 [3] 15120-21-5 [4]	Ox. Sol. 3 Repr. 1B Acute Tox. 3 Acute Tox. 4 STOT SE 3 Eye Dam. 1	H272 H360FD H331 H302 H335 H318	GHS03 GHS06 GHS05 GHS08 Dgr	H272 H360FD H331 H302 H335 H318		Inhalation: ATE = 0.75 mg/L Oral: ATE = 890 mg/kg bw/day Eye Dam. 1; H318: C ≥ 22 % Eye Irrit. 2; H319: 14 % ≤ C < 22 % §	#

§The generic concentration limit of 0.3% will apply for toxicity to reproduction.

#The inclusion of a specific note to apply additivity for boron compounds that exert their reproductive toxicity through the same toxic entity (boric acid/borate ion) should be considered: “Classification of mixtures is necessary if the sum of boron compounds that are classified as Repr. 1A/1B in the mixture as placed on the market is ≥ 0.3 %”.

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID,
SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC
ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3];
SODIUM PERBORATE [4]

Table 6: Reason for not proposing harmonised classification and status under public consultation

Hazard class	Reason for no classification	Within the scope of public consultation
Explosives	Hazard class not assessed in this dossier	No
Flammable gases (including chemically unstable gases)	Hazard class not assessed in this dossier	No
Oxidising gases	Hazard class not assessed in this dossier	No
Gases under pressure	Hazard class not assessed in this dossier	No
Flammable liquids	Hazard class not assessed in this dossier	No
Flammable solids	Hazard class not assessed in this dossier	No
Self-reactive substances	Hazard class not assessed in this dossier	No
Pyrophoric liquids	Hazard class not assessed in this dossier	No
Pyrophoric solids	Hazard class not assessed in this dossier	No
Self-heating substances	Hazard class not assessed in this dossier	No
Substances which in contact with water emit flammable gases	Hazard class not assessed in this dossier	No
Oxidising liquids	Hazard class not assessed in this dossier	No
Oxidising solids	Hazard class not assessed in this dossier	No
Organic peroxides	Hazard class not assessed in this dossier	No
Corrosive to metals	Hazard class not assessed in this dossier	No
Acute toxicity via oral route	Harmonised classification proposed	Yes
Acute toxicity via dermal route	Data conclusive but not sufficient for classification	Yes
Acute toxicity via inhalation route	Harmonised classification proposed	Yes
Skin corrosion/irritation	Hazard class not assessed in this dossier	No
Serious eye damage/eye irritation	Hazard class not assessed in this dossier	No
Respiratory sensitisation	Hazard class not assessed in this dossier	No
Skin sensitisation	Hazard class not assessed in this dossier	No
Germ cell mutagenicity	Hazard class not assessed in this dossier	No
Carcinogenicity	Hazard class not assessed in this dossier	No
Reproductive toxicity	Harmonised classification proposed	Yes
Specific target organ toxicity-single exposure	Hazard class not assessed in this dossier	No
Specific target organ toxicity-repeated exposure	Hazard class not assessed in this dossier	No
Aspiration hazard	Hazard class not assessed in this dossier	No
Hazardous to the aquatic environment	Hazard class not assessed in this dossier	No

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID,
SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC
ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3];
SODIUM PERBORATE [4]

Hazard class	Reason for no classification	Within the scope of public consultation
Hazardous to the ozone layer	Hazard class not assessed in this dossier	No

3 HISTORY OF THE PREVIOUS CLASSIFICATION AND LABELLING

Harmonised classification for toxicity to reproduction

As detailed in the minutes of the TC C&L meeting, the classification according to the Dangerous Substances Directive (Dir. 67/548/EEC) for toxicity to reproduction for the sodium per(oxo)borates covered by the current CLH-proposal as Repr. Cat. 2; R61 and Repr. Cat. 3; R62 (equivalent to Repr. 1B; H360D and Repr. 2; H361f; CLP Regulation, EC No 1272/2008) was based on the recommendation of the Specialised Experts from 2004 (ECBI/60/05 Rev. 3).

A summary of the discussion from the Specialised Experts (SE) meeting is enclosed in the EU RAR (2007). The only study available for the assessment of effects on fertility was a 28-day repeated dose toxicity study with sodium per(oxo)borate tetrahydrate (PBS-4) (OECD TG 407; limit test). The Specialised Experts concluded that the results of this study are very limited and insufficient for the purpose of classification and evidence that boric acid is a degradation product of per(oxo)borates was considered. It was also pointed out that *“boric acid as a metabolite of sodium perborate will be systemically available and thus, the same effects are expected and the data on boric acid and borates have to be taken into consideration for read-across. Based only on read-across, the classification for boric acid/borates should also apply for sodium perborate”*. In 2005, the recommended classification for boric acid was as Repr. Cat. 2; R60 (equivalent to Repr. 1B; H360F). It is not clear to the dossier submitter why the resulting classification of per(oxo)borates was Repr. 2; H361f and not category 1B similar to boric acid based on read-across.

A prenatal developmental toxicity study (PNDT) performed according to OECD TG 414 with PBS-4 was available for evaluation. Based on the results of this study, the Specialised Experts concluded that PBS-4 is a developmental toxicant due to the release of boron, as the malformations seen at the highest dose level are similar to those induced by boric acid and borates. Regarding the observed differences in malformations, it was further discussed that these could be explained by different kinetics due to different routes of administration (feed, oral gavage). Thus, it was concluded that *“the developmental effects of PBS-4 seen in one rat study, which are not a consequence of general systemic toxicity, warrant classification as Repr. Cat. 2; R62”*.

The issue of concentration limits for reproductive toxicity was discussed at a later TC C&L meeting (ECBI/90/06 Rev. 8). Different specific concentration limits (SCLs) for fertility and developmental toxicity were set using the approach proposed by BAuA (1998) where the molecular weights of the different per(oxo)borates were used to calculate the contribution of their boron contents to the overall hazard.

The existing SCLs for effects on development for the per(oxo)borates included in Annex VI of CLP were derived based on the limit dose of 1000 mg/kg bw/day as described in the OECD TG 414 performed with PBS-4 and using the NOAEL for embryotoxic/teratogenic effects of 100 mg PBS-4/kg bw/day (based on increased post-implantation loss, increased number of resorptions, decreased number of live foetuses, decreased foetal weight). The corresponding SCL for sodium per(oxo)borate monohydrate (PBS-1) was calculated from the SCL of PBS-4, using the molecular weight of PBS-1 and PBS-4. The SCLs for fertility effects were derived based on the SCLs for boric acid that were also set using the old approach proposed by BAuA and corrected for the differences in boron content (ECBI/38/03 Add.17).

Already in 2006, some MS signalled their concern about using the approach proposed by BauA (1998) to derive SCLs as it would imply an unreasonably high degree of scientific certainty and that it did not adequately distinguish between different categories of reproductive effects (ECBI/90/06 Rev. 8).

Harmonised classification for acute inhalation toxicity

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID,
SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC
ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3];
SODIUM PERBORATE [4]

In 2006, the TC C&L agreed upon the introduction of a “thoracic fraction” concept in the case of sodium per(oxo)borates, based on earlier discussions at the level of the Aerosols Working Group. Thus, split entries with a 50 µm particle diameter size cut-off point were proposed. This led to classifying only the thoracic fraction with T; R23 (Acute Tox. 3; H331) for PBS-1 and with Xn; R20 (Acute Tox. 4; H332) for PBS-4, while the non-thoracic fractions were not classified for inhalation toxicity (ECBI/90/06 Rev. 8).

In earlier discussions on this topic (TC C&L and Aerosol Working Group), it was highlighted that the thoracic fraction is a conservative approach that leads to differences in classification for inhalation of individual substances, and that deposition also occurs in the upper airways and can contribute to the lethality of a substance. Another issue that was brought forward was the difficulty in requesting various tests with different particle sizes to investigate if a substance could cause irritancy (bigger particles) or systemic effects (smaller particles) in different parts of the respiratory system (ECBI/55/05).

The “thoracic fraction” concept is an old approach no longer in practice. As it is difficult to predict the most responsive region of the respiratory tract or the most harmful particle size, the revised OECD TGs for acute inhalation toxicity recommend that the particle size distribution of dusts and aerosols should be such that exposure of all regions of the tract can be achieved. An aerosol with a mass median aerodynamic diameter (MMAD) ≤4 µm and a geometric standard deviation (GSD) in the range of 1.0 to 3.0 is recommended to ensure that comprehensive respiratory tract exposure occurs (OECD TG 403; OECD TG 433).

Harmonised classification for oxidising solids

The hazard class for oxidising solids (Ox. Sol.) is not evaluated in the current proposal for harmonised classification and is not subject to public consultation of this proposal. However, there is a need to clarify the reason for the resulting Ox. Sol 3 classification when merging Annex VI entries 005-019-00-8, 005-019-01-5, 005-017-00-7 and 005-017-01-4 to cover the same substance (PBS-1) in only one entry.

The Ox. Sol harmonised classification in Annex VI entries 005-019-00-8, 005-019-01-5, 005-017-00-7 and 005-017-01-4 emanates from the old directive and the risk phrase O;R8 which is not possible to directly translate into CLP Ox. Sol classification and different categories.

Sodium perborate (CAS 15120-21-5) is in the current Annex VI entries 005-017-00-7 and 005-017-01-4 included with sodium peroxometaborate (EC 231-556-4, CAS 7632-04-4) that has Ox. Sol. Category 2 classification. In contrast, Annex VI entries 005-019-00-8 and 005-019-01-5 (perboric acid, sodium salt [1]; perboric acid, sodium salt, monohydrate [2]; perboric acid (HBO(O₂)), sodium salt, monohydrate; sodium peroxoborate [3]) have Ox. Sol. Category 3 classification. Since sodium perborate and perboric acid, sodium salt [1]; perboric acid, sodium salt, monohydrate [2]; perboric acid (HBO(O₂)), sodium salt, monohydrate; sodium peroxoborate [3] all covers the same substance (PBS-1) this difference appears not to be logical and the only explanation is that sodium peroxometaborate (CAS 7632-04-4), included with sodium perborate (CAS 15120-21-5) in the current Annex VI entries 005-017-00-7 and 005-017-01-4, is the reason for the category 2 classification. Sodium peroxometaborate (CAS 7632-04-4) is a substance with higher H₂O₂ content (also reflected in its Acute Tox. classification) and an Ox. Sol. classification in category 2 therefore appears justified. In contrast, sodium perborate (CAS 15120-21-5) and perboric acid, sodium salt [1]; perboric acid, sodium salt, monohydrate [2]; perboric acid (HBO(O₂)), sodium salt, monohydrate; sodium peroxoborate [3] covering PBS-1 should have the same Ox. Sol. classification in category 3. Sodium peroxometaborate (CAS 7632-04-4) is in the current CLH-proposal suggested to be removed from entries 005-017-00-7 and 005-017-01-4, and included in a separate entry. Consequently, a separate CLH-report for sodium peroxometaborate is submitted in parallel with this one.

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID,
SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC
ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3];
SODIUM PERBORATE [4]

RAC general comment

The proposal submitted by Sweden concerns per(oxo)borates with four existing entries in Annex VI to the Regulation (EC) No 1272/2008 (CLP Regulation). Perboric acid, sodium salt, monohydrate (PBS-1) has currently harmonised classification as

- toxic to reproduction for both developmental and fertility effects, i.e. Repr. 1B; H360Df,
- Ox. Sol 2 or 3 (H272),
- STOT SE3 (H335),
- Eye Dam 1 (H319; C ≥ H318; 22 %) / Eye Irri. 2 (H319; 14 % ≤ C < 22 %), and
- acutely toxic via inhalation and oral route, i.e. Acute Tox. 3*; H331 (two of the four entries), and Acute Tox. 4*, H302.

Currently, the entries also have specific concentration limits (SCLs), which were set at that time based on the developmental effects of the boron moiety (B) using an approach proposed by the German Federal Institute for Occupational Safety and Health (BAuA, 1998).

Table 1: Overview of entry numbers, substances and notes as presented in the proposal by Sweden

Current Annex VI entries	International Chemical identification	Specifications	Proposal for one Annex VI entry
005-019-00-8	1. perboric acid, sodium salt ^a 2. perboric acid, sodium salt, monohydrate ^a 3. perboric acid (HBO(O ₂)), sodium salt, monohydrate ^b	[containing < 0.1 % (w/w) of particles with an aerodynamic diameter of below 50 µm]	1. perboric acid, sodium salt 2. perboric acid, sodium salt, monohydrate 3. perboric acid (HBO(O ₂)), sodium salt, monohydrate 4. sodium perborate *
005-019-01-5	1. perboric acid, sodium salt ^a 2. perboric acid, sodium salt, monohydrate ^a 3. perboric acid (HBO(O ₂)), sodium salt, monohydrate ^b	[containing = 0.1 % (w/w) of particles with an aerodynamic diameter of below 50 µm]	
005-017-00-7	4. sodium perborate 5. sodium peroxometaborate ^b	[containing < 0.1 % (w/w) of particles with an aerodynamic diameter of below 50 µm]	
005-017-01-4	4. sodium perborate 5. sodium peroxometaborate ^b	[containing ≥ 0.1 % (w/w) of particles with an aerodynamic diameter of below 50 µm]	

^a Substance number 1 and 2 have similar EC numbers, but a different CAS number

^b Substance number 3 and 5 have similar EC numbers, but a different CAS number

* For substance number 5 (sodium peroxometaborate), a separate CLH report is submitted.

The changes proposed in the current proposal by the DS are:

- The EC number 231-556-4 is linked to a not well-defined dehydrated sodium perborate (with CAS number 7632-04-4) and is therefore removed.
- Create a separate entry for sodium peroxometaborate, because sodium perborate has a dimeric cyclic structure. On the other hand, sodium peroxometaborate is not a

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID, SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3]; SODIUM PERBORATE [4]

well-defined substance, and it differs from the dimeric cyclic structures of the other sodium per(oxo)borates. In addition, sodium perborate and sodium peroxometaborate have different acute toxicity estimates (ATEs) for acute oral and inhalation toxicity.

- The cut-off values for particle size are not considered justified and hence should be removed, so merging entries 005-019-00-8 and 005-019-01-5.

The harmonised classification on oxidising solids (Ox. Sol.) is not evaluated in the proposal. However, the Dossier Submitter (DS) argues the existing Ox. Sol. 2 classification is due to the inclusion of sodium perborate (CAS 15120-21-5) in the current Annex VI entries 005-017-00-7 and 005-017-01-4. In this proposal Annex VI entries of perboric acid, sodium salt; perboric acid, sodium salt, monohydrate; perboric acid (HBO(O₂)), sodium salt, monohydrate and sodium perborate are all covering PBS-1 and merged in one entry with a corresponding harmonised classification of Ox. Sol. 3.

RAC has not assessed this physical hazard and it has not been open for consultation. Open for discussion are the proposals for harmonised classification on acute toxicity and reproductive toxicity.

Previous RAC evaluations of boric acid and other borates

RAC assessed proposals for harmonised classification of boric acid (CAS 10043-35-3) and several related substances in the past. Harmonised classification for Repr. 1B; H360FD of boric acid and several related compounds was adopted into Annex VI of the CLP regulation during the 1st ATP. In 2014, RAC adopted proposals for harmonised classification for disodium octaborate anhydrate⁵ and disodium octaborate tetrahydrate,⁶ based on read-across from other borates such as boric acid (Repr. 1B; H360FD). In the same year a proposal for modification of harmonised classification of boric acid from Repr. 1B; H360FD to Repr. 2; H361d was not adopted by RAC.⁷ In 2019, RAC adopted a proposal to remove SCLs for effects on sexual function and fertility and development (Repr. 1B; H360FD) for boric acid, diboron trioxide, tetraboron disodium heptaoxide hydrate, disodium tetraborate anhydrous, orthoboric acid sodium salt, disodium tetraborate decahydrate and disodium tetraborate pentahydrate.⁸ For all substances, using the new guidance, a GCL of 0.3 % w/w was applied.

PBS-1

In aqueous conditions, sodium per(oxo)borates dissociates into boric acid and hydrogen peroxide. Boric acid is the main product at physiological and acidic pH and hydrogen peroxide decomposes into water and oxygen *in vivo*. Based on available toxicokinetic data for per(oxo)borates and boric acid, absorption is almost 100 % upon oral or inhalation exposure. Minimal absorption is reported upon dermal exposure.

⁵ <https://echa.europa.eu/documents/10162/7d740d8c-5cd5-872b-5da2-e549983a9ff9>

⁶ <https://echa.europa.eu/documents/10162/658b802c-1ca3-663e-4bd4-437369d715de>

⁷ <https://echa.europa.eu/documents/10162/4db9bc68-844e-c557-8914-ab491743d471>

⁸ <https://echa.europa.eu/documents/10162/584263da-199c-f86f-9b73-422a4f22f1c3>

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID, SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3]; SODIUM PERBORATE [4]

PBS-1 is used as oxidising and bleaching agent in detergents and cleaning products. Only EC 234-390-0 (perboric acid, sodium salt) is registered under REACH (10 000- 100 000 tonnes per annum). This substance is used by consumers, professional workers (widespread uses), in formulation and re-packing in manufacturing.

Read-across

Read-across to sodium perborate tetrahydrate (PBS-4; CAS 10486-00-7), boric acid and other borates is supported based on hydrolytic and toxicokinetic behavior. Therefore, read-across based on boron content can be applied in line with the previous assessments by RAC for reproductive toxicity.

For acute toxicity, sodium per(oxo)borates show a higher acute toxicity compared to borates, which is caused by the formation of hydrogen peroxide and thus read-across for acute toxicity to borates does not apply. In any case, PBS-1 has been tested in acute oral and dermal studies (see below).

Comments received during consultation

A MSCA noted several inconsistencies in Table 5 in the CLH-dossier. In the responses to the comments (RCOM) the DS made a correction. The corrected version is included in this opinion.

4 JUSTIFICATION THAT ACTION IS NEEDED AT COMMUNITY LEVEL

- Change in existing entry due to changes in the criteria for acute toxicity
- The justification for modification of the harmonised classification Acute Tox. 3* H331 and Acute Tox. 4* H302 is that these are minimum classifications, and it is concluded that removal of the asterisks is warranted. Moreover, ATE:s have been set.
- Change in existing entry due to new data and new evaluation of existing data for reproductive toxicity.

Since the per(oxo)borates covered by the present proposal was subject to harmonised classification, new recommendations on how to derive concentration limits for reproductive toxicity have been agreed upon (CLP Guidance, 2017). Revising the SCLs for the per(oxo)borates included in Annex VI of the CLP Regulation will ensure that all per(oxo)borates are assessed similarly and according to the new guidance. It will result in a level playing field in between the per(oxo)borates as well as in relation to other classified substances. Moreover, it is also considered appropriate to read-across data from boric acid to revise the current classification for adverse effects on sexual function and fertility.

5 IDENTIFIED USES

Sodium per(oxo)borates mono- and tetrahydrates are used as oxidising and bleaching agents mainly in detergents (household detergents as well as detergents for institutional uses) and in cleaning products (stain removers in form of bleach booster tablets and dishwashing tablets). Per(oxo)borates are used in both regular and compact heavy-duty laundry powders.

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID, SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3]; SODIUM PERBORATE [4]

Per(oxo)borates were also used in cosmetic products such as hair dyes, teeth whitening or bleaching products and nail hardening products. Due to their harmonised classification as Repr. 1B, per(oxo)borates are restricted in cosmetic products according to the EU Cosmetics Regulation (1223/2009/EC) since December 2010.

6 DATA SOURCES

Experimental data and information included in this CLH-report mainly come from the publicly disseminated REACH Registration dossier of “perboric acid, sodium salt” EC No. 234-390-0 (CAS No. 11138-47-9). These numerical identifiers have been used as “collective” identifiers in order to describe sodium per(oxo)borates having a dimeric cyclic structure in various hydrated forms. Assessment reports such as EU RAR (2007; 2003), Annex XV identification proposals (2014), SCCS Opinion (2010), ATSDR (2010) and RAC Opinions (2014; 2019;2020) on sodium per(oxo)borates, boron compounds and hydrogen peroxide as well as relevant studies available in the scientific literature have also been included.


7 PHYSICOCHEMICAL PROPERTIES

Only EC No. 234-390-0 (CAS No. 11138-47-9) is registered under REACH. The information on physicochemical properties on sodium per(oxo)borates presented below also comes from the EU RAR (2007), Annex XV report on sodium perborate (2014) and scientific literature.

Sodium per(oxo)borates are white, odourless, crystalline, water-soluble powders. Their molecular crystalline structure consists of dimeric [(HO)₂(BOO)]⁻ units which form symmetric cyclic hexagonal anions with two peroxy bridges each. This dimeric structure was confirmed by X-ray crystallography, infra-red and Raman spectroscopies (Carrondo et al. 1978 and Flanagan et al. 1979, as cited by Grootveld et al. 2020).

Therefore, owing to the dimeric structure of the peroxoboron anions, it means that in reality there are only two types of sodium per(oxo)borates:

- The dimeric cyclic structure with two peroxy bridges, which has been historically referred to as “*sodium perborate monohydrate*” (empirical formula NaBO₃·H₂O). These old name and formula do not take into account the dimeric cyclic nature of the substance. The same structure may also have been wrongly represented by the empirical formula NaBO₂·H₂O₂. In reality, there would not be any crystalline water in “sodium perborate monohydrate”.



- Hydrates of the dimeric structure also exist. What was historically known as “*sodium perborate tetrahydrate*” (empirical formula NaBO₃·4H₂O) is in fact the hexahydrate of the sodium salt with the dimeric structure shown above.
- The “dehydrated” form which is obtained from the “*sodium perborate monohydrate*” (which is not a true hydrated form as explained above) with the empirical formula NaBO₃; it is supposed to consist of sodium borate and boron oxygen radical and is also known as “oxoborate” or “dexol”. This structure is presented in the literature as an anhydrous perboric acid species, which can be produced by the “dehydration” of the dimeric salts commonly referred to as the sodium perborate

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID,
SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC
ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3];
SODIUM PERBORATE [4]

monohydrate or tetrahydrate, but this reference to “dehydration” may be confusing as chemical transformations other than crystalline water removal are involved (Ullmann’s, Peroxo Compounds, inorganic as cited in Annex XV report on sodium peroxometaborate, 2014).

- As detailed in a clarification document regarding the entries of sodium perborates into Annex I of Directive 67/548/EEC, brought forward at the TC C&L meeting in 2006, the substance with EINECS No. 231-556-4, CAS No. 7632-04-4 also known as oxoborate, does not have a dimeric cyclic structure as the hexahydrate (ECBI/38/03 Add. 15).

Furthermore, it is detailed in the EU RAR (2007) that “sodium peroxoborate trihydrate” (correct term should be “sodium perborate tetrahydrate”) has also been described in the literature but is not of commercial importance.

Since it is still customary to use the “old” formulas and nomenclature, even if they disregard the dimeric structure of the molecules, the terms “sodium perborate monohydrate” or PBS-1 and “sodium perborate tetrahydrate” or PBS-4 are used throughout this CLH-proposal. The current CLH-proposal focuses on sodium perborate monohydrate and the term “PBS-1” covering all per(oxo)borates listed in Annex VI under Index No. 005-019-00-8, 005-019-01-5, 005-017-00-7 and 005-017-01-4 will be used in the current proposal. In addition, the term “sodium per(oxo)borates” instead of sodium perborates will be used throughout the current report in order to better reflect the nature of these compounds.


8 EVALUATION OF PHYSICAL HAZARDS

Not assessed in this CLH-proposal.

9 TOXICOKINETICS (ABSORPTION, METABOLISM, DISTRIBUTION AND ELIMINATION)

9.1 Properties of aqueous solutions of per(oxo)borates

Sodium per(oxo)borates are water-soluble compounds that in aqueous conditions release hydrogen peroxide with the formation of boric acid.. The main species present in aqueous solutions of per(oxo)borates at physiological and acidic pH is boric acid, while hydrogen peroxide will rapidly decompose to water and oxygen in vivo. At room temperature, an equilibrium between sodium per(oxo)borates and their degradation products instantly establishes (EU RAR 2007). The equilibrium will largely shift towards the side of the degradation products at environmentally relevant concentration ranges and at low concentrations (i.e. ≤ 2 g/L), whereas at higher concentrations (i.e. ≥ 12 g/L), the undissociated molecule of sodium per(oxo)borate will mostly be present in the aqueous solution. The equilibrium is shifted irreversibly towards the degradation products by hydrogen peroxide removal, either catalyzed by metal ions or by catalase and peroxidase enzymes in blood (Urschel 1967).




One of the degradation products, sodium metaborate, is the salt of a strong base (sodium hydroxide) and of a weak acid (boric acid), and it is expected to be present in aqueous solutions at environmental temperature and pH, as the weakly dissociated boric acid (EU RAR, 2007):

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID, SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3]; SODIUM PERBORATE [4]



Boric acid



9.2 Toxicokinetic data on per(oxo)borates

No studies according to validated and/or internationally accepted test guidelines on the toxicokinetics of per(oxo)borates in experimental animals were available. The following data are gathered from what is available in the open scientific literature and published assessment reports (ATSDR Report, 2010; EU RAR, 2003; 2007; HERA Report, 2002;2005).

Absorption

Oral

Based upon the below-described studies, per(oxo)borates are 100% absorbed from the gastrointestinal (GI) tract after oral exposure, while oral mucosa absorption is considered negligible.

The oral absorption of sodium perborate monohydrate by the oral mucosa or the GI tract was investigated in studies with volunteers using Bocosept as mouthwash solution (Edwall et al. 1979). In order to obtain a mouthwash solution, one Bocosept package (containing 1.2 g sodium perborate monohydrate and 0.5 g sodium bitartrate) was dissolved in a small volume of water, which was circulated in the mouth for approximately 3 minutes and then spat out. Blood boron levels were measured after a single administration of Bocosept to two healthy volunteers and two gingivitis patients, with a mean blood boron concentration of 0.04 µg/mL measured prior to the experiment. The blood boron concentration increased gradually, measuring 0.06 µg/mL after 2 minutes and 0.14 µg/mL after 2 hours since the mouthwash administration. The mean blood boron concentration after 24 hours was 0.07 µg/mL, and no differences between healthy volunteers and gingivitis patients were found. The authors calculated that 97% of the administered mouthwash dose was spat out. The remaining 3% that was available for absorption corresponds to 36 mg sodium perborate monohydrate. Based on the results of the study the authors concluded that the oral mucosal absorption was negligible and thus, the GI tract was the main route of absorption, following ingestion of residual amounts left in the mouth after the treatment.

In another study, volunteers used Bocosept as mouthwash solution twice a day, for seven consecutive days (Dill et al. 1977). During the experiment, the mean blood boron concentration was between 0.15 – 0.20 µg/mL, whereas the mean blood boron concentration measured before administering Bocosept was 0.07 µg/mL. Two and four days after the cessation of the treatment, the blood and urine boron concentrations, respectively, returned to the background levels. The mean total amount of boron excreted in the urine for four days after the end of the treatment was approx. 2.8% of the total administered sodium perborate monohydrate amount. Since 3% is the amount equivalent to that which is not spat out (as shown by Edwall et al. 1979), and approximately the same amount was found in the urine, a 100% absorption rate from the GI tract is thus assumed.

Peak human plasma levels of boron after oral ingestion of sodium per(oxo)borates are presumed to be reached after 2h, with the half-life in plasma of 6 – 10 h.

Inhalation

No information was found on the absorption rate via inhalation for sodium per(oxo)borates.

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID,
SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC
ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3];
SODIUM PERBORATE [4]

Dermal

No information on the dermal absorption of sodium per(oxo)borates was available.

Distribution

No information on the distribution of sodium per(oxo)borates was available. Based upon the data on degradation of per(oxo)borates, boron will primarily exist in the body as boric acid.

Metabolism

No information on the metabolism of sodium per(oxo)borates was found. Based upon the data on degradation of per(oxo)borates, boron will primarily exist in the body as boric acid. Boric acid is not metabolised further in the body.

Excretion and elimination

According to the above-described studies performed with human volunteers, boron will be primarily eliminated as boric acid .

9.3 Toxicokinetic data on boric acid

No studies according to validated and/or internationally accepted test guidelines on the toxicokinetics of boric acid or borate salts are available. The data described below are mainly represented by what is available in the open scientific literature as experimental (animal data) and occupational studies, and literature reviews (ATSDR Report, 2010).

Absorption

Oral

Humans and animals (rats, rabbits, sheep and cattle) absorb orally administered boric acid in a similar way, readily and completely from the gastrointestinal tract, with 92 – 95% of the dose being recovered in the urine.

Inhalation

After boric acid exposure via inhalation, boron is systemically distributed through absorption across pulmonary tissues and into the bloodstream.

Dermal

The available studies show that there is minimal dermal absorption (i.e. 0.5%) of boric acid through intact skin for both animals and humans. Absorption through non-intact skin varies with the used vehicle: as opposed to oil-based vehicle, aqueous-based ones lead to a greater dermal absorption of boric acid.

Distribution

After administration of boric acid, boron has a similar distribution for both humans and animals with the following common aspects:

- Boron is rapidly distributed throughout body fluids;
- Boron does not accumulate in soft tissue;
- Boron accumulates in the bone, reaching 2 – 3 times higher levels than in plasma.

Furthermore, the plasma and soft tissue concentrations of boron are equivalent for humans, while in rats, the adipose tissue levels of boron represent only 20% of the plasma ones. The testis levels of boron in male rats were almost equal to the ones measured in plasma. Moreover, in male rats, a close correlation between testicular and blood levels of boron was found, with testicular concentrations of 5.6 µg B/g (equivalent to 26 mg B/kg bw) and 11.9 µg B/g (equivalent to 52 mg B/kg bw) being associated with inhibited spermiation and testicular atrophy, respectively (Murray et al. 1998).

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID, SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3]; SODIUM PERBORATE [4]

Metabolism

Boric acid is not metabolised in either humans or animals, boron being a trace element which exists in the body as boric acid (the only form of boron recovered in the urine).

Excretion and elimination

Independently of the route of exposure, boric acid is primarily excreted through renal elimination and has a half-life less than 24h for both humans and animals. Based on literature data, eliminated fractions of absorbed boron were estimated to be 67 – 98% for humans and 99% for rats (ATSDR 2010), and the calculated clearance values were 40 mg/kg/hour in humans and 163 mg/kg/hour in rats, respectively. In addition, the glomerular filtration rate appears to be the determining factor in the renal elimination of boron.

9.4 Toxicokinetic data on hydrogen peroxide

No studies according to validated and/or internationally accepted test guidelines on the toxicokinetics of hydrogen peroxide are available. The following data are gathered from what is available in the open scientific literature as experimental studies, case reports and published assessment reports (EU RAR, 2003; HERA Report, 2005).

Absorption

It is expected that hydrogen peroxide is readily taken up by the cells at the absorption surfaces due to the high permeability of the biological membranes to H₂O₂. The permeability constants for peroxisomal membranes (0.2 cm/min) and for erythrocyte plasma membranes (0.04 cm/min) are comparable to those for water for several types of cell membranes, ranging between 0.02 – 0.42 cm/min (Chance et al. 1979).

Oral

Hydrogen peroxide is readily absorbed after oral exposure. It may be demonstrated by effects such as tachycardia, lethargy, coma, convulsions, apnoea, cyanosis and cardiorespiratory arrest were reported in humans within minutes of ingestion, as a result of oxygen embolism (Watt et al. 2004).

Inhalation

Hydrogen peroxide is readily absorbed after exposure via inhalation in rabbits. Hydrogen peroxide as 1 – 6% aerosol was administered via a ventilation apparatus to anaesthetised rabbits (Urschel 1967). The blood collected from the left atrium was found to be supersaturated with oxygen at a level equivalent to oxygen administration at 3 atm. The 1% aerosol provided the same level of oxygen as the other higher H₂O₂ > 1% concentrations.

Dermal

In rats, trace amounts of 5 – 30% hydrogen peroxide solutions were found to penetrate the skin, by being localised in the excised epidermis a few minutes after application. *In vitro* tests with human cadaver skin show that H₂O₂ was found in the dermis only after the application of high concentrations or after the treatment with hydroxylamine that acts as a catalase inhibitor. The performed histochemical analysis showed that the passage was trans-epidermal and that H₂O₂ was not metabolised in the epidermis (EU RAR 2003). This is in line with the findings of Riihimaki et al. 2002 who observed that unintentional dermal contact to concentrated H₂O₂ solutions led to the appearance of white spots, due to oxygen microbubble formation, which disappeared with time.

Distribution

According to available animal and human data, H₂O₂ is distributed to a variety of tissues (i.e. brain, myocardium, intestines, lungs, spleen and kidneys).

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID, SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3]; SODIUM PERBORATE [4]

Hydrogen peroxide is a normal metabolite in aerobic cells, occurring at an intracellular level of approx. 10 nM, the steady state level depending on the balance between H₂O₂ generation and degradation.

Metabolism

Hydrogen peroxide is rapidly metabolised to oxygen and water in the body by two main enzymes, catalase and glutathione (GSH) peroxidase, which maintain H₂O₂ concentration at certain levels in different parts of the cells. At levels lower than 10 µM, 80 – 90% H₂O₂ is decomposed by GSH peroxidase while catalase deals with larger amounts of H₂O₂ that may be generated in peroxisomes, the contribution of catalase increasing with the increase in H₂O₂ concentration (Makino et al. 1994).

Catalase and GSH peroxidase are present in excess quantities in the blood (Urschel 1967) and lung. Enzyme activity is unevenly distributed in different tissues for different species. In general, the brain and the heart have low catalase activity, while GSH peroxidase is lacking in the muscle tissue (Chance et al. 1979).

Excretion and elimination

The excretion of hydrogen peroxide in urine was assessed through a radioactive method (based on the decarboxylation of alfa-ketoglutaric acid by H₂O₂) from samples of healthy volunteers aged 20 – 35 years. The average concentration of H₂O₂ in the urine of male subjects was 106 µM, while for the female volunteers was 89 µM (Varma and Demanoharan 1989).

9.5 Short summary and overall relevance of the provided toxicokinetic information on the proposed classification(s)

As described in Section 9.1, the main species present in physiological solutions of per(oxo)borates at neutral and acidic pH is boric acid, while hydrogen peroxide will rapidly decompose to water and oxygen *in vivo*. Hydrogen peroxide is therefore not considered to contribute significantly to repeated dose toxicity. The view that boric acid is a degradation product of per(oxo)borates at physiological conditions and expected to have the same toxicological effects, was already expressed in 2005 at the TC C&L meeting (ECBI/60/05 Rev. 3).

Available toxicokinetic data show that per(oxo)borates/boric acid are readily absorbed after oral exposure (100 and 92-95 % respectively). Boric acid is also rapidly absorbed after inhalation exposure whereas it is minimal via skin (0.5%). Boric acid is distributed throughout the body and is eliminated as such from the body via urine. A close correlation between blood boron levels, testicular levels of boron and effects such as inhibited spermiation and testicular atrophy has been found.

9.5.1 Justification for read-across

From data on boric acid and borates

In aqueous solutions at room temperature, an equilibrium between per(oxo)borates and their degradation products will be established (see Section 9.1). Sodium metaborate, i.e. one such degradation product, is expected to be present in aqueous solutions (at environmental temperature, physiological and acidic pH) mainly as weakly dissociated boric acid (pK_a = 9.25) (SCCS Opinion, 2010). As also discussed at the Specialised Experts Meeting (in Ispra, 2004), boric acid as a degradation product of sodium per(oxo)borates will be systemically available and the same effects are expected, and thus, the data on boric acid and borates have to be taken into account for read-across (EU RAR, 2007). Furthermore, the report on boron performed in 1998 by the International Programme on Chemical Safety (IPCS)⁹ stated that the chemical and

⁹ <http://www.inchem.org/documents/ehc/ehc/ehc204.htm#PartNumber:6>

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID, SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3]; SODIUM PERBORATE [4]

toxicological effects of boric acid and other borates are similar on a mol boron/litre equivalent basis, when dissolved in water or in biological fluids at low concentration and at the same pH.

Moreover, as stated in the CLH-reports of disodium octaborate, anhydrate and disodium octaborate tetrahydrate (2013) and in the CLH-proposal on revising the SCLs for boric acid and borate salts (2019), read-across from boric acid to other borates and between borates has long been accepted in a regulatory context. Experts from the CL Working Group, the TC C&L and the ATP Committee agreed that borates have similar properties and therefore that read-across between substances can be applied.

Reproductive toxicity

Limited toxicity data are available for the hazard assessment of fertility of per(oxo)borates. Therefore, classification for sexual function and fertility following oral exposure in Category 1B (H360F) is supported using a read-across approach based on boron equivalents, from tested borates (borax or disodium tetraborate decahydrate, disodium octaborate anhydrate, disodium octaborate tetrahydrate) and boric acid, justified on the basis of hydrolytic and toxicokinetic behaviour, and toxicological data. A comparable toxicity profile is demonstrated in teratogenicity studies with boric acid and sodium borates, and sodium per(oxo)borates. Moreover, according to the minutes of the TC C&L (2005 – 2006) where the classification of the sodium per(oxo)borates was discussed and adopted, the SCLs currently included in the Annex VI of CLP for effects on fertility were indeed derived on a boron-equivalent basis, using the SCL of boric acid of that time¹⁰ as a starting point. It can, therefore, be assumed that a similar read-across may be used in the derivation of new concentration limits for effects on fertility, based upon the method described in the ECHA Guidance on the application of the CLP criteria (2017).

Read-across of experimental data from boric acid and borates is not applied for the assessment of adverse effects of sodium per(oxo)borates on the development of the offspring. The sodium per(oxo)borates included in Annex VI of CLP have a harmonised classification as Repr. 1B; H360D based on a PNDT (OECD TG 414) study conducted with PBS-4. However, since no data on the effect of sodium per(oxo)borates on human fertility, development and lactation are available, read-across of data from epidemiological studies of boric acid and borates are used.

Acute toxicity

Read-across from boric acid and borates is not considered appropriate for the assessment of acute toxicity since per(oxo)borates and boric acid/borates have an uncommon degradation product: hydrogen peroxide. The available studies show that the higher acute oral toxicity of sodium per(oxo)borates as compared to borates is due to the in vivo formation of hydrogen peroxide (which leads to local irritation and oxygen accumulation) and not to boron-exposure.

From data on sodium perborate tetrahydrate (PBS-4)

As detailed above, PBS-1 and PBS-4 are sodium salts of the peroxoboron anions that have different hydration degrees and will both degrade to sodium metaborate and hydrogen peroxide, at environmental temperatures and pH. Thus, the similar toxicological effects are expected for PBS-1 and PBS-4, however, the potency will differ. Read-across of data from PBS-4 was also used in the EU RAR (2007) and by the dossier submitter in 2005-2006, which led to the harmonised classification of PBS-1 as Acute Tox. 3*; H331 and Repr. 1B; H360D as adopted by the TC C&L.

Acute toxicity

¹⁰ The SCL of 5.5% for boric acid was calculated based on the approach proposed by BauA (2005-2006). In 2019, the RAC has removed the SCLs calculated through this old approach and concluded on the harmonisation of GCL values to 0.3% w/w for boric acid and six sodium borates that have a harmonised classification as Repr. 1B.

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID,
SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC
ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3];
SODIUM PERBORATE [4]

Read-across approach of data from studies conducted with PBS-4 is considered appropriate to use in order to support the proposed harmonised classification of PBS-1 for acute inhalation toxicity justified on the basis of water dissolution behaviour and toxicological data. For acute oral toxicity there is sufficient substance specific evidence on PBS-1 itself that warrants classification.

Reproductive toxicity

Read-across of data from studies conducted with PBS-4) is considered appropriate to use in order to support the proposed ED10 derivation for developmental toxicity (on a boron-equivalent basis), justified on the basis of water dissolution behaviour and toxicological data.

Consideration of hydrogen peroxide

PBS-1 is a reactive oxidant and liberate hydrogen peroxide in aqueous solution under formation of sodium borate/ boric acid. Thus, the toxicity profile of hydrogen peroxide is also considered in the assessment of acute toxicity and reproductive toxicity for comparison. However, hydrogen peroxide is not expected to contribute significantly to the reproductive toxicity of per(oxo)borates since it is rapidly decomposed to water and oxygen and is expected to exert local/site of contact effects.

10 EVALUATION OF HEALTH HAZARDS

Acute toxicity

10.1 Acute toxicity - oral route

Table 7: Summary table of animal studies on acute oral toxicity

Method, guideline, deviations if any ¹¹	Species, strain, sex, no/group	Test substance	Dose levels, duration of exposure	Value LD ₅₀	Reference												
<i>Sodium perborate monohydrate (PBS-1)</i>																	
EPA OPP 81-1, GLP (Acute Oral Toxicity) Reliability: 1 (reliable without restriction), key study	Rat, Sprague-Dawley Male/female n = 5/sex/dose group	Sodium perborate monohydrate (grade A) Purity: unknown Vehicle: water Oral gavage	500, 1000 and 2000 mg/kg bw 14 days post-exposure observation period	Male: 1300 mg/kg bw Female: 890 mg/kg bw Male/female: 1120 mg/kg bw	REACH registration (ECHA dissemination, [2020]) Study Report, 1988 See also Annex I to the CLH-report												
				<table border="1"> <thead> <tr> <th>Dose (mg/kg)</th> <th>Lethality M</th> <th>Lethality F</th> </tr> </thead> <tbody> <tr> <td>500</td> <td>0/5</td> <td>0/5</td> </tr> <tr> <td>1000</td> <td>1/5 (on day 1)</td> <td>3/5 (1/5 on day 1 and 2/5 on day 2)</td> </tr> <tr> <td>2000</td> <td>5/5 (3/5 on day 0 and 2/5 on day 1)</td> <td>5/5 (on day 0)</td> </tr> </tbody> </table>		Dose (mg/kg)	Lethality M	Lethality F	500	0/5	0/5	1000	1/5 (on day 1)	3/5 (1/5 on day 1 and 2/5 on day 2)	2000	5/5 (3/5 on day 0 and 2/5 on day 1)	5/5 (on day 0)
				Dose (mg/kg)		Lethality M	Lethality F										
				500		0/5	0/5										
1000	1/5 (on day 1)	3/5 (1/5 on day 1 and 2/5 on day 2)															
2000	5/5 (3/5 on day 0 and 2/5 on day 1)	5/5 (on day 0)															

¹¹ Where applicable and unless stated otherwise, the reliability scores of the studies presented in Table 7 are according to the publicly disseminated REACH Registration dossier for EC no. 234-390-0, available at <https://echa.europa.eu/registration-dossier/-/registered-dossier/13523/7/3/2>

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID,
SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC
ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3];
SODIUM PERBORATE [4]

Method, guideline, deviations if any ¹¹	Species, strain, sex, no/group	Test substance	Dose levels, duration of exposure	Value LD ₅₀	Reference																		
EPA OPP 81-1, GLP (Acute Oral Toxicity) Reliability: 1 (reliable without restriction), supporting study	Rat, Wistar Male/female n = 5/sex/dose group	Sodium perborate monohydrate Purity: unknown Vehicle: water Oral gavage	1200, 1500, 1900, 2500 and 5000 mg/kg bw 14 days post-exposure observation period	Male: 2100 mg/kg bw Female: 1700 mg/kg bw Male/female: 1800 mg/kg bw	REACH registration (ECHA dissemination, [2020]) Study Report, 1987a																		
				<table border="1"> <thead> <tr> <th>Dose (mg/kg)</th> <th>Lethality M</th> <th>Lethality F</th> </tr> </thead> <tbody> <tr> <td>1200</td> <td>0/5</td> <td>0/5</td> </tr> <tr> <td>1500</td> <td>0/5</td> <td>1/5 (on day 1)</td> </tr> <tr> <td>1900</td> <td>3/5 (2/5 on day 1 and 1/5 on day 2)</td> <td>4/5 (1/5 on day 0 and 3/5 on day 1)</td> </tr> <tr> <td>2500</td> <td>4/5 (2/5 on day 0 and 2/5 on day 1)</td> <td>5/5 (2/5 on day 0 and 3/5 on day 1)</td> </tr> <tr> <td>5000</td> <td>5/5 (on day 0)</td> <td>5/5 (on day 0)</td> </tr> </tbody> </table>		Dose (mg/kg)	Lethality M	Lethality F	1200	0/5	0/5	1500	0/5	1/5 (on day 1)	1900	3/5 (2/5 on day 1 and 1/5 on day 2)	4/5 (1/5 on day 0 and 3/5 on day 1)	2500	4/5 (2/5 on day 0 and 2/5 on day 1)	5/5 (2/5 on day 0 and 3/5 on day 1)	5000	5/5 (on day 0)	5/5 (on day 0)
				Dose (mg/kg)		Lethality M	Lethality F																
				1200		0/5	0/5																
				1500		0/5	1/5 (on day 1)																
				1900		3/5 (2/5 on day 1 and 1/5 on day 2)	4/5 (1/5 on day 0 and 3/5 on day 1)																
				2500		4/5 (2/5 on day 0 and 2/5 on day 1)	5/5 (2/5 on day 0 and 3/5 on day 1)																
5000	5/5 (on day 0)	5/5 (on day 0)																					
Non-guideline, non-GLP, standard acute method (publication) Reliability: 2 (reliable with restrictions), supporting study	Rat, strain not specified Sex not specified n = 10 – 33 /dose group	Sodium perborate monohydrate Purity: unknown Vehicle: presumably water Oral gavage	130 – 650 mg/kg bw	Male/female: > 650 mg/kg bw	REACH registration (ECHA dissemination, [2020]) Mulinos et al. 1952																		

Table 8: Summary table of human data on acute oral toxicity

Type of data/report	Test substance	Relevant information about the study (as applicable)	Observations	Reference
A summary of the reported human data is presented below				

Table 9: Summary table of other studies relevant for acute oral toxicity

Type of study/data	Test substance	Relevant information about the study (as applicable)	Observations	Reference
No other relevant studies for the acute oral toxicity of perborates were available				

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID, SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3]; SODIUM PERBORATE [4]

10.1.1 Short summary and overall relevance of the provided information on acute oral toxicity

Animal studies

PBS-1

The US EPA-guideline acute toxicity studies performed with PBS-1 established an LD₅₀ of 1120 mg/kg bw and of 1800 mg/kg bw, in Sprague-Dawley and Wistar rats, respectively (Study report, 1988; Study Report, 1987a). Both studies showed that females are more sensitive than male rats, with the lowest reported ATE of 890 mg/kg bw in the Sprague-Dawley strain.

The reported acute oral toxic effects in both strains consisted of irregular respiration, diarrhoea, bloated abdomen, hypoactivity, ataxia, lethargy, chromorhinorrhoea, flaccid muscle tone and negative righting reflex. The necropsy examination revealed very distended stomach, filled with gas, with thickened walls and brown and red-stained glandular mucosa, and enlarged pelvis in the kidneys for both high-dose male and female Sprague-Dawley rats (Study Report, 1988). The necropsy performed in Wistar rats revealed congested and haemorrhagic lungs, liver mottled with dark areas, pale margins of the spleen, distended stomach with gas and white milky fluid, distended red intestines, and some abnormalities of the kidneys (Study Report, 1987a).

An older non-guideline, non-GLP study established an LD₅₀ of over the highest tested dose in rats, i.e. > 650 mg/kg bw (Mulinos et al. 1952). Slight hyperaemia of the gastric mucosa and reversible epithelial degeneration of the fundic mucosa were seen. However, the full study was not available for evaluation.

The below data on boric acid, borate salts and hydrogen peroxide are presented only for comparison.

Boric acid and borate salts

According to the disseminated REACH registration dossier¹², based on a non-guideline study performed in rats, an LD₅₀ of 3450 mg/kg bw was established for boric acid. Other non-guideline acute oral toxicity studies in rats also reported LD₅₀ > 2000 mg/kg bw.

Moreover, acute oral toxicity studies performed in rats for disodium octaborate anhydrate, disodium tetraborate anhydrous, disodium tetraborate pentahydrate and diboron trioxide revealed LD₅₀ levels of > 2000 mg/kg bw, for each substance.

Hydrogen peroxide

According to the disseminated REACH registration dossier¹³, two acute oral toxicity studies according to OECD TG 401 were performed in rats. Thus, LD₅₀ values of 805 mg/kg bw hydrogen peroxide 70% (Study Report, 1996) and of 801 – 872 mg/kg bw hydrogen peroxide 60% (Study Report, 1981) were established.

Another acute oral toxicity study (according to US EPA PB 82-232948) performed in rats with hydrogen peroxide 35% established an LD₅₀ of 1193 mg/kg bw for males and 1270 mg/kg bw for females (Study Report, 1983).

¹² <https://www.echa.europa.eu/web/guest/registration-dossier/-/registered-dossier/15472/7/3/1>

¹³ <https://echa.europa.eu/registration-dossier/-/registered-dossier/15701/7/3/2>

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID, SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3]; SODIUM PERBORATE [4]

Other acute oral toxicity studies (non-guideline, non-GLP) in rats reported LD₅₀ values of > 225 mg/kg bw for hydrogen peroxide 50% and LD₅₀ values of 1520 mg/kg bw for males and 1620 mg/kg bw for females administered hydrogen peroxide 9.6%. Furthermore, an LD₅₀ of >5000 mg/kg bw was reported by another non-guideline study for rats administered hydrogen peroxide 10% (Study Report, 1990).

Main acute toxicity effects such as lethargy, immobility, irregular respiration, ataxia and tremors were noted in the above-mentioned studies.

Hydrogen peroxide has a harmonised minimum classification as Acute Tox. 4*, H302.

Human data

Sodium per(oxo)borates

Accidental swallowing cases of powder/liquid detergents or other household products containing sodium per(oxo)borates mostly involving children (0 - 4 years) have been recorded in a UK Poison Centre report (as detailed in the HERA Report, 2002). Effects such as transient irritation of the eyes and mucous membranes were mainly described. No fatalities were reported and approx. 60% of the incidents involving laundry detergents were treated at home. The amounts swallowed in these cases are not noted. However, based upon the available information, it is estimated that a maximum amount of 1.5 g of sodium per(oxo)borate (approx. 5 g of detergent) could be swallowed. This amount results in approx. 150 mg/kg bw for a 10 kg child (HERA Report, 2002).

In the disseminated REACH registration dossier¹⁴, the human health surveillance data on workers employed at detergent production plants do not provide any information on acute oral toxicity of sodium per(oxo)borates.

The below data on boric acid, borate salts and hydrogen peroxide are presented only for comparison.

Boric acid and borate salts

As detailed in the disseminated REACH registration dossier of boric acid¹⁰, intentional or accidental poisoning incidents with boric acid or borate salts have been reported. Based on an old case review study, the human oral lethal dose was reported as 2-3 g boric acid for infants, 5-6 g boric acid for children and 15-30 g boric acid for adults. None of the more recent poisoning cases with an estimated dose range of 0.01 – 88.8 g boric acid were reported to be fatal. The reported acute effects are mainly represented by nausea, vomiting, gastric effects, skin flushing, convulsions, depression and vascular collapse.

Hydrogen peroxide

Two case reports involving lethal ingestion of hydrogen peroxide by children were available (EU RAR 2003). The first case report described a 2-year-old child who accidentally ingested 113 to 170 g of hydrogen peroxide 35%, becoming immediately cyanotic and unresponsive, remaining paralysed. The child died on day 4 after arriving at the hospital, where a chest radiograph showed gas accumulation in the right heart ventricle and portal venous system. The autopsy revealed marked diffuse cerebral oedema, due to gas embolism. Assuming a weight of 13 kg and that the child ingested approx. 142 g of a 35% hydrogen peroxide solution, this would correspond to approx. 50 g of hydrogen peroxide, and thus the lethal dose in this case would be approx. 3846 mg/kg bw.

¹⁴ <https://echa.europa.eu/registration-dossier/-/registered-dossier/13523/7/11/2>

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID, SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3]; SODIUM PERBORATE [4]

The second case report describes a 16-month-old child who accidentally ingested approx. 230g of hydrogen peroxide 3% and was found dead 10h later. The autopsy revealed foamy blood in the right heart ventricle and the portal venous system, red gastric mucosa, cerebral and lung oedema. Gas embolism was seen in the pulmonary vasculature, intestinal and gastric lymphatics. The ingested dose of hydrogen peroxide would thus correspond to approx. 7g (i.e. 230 g of 35% hydrogen peroxide solution), which further gives a lethal dose of 603 mg/kg bw (taking into account the body weight of 11.6 kg of the child).

Conclusion

The available acute oral toxicity studies for PBS-1 meet the criteria for classification in Acute Tox. 4, where the lowest LD₅₀ is 890 mg/kg bw in the female rat.

The available studies show that acute oral toxicity of sodium per(oxo)borates is due to the *in vivo* formation of hydrogen peroxide which leads to local irritation and oxygen accumulation. The reported LD₅₀ values for hydrogen peroxide correspond to Category 4 (801 – 872 mg/kg bw). The necropsy results from the PBS-1 and PBS-4 studies are consistent with oxygen formation in visceral cavities (gas embolism) due to the degradation of the formed hydrogen peroxide.

10.1.2 Comparison with the CLP criteria

According to the CLP Regulation (EC) No 1272/2008, classification for acute oral toxicity is required for substances with acute toxicity estimate values (based on LD₅₀) below 2000 mg/kg bw.

The two acute oral toxicity guideline studies performed in rats with PBS-1 established LD₅₀ values > 300 and < 2000 mg/kg bw (Category 4), where the lowest LD₅₀ was 890 mg/kg bw seen in female rats in Study report, 1988, and in Study report, 1987a the lowest LD₅₀ was 1700 mg/kg in females. According to the Guidance on the application of CLP criteria 3.1.2.3.2 *In general, classification is based on the lowest ATE value available i.e. the lowest ATE in the most sensitive appropriate species tested.* Since there are no apparent reasons for the different results obtained in Study report, 1988 and Study Report, 1987a, apart from using two different rat strains, the lowest available LD₅₀ of 890 mg/kg appears appropriate as a basis to set ATE.

10.1.3 Conclusion on classification and labelling for acute oral toxicity

Currently, PBS-1 has a harmonised classification as Acute Tox. 4* (H302) for the oral route of exposure, as listed in two entries (Index No. 005-019-00-8 and 005-019-01-5) in Annex VI of CLP. **Removal of the asterisk (*) indicating minimum classification and the inclusion of an ATE of 890 mg/kg bw are proposed. Thus, the new proposed classification for PBS-1 is: Acute Tox 4, H302, oral: ATE = 890 mg/kg bw/day.**

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID,
SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC
ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3];
SODIUM PERBORATE [4]

10.2 Acute toxicity - dermal route

Table 10: Summary table of animal studies on acute dermal toxicity

Method, guideline, deviations if any ¹⁵	Species, strain, sex, no/group	Test substance	Dose levels of duration exposure	Value LD ₅₀	Reference
<i>Sodium perborate monohydrate</i>					
OECD TG 402 (Acute Dermal Toxicity) Reliability: 1 (reliable without restriction), key study	Rabbit, New Zealand White Male/female n = 5/sex/dose group	Sodium perborate monohydrate Purity: unknown Vehicle: water Occlusive dermal application	2000 mg/kg bw Single dermal dose, 24 h exposure 14 days post-exposure observation period	Male/female: > 2000 mg/kg bw	REACH registration (ECHA dissemination, [2020]) Study Report, 1987b See also Annex I to the CLH-report

Table 51: Summary table of human data on acute dermal toxicity

Type of data/report	Test substance	Relevant information about the study (as applicable)	Observations	Reference
No human data on the acute dermal toxicity of sodium per(oxo)borates were available				

Table 62: Summary table of other studies relevant for acute dermal toxicity

Type of study/data	Test substance	Relevant information about the study (as applicable)	Observations	Reference
No other relevant studies for the acute dermal toxicity of perborates were available				

10.2.1 Short summary and overall relevance of the provided information on acute dermal toxicity

Animal studies

PBS-1

The acute dermal toxicity study (OECD TG 402) performed in rabbits with sodium perborate monohydrate established an LD₅₀ > 2000 mg/kg bw. Clinical signs such as diarrhoea, few faeces, yellow nasal discharge and anogenital soiling were reported. One male rabbit died on day 13 post-treatment revealing abnormalities of the gastrointestinal tract, spleen, liver and lung. On day 1 post-treatment, 2/9 surviving rabbits showed skin irritation, which decreased in severity during the 14-day observation period, and distended intestines at the necropsy evaluation. No statistically significant effects on body weight were recorded.

The below data on boric acid, borate salts and hydrogen peroxide are presented only for comparison.

¹⁵ Where applicable and unless stated otherwise, the reliability scores of the studies presented in Table 10 are according to the publicly disseminated REACH Registration dossier for EC no. 234-390-0, available at <https://echa.europa.eu/registration-dossier/-/registered-dossier/13523/7/3/4>

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID,
SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC
ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3];
SODIUM PERBORATE [4]

Boric acid and borate salts

According to the disseminated REACH registration dossier¹² of boric acid, an LD₅₀ > 2000 mg/kg bw was established based on a non-guideline study performed in rabbits. Moreover, acute dermal toxicity studies performed in rats or rabbits for disodium octaborate anhydrate, disodium tetraborate decahydrate and disodium tetraborate pentahydrate revealed LD₅₀ levels of > 2000 mg/kg bw, for each substance.

Hydrogen peroxide

An acute dermal toxicity study performed in rabbits according to EPA PB82-232984 guideline (Study Report, 1982) is available in the disseminated REACH registration dossier¹⁶ of H₂O₂. No deaths occurred and the established LD₅₀ value for hydrogen peroxide 35% was > 2000 mg/kg bw. All 10 animals showed erythema, oedema, blanching of the skin after 24 h, and eschar and exfoliation at study cessation. The necropsy examination did not reveal any gross internal lesions.

Other non-guideline acute dermal toxicity studies performed in rabbits established an LD₅₀ of 9200 mg/kg bw for 70% hydrogen peroxide, whereas LD₅₀ values for rats seem to be > 3500 mg/kg bw for 90% hydrogen peroxide.

Human data

Sodium per(oxo)borates

Several cases describing accidental skin contact with powder/liquid detergents or other household products containing sodium per(oxo)borates mostly involving small children (0 - 4 years) have been recorded in a UK Poison Centre report. No fatalities were reported and none of the exposed children required treatment in a hospital. Most of the injuries were recorded as “chemical injury”, with 2 cases of skin corrosion (HERA Report, 2002).

The below data on boric acid, borate salts and hydrogen peroxide are presented only for comparison.

Boric acid and borate salts

As detailed in the disseminated REACH registration dossier of boric acid¹⁷, several poisoning cases were reported in humans due to the use of skin and mucosa antiseptic pharmaceutical preparations containing boric acid. Moreover, case reports of accidental exposure of the head were also reported, with effects such as general or focal alopecia of the scalp (ATSDR Report, 2010).

Hydrogen peroxide

There are no available data on the acute dermal toxicity of hydrogen peroxide in humans. The main effects after dermal exposure consist of local irritation or corrosion and the appearance of white spots on the skin (HERA Report, 2005).

Conclusion

The available data indicate that sodium per(oxo)borate monohydrate displays low acute dermal toxicity with LD₅₀ > 2000 mg/kg bw, and therefore do not require classification. The described animal studies are comparable for PBS-1, boric acid and borate salts and hydrogen peroxide,

¹⁶ <https://echa.europa.eu/registration-dossier/-/registered-dossier/15701/7/3/4>

¹⁷ <https://www.echa.europa.eu/web/guest/registration-dossier/-/registered-dossier/15472/7/3/4>

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID,
SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC
ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3];
SODIUM PERBORATE [4]

10.2.2 Comparison with the CLP criteria

Classification under the CLP regulation (EC No 1272/2008) for acute dermal toxicity is required for substances with acute toxicity estimates (based on LD₅₀) below 2000 mg/kg bw. The reported LD₅₀ values for sodium per(oxo)borates do not meet the criteria for acute dermal toxicity.

10.2.3 Conclusion on classification and labelling for acute dermal toxicity

Since the experimental data revealed LD₅₀ values > 2000 mg/kg bw, classification for acute dermal toxicity of PBS-1 is not warranted.

10.3 Acute toxicity - inhalation route

Table 73: Summary table of animal studies on acute inhalation toxicity

Method, guideline, deviations if any ¹⁸	Species, strain, sex, no/group	Test substance, form and particle size (MMAD)	Dose levels, duration of exposure	Value LC ₅₀	Reference															
<i>Sodium perborate tetrahydrate</i>																				
<p>Non-guideline acute inhalation toxicity study, GLP</p> <p>Similar to OECD TG 403 (acute inhalation toxicity) with the following deviations: only one sex investigated, macroscopic and histopathological examinations not performed, different humidity range.</p> <p>Reliability: 2 (reliable with restrictions), key study</p>	<p>Rat, CrI:CD BR</p> <p>Male</p> <p>n = 6/dose group</p>	<p>Sodium perborate tetrahydrate</p> <p>Purity: 98.6%</p> <p>MMAD: 3.3, 3.5, 3.5 and 4.2 µm for 0.16, 0.48, 1.10 and 2.90 mg/L, respectively</p> <p>Inhalation (nose-only): dust</p>	<p>0.16, 0.48, 1.10 and 2.90 mg/L</p> <p>Exposure duration: 4h</p> <p>14 days post-exposure observation period</p>	Male: 1.16 mg/L	<p>Study Report, 1987c</p> <p>REACH registration (ECHA dissemination, [2020])</p> <p>See also Annex I to the CLH-report</p>															
				<table border="1"> <thead> <tr> <th>Conc. (mg/L)</th> <th>MMAD (µm)</th> <th>Lethality</th> </tr> </thead> <tbody> <tr> <td>0.16</td> <td>3.3</td> <td>0/6</td> </tr> <tr> <td>0.48</td> <td>3.5</td> <td>1/6</td> </tr> <tr> <td>1.10</td> <td>3.5</td> <td>3/6</td> </tr> <tr> <td>2.90</td> <td>4.2</td> <td>5/6</td> </tr> </tbody> </table>		Conc. (mg/L)	MMAD (µm)	Lethality	0.16	3.3	0/6	0.48	3.5	1/6	1.10	3.5	3/6	2.90	4.2	5/6
				Conc. (mg/L)		MMAD (µm)	Lethality													
				0.16		3.3	0/6													
				0.48		3.5	1/6													
1.10	3.5	3/6																		
2.90	4.2	5/6																		

¹⁸ Where applicable and unless stated otherwise, the reliability scores of the studies presented in Table 13 are according to the publicly disseminated REACH Registration dossier for EC no. 234-390-0, available at <https://echa.europa.eu/registration-dossier/-/registered-dossier/13523/7/3/3>.

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID,
SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC
ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3];
SODIUM PERBORATE [4]

Table 84: Summary table of human data on acute inhalation toxicity

Type of data/report	Test substance	Relevant information about the study (as applicable)	Observations	Reference
No human data on the acute inhalation toxicity of sodium per(oxo)borates were available				

Table 95: Summary table of other studies relevant for acute inhalation toxicity

Type of study/data	Test substance	Relevant information about the study (as applicable)	Observations	Reference
No other relevant studies for the acute dermal toxicity of perborates were available				

10.3.1 Short summary and overall relevance of the provided information on acute inhalation toxicity

Animal studies

Sodium per(oxo)borates

One non-guideline, GLP-compliant study of acceptable quality and reliability assessing the acute inhalation toxicity of PBS-4 in rats was available (Study Report, 1987c). Male rats (6/dose group) were exposed nose-only to 0.16, 0.48, 1.10 and 2.90 mg/L PBS-4, with the MMAD value for the highest concentration slightly over the respirable range (3.3 – 4.2 µm vs. 1 – 4 µm). During or shortly after exposure, males from all dose groups showed red nasal discharge, gasping and compound-covered faces while the rats exposed to ≥ 1.10 mg/L did not exhibit a startle response. A slight to severe decrease in body weight (up to 18%) was recorded within 1 day of exposure. All deaths occurred within 24h after exposure, as follows: 0/6, 1/6, 3/6 and 4/6 at 0.16, 0.48, 1.10 and 2.90 mg/L, respectively. Additionally, 1 rat from the highest dose group died 8 days after exposure. The acute inhalation toxicity effects in the surviving rats consisted of red ocular, nasal or oral discharge, diarrhoea, gasping and lung noise. Necropsy was not performed. An LC₅₀ of 1.16 mg/L was calculated by Probit Analysis.

A short description of another non-guideline inhalation toxicity study was available in the EU RAR (2007). Experimental animals (species not specified) were exposed to 3.7, 11.3, 39, 58 and 74 mg/ m³ of PBS-4 (equivalent to 0.0037, 0.0113, 0.039, 0.058 and 0.074 mg/L). Symptoms of respiratory irritation such as reduced respiration rate and an increase in the total number of cells in the lung lavage fluid were noted at 39-74 mg/m³. Toxic effects were seen at 74 mg/m³, however the lethality rate was not reported (Silajev, 1984 as cited in the EU RAR, 2007). The study is poorly described and no information on the exposure conditions and time, number/sex of animals, mortality or the calculation of an LC₅₀ was available.

The below data on boric acid, borate salts and hydrogen peroxide are presented only for comparison.

Boric acid and borate salts

According to the disseminated REACH registration dossier¹⁹ of boric acid, based on an OECD TG 403 study performed in rats, an LC₅₀ > 2.03 mg/L was established. Half an hour after exposure, effects such as ocular

¹⁹ <https://echa.europa.eu/registration-dossier/-/registered-dossier/15472/7/3/3>

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID, SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3]; SODIUM PERBORATE [4]

and/or nasal discharge, hunched posture and hypoactivity were noted. In addition, an US EPA FIFRA study performed in rats, reported an LC₅₀ of > 2.12 mg/L.

Moreover, acute inhalation toxicity studies performed in rats for disodium octaborate tetrahydrate and disodium tetraborate pentahydrate revealed LC₅₀ levels > 2 mg/L, for each substance.

Hydrogen peroxide

As described in the disseminated REACH registration dossier of hydrogen peroxide, based on a GLP-compliant, US EPA guideline (OTS 798.1150) acute inhalation toxicity study in rats, male and female rats were administered 0.17 mg/L H₂O₂ as vapour for 4h, via whole-body exposure. Eye closure, decreased activity, excessive salivation and nasal discharge were reported. A slight decrease in body weight on day 2 post-exposure was noted, but all rats recovered by the termination of the study. No deaths occurred at 0.17 mg/L, i.e. the maximum attainable concentration of hydrogen peroxide 50%, and thus an LC₅₀ could not be established. Lung weights were comparable to controls and it was stated that the necropsy examination did not reveal any treatment-related findings (Study Report, 1990b).

A non-guideline, GLP-compliant study investigated the respiratory irritation potential of hydrogen peroxide 50% administered as aerosols (Study Report, 1995a). Four male mice were exposed nose-only to 0.3, 0.616, 1.135 and 1.856 mg/L H₂O₂ for 30 minutes. The concentration at which a 50% reduction of the respiratory rate was observed was 0.665 mg/L. No animals died during the exposure. The necropsy examination showed local degenerative changes in the liver of 2 males from the lowest and highest dose groups.

Inhalation of highly concentrated solutions of hydrogen peroxide led to severe irritation and inflammation of the mucous membranes, coughing and dyspnoea. Shock, coma, convulsions and pulmonary oedema were reported up to 24-72 h post-exposure in experimental animals administered 90% hydrogen peroxide as vapour (Watt et al. 2004).

As detailed in the EU RAR (2003) of hydrogen peroxide, mice and rats have been exposed (whole-body) to the vapour of hydrogen peroxide for 4-8 hours in two series of rat studies with a different experimental setup (1) to a calculated concentration of 4,000 mg/m³ (eq. to 4 mg/L) for 8 hours or, (2) to measured concentrations ranging from 338 to 427 mg/m³ (eq. to 0.338 to 0.427 mg/L) for 4 or 8 hours. In study (1) no deaths were reported and no signs of intoxication were observed. No abnormal signs were noted in rats other than scratching and licking themselves. Pathological examination revealed congestion in the trachea and lungs. Small, localised areas of pulmonary oedema without haemorrhage and areas of alveolar emphysema were present among the rats killed during the first three days. Most of the lungs exhibited many areas of alveolar emphysema in addition to severe congestion. All other organs examined appeared normal. In study (2) no deaths were reported from either the single four-hour or eight-hour exposure. Pathological examination of the animals showed results similar to those described in study (1). Another poorly reported study which concerned a whole-body (shaved skin) exposure of rats to hydrogen peroxide vapour for 4 hours, gave an LC₅₀ value of 2,000 mg/m³ (eq. to 2 mg/L) and noted that the primary cause of death in the animals was gas embolism (Kondrashov, 1977; as cited in the EU RAR, 2003).

Hydrogen peroxide has a harmonised minimum classification as Acute Tox. 4*, H332.

Human data

Sodium per(oxo)borates

No information on the acute inhalation toxicity of sodium per(oxo)borates in humans was available. Health surveillance data on occupational exposure of workers from perborate production factories were available in the disseminated REACH registration dossier²⁰. Several unnamed epidemiological studies did not report any

²⁰ <https://echa.europa.eu/registration-dossier/-/registered-dossier/13523/7/11/2>

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID,
SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC
ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3];
SODIUM PERBORATE [4]

effects on the lung function of the workers, measured as forced vital capacity (FVC), forced expiratory volume (FEV), vital capacity (VC) and peak expiratory flow. However, it should be noted that these parameters are not very sensitive for small airway disease. Reversible eye irritation and partially reversible irritative effects on the nasal mucosa were reported.

The below data on boric acid, borate salts and hydrogen peroxide are presented only for comparison.

Boric acid and borate salts

Healthy volunteers were exposed to 0, 5, 10, 20, 30 and 40 mg/m³ sodium tetraborate pentahydrate as dust for 20 min, while cycling (Cain et al. 2004). Effects such as nasal and throat irritation were seen at levels \geq 30 mg/m³, the subjects reporting time-dependent feel due to sodium tetraborate pentahydrate exposure primarily in the nose and hardly in the eyes. Similarly, healthy volunteers were exposed to 0, 10 mg/m³ sodium borate, and to 0, 2.5, 5 and 10 mg boric acid/m³ for 47 minutes while exercising (Cain et al. 2008). Increased nasal secretions and decreased nasal airway resistance were observed at 10 mg/m³ sodium borate.

Hydrogen peroxide

No information on the acute inhalation toxicity of hydrogen peroxide in humans was found. The available reported cases of accidental hydrogen peroxide intoxications mainly involve the oral route (see Section 10.1.1).

Occupational exposure to hydrogen peroxide as aerosols was aetiologically linked with the development of diffuse interstitial lung disease in a 41-year-old dairy worker who also smoked. Withdrawal from exposure to hydrogen peroxide led to an improvement of his condition (Watt et al. 2004).

Conclusion

No acute inhalation toxicity studies were available with PBS-1. The LC₅₀ of 1.16 mg/L for PBS-4 in available acute inhalation toxicity study meets the criteria for classification of PBS-4 as Acute Tox. 4, H 332 (1.0 < ATE \leq 5.0 mg/L). The LC₅₀ established for PBS-4 was used to calculate the LC₅₀ values for PBS-1 according to their respective H₂O₂ content, based upon their respective hydrolysis reactions and molecular masses, taking into account that molar ratios of PBS-1:H₂O₂ are 1:1 in the hydrolysis reaction. This yielded LC₅₀ values of 0.75 mg/L for PBS-1. These calculated concentrations are in line with the hydrogen peroxide content of each per(oxo)borate (see Table 16 below) that anticipates potentially higher toxicity of PBS-1 as compared to PBS-4.

In comparison, the reported LC₅₀ values for boric acid and borate salts were > 2 mg/L, which therefore do not require classification. The available evidence shows that the higher acute inhalation toxicity of the PBS-4 as compared to borates is due to the *in vivo* formation of hydrogen peroxide, and not due to boron-exposure.

10.3.2 Comparison with the CLP criteria

According to the CLP Regulation (EC) No 1272/2008, classification for acute inhalation toxicity is required for substances with acute toxicity estimate values (based on LC₅₀) below 5 mg/L, in the case of dusts and mists. Category 3 is assigned for ATE values > 0.5 and \leq 1 mg/L, while Category 4 is assigned for substances with ATE values > 1 and \leq 5 mg/L.

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID,
SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC
ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3];
SODIUM PERBORATE [4]

The only study available for acute inhalation toxicity was a non-guideline study performed in rats with PBS-4. The study is considered reliable and appropriate as a basis to set ATE for acute inhalation toxicity of PBS-1 when the LC₅₀ of PBS-1 is calculated based on the H₂O₂ content compared to PBS-4. This basis for ATE is considered more appropriate than using acute toxicity point estimates (Table 3.1.2 in CLP) corresponding to category 4 of PBS-4. As shown in Table 16, the LC₅₀ values calculated for PBS-1 correspond to Category 3.

Table 16: Experimental and calculated LC₅₀ values for sodium per(oxo)borates

Substance	H ₂ O ₂ content (%) ²¹	LC ₅₀ (mg/L for dusts and mists)	Acute Toxicity Hazard Category and Hazard Statement Codes (according to CLP Regulation)
PBS-1	32.1	0.75 (calculated based on LC ₅₀ for PBS-4)	Acute Tox.3, H331
PBS-4	21	1.16 (experimental)	Acute Tox.4, H332

In addition, the current CLH-report also proposes the removal of the cut-off values for particle size, proposed on the basis of the thoracic fraction concept, discussed and adopted by the Technical Committee for Classification and Labelling (TC C&L) in 2006 (ECBI/90/06 Rev. 8). The main reason for this is that the thoracic fraction is a conservative approach no longer used that leads to differences in classification for acute inhalation toxicity of the same substance.

10.3.3 Conclusion on classification and labelling for acute inhalation toxicity

Currently, PBS-1 has a harmonised classification as Acute Tox. 3* (H331) as listed in two entries (Index No. 005-019-00-8 and 005-019-01-5) in Annex VI of CLP.

A removal of the asterisk (*) indicating minimum classification and the cut-off values for particle size distribution “[containing = 0,1 % (w/w) of particles with an aerodynamic diameter of below 50 µm]” and “[containing < 0,1 % (w/w) of particles with an aerodynamic diameter of below 50 µm]” is proposed. In addition, an ATE of 0.75 mg/L is also proposed. Thus, the new proposed classification for PBS-1 is: Acute Tox 3, H331, inhalation: ATE = 0.75 mg/L.

RAC evaluation of acute toxicity

Summary of the Dossier Submitter’s proposal

A harmonised classification Acute Tox. 4* for the oral route is currently in place for all entries for PBS-1 and Acute Tox. 3* for the inhalation route for two entries (Index No. 005-019-00-8 and 005-019-01-5).

²¹ Calculated as % of hydrogen peroxide of the molecular masses of each sodium per(oxo)borate, excluding the molecular mass of hydrogen. Based on the method for hydrogen peroxide content calculation provided by the Industry during the TC C&L meetings in 2005-2006 (ECBI/38/03 Add. 10).

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID, SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3]; SODIUM PERBORATE [4]

Acute oral and dermal toxicity studies are available for PBS-1. No acute inhalation toxicity studies are performed with PBS-1 and therefore read-across is proposed to PBS-4. Data on other boric acid, borate salts and hydrogen peroxide were presented for comparison. These data did not contradict the classification derived from available data on PBS-1 or PBS-4.

The DS proposes removal of the asterisk indicating minimum classification and the inclusion of an ATE of 890 mg/kg bw for the oral route. No classification on acute toxicity was proposed for the dermal route. For the inhalation route, the DS proposes the removal of the asterisk indicating minimum classification and the inclusion of an ATE of 0.75 mg/L, based on hydrogen peroxide release and the respective hydrogen peroxide content. In addition, the removal of the cut-off values for particle size distribution is proposed as the thoracic fraction concept, used by the Technical Committee for Classification and Labelling (TC C&L) in 2006 (ECBI/90/06 Rev. 8), is a conservative approach which is no longer used.

Comments received during consultation

Two Member State Competent Authorities (MSCAs) submitted comments on acute toxicity. One MSCA agreed with the proposals for classification on acute oral and inhalation toxicity and also agreed that the cut-off value of 50 µm for particle size should be removed. Another MSCA supported the DS proposals for classification on acute oral and inhalation toxicity, and no classification on acute dermal toxicity.

Assessment and comparison with the classification criteria

Oral route

Two reliable, GLP-compliant acute oral toxicity studies (EPA OPP 81-1) are available for PBS-1 in Sprague-Dawley or Wistar rats. In these studies, rats (n = 5/sex/group) were administered 500, 1000 and 2000 mg/kg bw or 1200, 1500, 1900, 2500 and 5000 mg/kg bw PBS-1 (purity unknown) via gavage, followed by a 14-day observation period. Lethality was reported on day 0-2 post-exposure, at ≥ 1000 mg/kg bw in Sprague-Dawley rats and at ≥ 1500 mg/kg bw in Wistar rats. Evident acute toxicity was noted (e.g. irregular respiration, diarrhoea, bloated abdomen) and necropsy revealed distended stomach with gas and kidney abnormalities in both strains. Female rats appeared more sensitive than male rats, with the lowest LD₅₀ reported of 890 mg/kg bw. Another acute oral toxicity study in rat is available with some limitations (e.g. strain and sex not specified) and therefore of lower reliability. In this study an LD₅₀ of > 650 mg/kg bw is reported.

Use of read-across data is not necessary as studies for PBS-1 are available for this endpoint. However, studies on boric acid, borate salts and hydrogen peroxide are discussed for comparison. For boric acid and borate salts LD₅₀ values of > 2000 mg/kg bw are reported based on acute oral toxicity studies in rats. Multiple acute oral toxicity studies in rats are available for hydrogen peroxide; three guideline studies and three non-guideline studies. LD₅₀ values reported for hydrogen peroxide depend on concentrations (percentage, see Table 2 below). Oral toxicity of hydrogen peroxide is

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID, SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3]; SODIUM PERBORATE [4]

known and is relevant, depending on its concentration, to assess for comparison with PBS-1.

Table 2: Reported LD₅₀ values for hydrogen peroxide

H ₂ O ₂ (%)	LD ₅₀ (mg/kg bw)
9.6	1520-1620 (m: 1520; f: 1620)
10	>5000
35	1193-1270 (m: 1193; f: 1270)
50	>225
60	801-872
70	805

In humans, upon exposure to sodium per(oxo)borates, irritation is reported but no related deaths. For boric acids, borate salts and hydrogen peroxide exposure-related deaths are known. Toxic effects such as vomiting, gastric effects and convulsions are reported for boric acid. Autopsy upon accidental exposure to hydrogen peroxide in children revealed gas oedema-related findings, such as gas accumulation in the right heart ventricle.

The data from the two reliable acute oral toxicity studies in rats with PBS-1 are preferred over the less reliable study. RAC agrees with the DS that the lowest LD₅₀ value of 890 mg/kg bw is most appropriate as ATE. This ATE falls within the limits of Category 4 (oral LD₅₀ is >300 but ≤ 2000 mg/kg bw). Therefore, RAC agrees with the DS to remove the asterisk indicating minimum classification and the inclusion of an ATE of 890 mg/kg bw. This results in classification Acute Tox. 4; H302, oral: ATE = 890 mg/kg bw.

Dermal route

In an acute dermal toxicity study (OECD TG 402), New Zealand White rabbits (n = 5/sex/group) received a single dermal application (24 h) of 2000 mg PBS-1 (purity unknown)/kg bw. Clinical signs (e.g. diarrhoea, few faeces, yellow nasal discharge and anogenital soiling) were reported, which decreased in severity over time. Skin irritation (decreased in severity in recovery period) on day 1 post-treatment and distended intestines at necropsy were noted in 2/9 animals. One death (male) on day 13 post-treatment was noted, including abnormalities: gastrointestinal tract, spleen, liver and lung) were reported. An LD₅₀ of > 2000 mg/kg bw is derived based on this study.

LD₅₀ values of > 2000 mg/kg bw are reported for boric acid and borate salts (e.g. boric acid) and hydrogen peroxide.

Cases of poisoning in humans upon dermal contact to sodium per(oxo)borates are known, but none of these cases resulted in fatalities or required treatment.

Available data together demonstrate low acute dermal toxicity for PBS-1 and LD₅₀ values are > 2000 mg/kg bw. RAC agrees with the DS that classification of PBS-1 for acute dermal toxicity is not warranted.

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID, SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3]; SODIUM PERBORATE [4]

Inhalation route

There are no acute inhalation toxicity studies available for PBS-1. Read-across to PBS-4 can be applied based on one reliable acute inhalation toxicity study (similar to OECD TG 403) in rats. Sprague-Dawley rats (male, n=6/group) were exposed (nose-only) to 0.16, 0.48, 1.10 and 2.90 mg/L PBS-4 (aerosols; purity 98.6%; mass median aerodynamic diameter (MMAD) 3.3-4.2 µm) for 4 h, followed by a 14-day observation period. Clinical signs (red ocular, nasal or oral discharge, diarrhoea, gasping and lung noise), reduced body weight (≤ 18 %) and lethality were noted (24 h post-exposure: 0/6, 1/6, 3/6, 4/6; 8 days post-exposure: 1 death at highest dose). An LC₅₀ of 1.16 mg/L was derived from this study. The MMAD of PBS-4 in the high-dose group in the acute inhalation toxicity study is slightly above the range generally used for classification (CLP Guidance 3.1.2.3.2.). Nevertheless, these data are relevant for classification as signs of toxicity were noted in a lower dose group (at 1.10 mg/L) as well.

Another non-test guideline inhalation toxicity study is available for PBS-4 with major limitations (e.g. limited documentation on methods and results, no calculations available for the LC₅₀ value). This study is therefore not further considered.

LC₅₀ values of > 2 mg/L are derived for boric acid and borate salts based on animal studies on boric acid, disodium octaborate tetrahydrate and disodium tetraborate pentahydrate. In addition, multiple animal studies are described for hydrogen peroxide. However, in most studies no LC₅₀ values could be derived as no deaths or evident toxicity were observed. Inhalation of hydrogen peroxide leads to severe irritation and inflammation of the mucous membranes, coughing and dyspnoea. Hydrogen peroxide has a harmonised minimum classification as Acute Tox. 4*, H332.

No human data for sodium per(oxo)borates, boric acid, borate salts or hydrogen peroxide relevant for classification are available. Nasal secretions and irritation, and decreased nasal airway resistance in healthy volunteers were noted upon exposure to sodium tetraborate pentahydrate (dust; 0-40 mg/m³) or boric acid (0-10 mg/m³). No information on the acute inhalation toxicity of hydrogen peroxide in humans was found.

The DS anticipates a higher toxicity of PBS-1 compared to PBS-4 based on the hydrogen peroxide content. This is supported also by the difference in classification for acute oral toxicity i.e. Category 4 for PBS-1 and no classification for PBS-4. Although there is some uncertainty in the extrapolation from PBS-4 to PBS-1, RAC agrees with the DS to use the PBS-4 data. RAC derives an ATE of 0.75 mg/L, based on a calculation on molecular weight of the monomers²².

RAC agrees with the DS that the removal of the cut-off values for particle size is justified, as the MMAD of PBS-4 in the available acute inhalation toxicity study are relevant for classification.

²² Calculation based on molecular weight (monomer): MW PBS-1 vs. PBS-4 leads to $[100/154]*1.16 \text{ mg/L} = 0.75 \text{ mg/L}$.
The option of the DS: H₂O₂ content as stated in CLH report, PBS-1 32.1% and PBS-4 21.0 %. leads to $[21/32.1]*1.16 \text{ mg/L} = 0.75 \text{ mg/L}$

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID, SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3]; SODIUM PERBORATE [4]

To conclude, RAC supports the proposal for the removal of the asterisk indicating minimum classification and removal of the cut-off values for particle size distribution for PBS-1. The derived ATE of 0.75 mg/L falls within Category 3 (inhalation LC₅₀ (dusts or mists) > 0.5 but ≤ 1 mg/L). This results in harmonised classification on Acute Tox. 3; H331, inhalation ATE=0.75 mg/L (dusts or mists).

Overall conclusion

For PBS-1 the following classification is warranted:

- Acute Tox. 4; H302 with ATE= 890 mg/kg bw for the oral route,
- No classification for dermal route and
- Acute Tox. 3; H331 with ATE=0.75 mg/L (dusts or mists) for inhalation route.

10.4 Skin corrosion/irritation

Hazard class not assessed in this CLH-proposal.

10.5 Serious eye damage/eye irritation

Hazard class not assessed in this CLH-proposal.

10.6 Respiratory sensitisation

Hazard class not assessed in this CLH-proposal.

10.7 Skin sensitisation

Hazard class not assessed in this CLH-proposal.

10.8 Germ cell mutagenicity

Hazard class not assessed in this CLH-proposal.

10.9 Carcinogenicity

Hazard class not assessed in this CLH-proposal.

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID,
SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC
ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3];
SODIUM PERBORATE [4]

10.10 Reproductive toxicity

10.10.1 Adverse effects on sexual function and fertility

Table 17: Summary table of animal studies on adverse effects on sexual function and fertility

Method, guideline, deviations if any, species, strain, sex, no/group ²³	Test substance, dose levels, duration of exposure	Results	Reference
<i>Sodium perborate tetrahydrate (PBS-4)</i>			
<p>OECD TG 407 (Repeated dose 28-day oral toxicity study, OECD TG 1981), carried out according to GLP guidelines</p> <p>Rat (Wistar) male/female</p> <p>n = 5/sex/dose group</p> <p>Reliability: 1 (reliable without restriction)</p>	<p>Test material: sodium perborate tetrahydrate</p> <p>Purity: > 98%</p> <p><u>Limit test:</u> 0 and 1000 mg/kg bw/day (equivalent to 0 and 70 mg B/kg bw/day, respectively) in 1% aqueous tylose suspension</p> <p><u>Exposure:</u> 28 days, daily via oral gavage</p>	<p>Effects observed in males:</p> <p><u>Clinical signs:</u></p> <ul style="list-style-type: none"> - salivation after administration occurred in 5/5 males from day 7 of treatment - temporary piloerection in 2/5 males - one male showed stilted gait and sunken sides - no deaths were reported <p><u>Food consumption and body weight:</u></p> <ul style="list-style-type: none"> - stat. sign. reduction in food consumption by 15% (17.2 g vs. 20.2 g in controls) - stat. sign. (p<0.05) reduction in bw by 16% in the last week of treatment (216.1 g vs 258.4 g in controls) <p><u>Organ weights:</u></p> <ul style="list-style-type: none"> - stat. sign. (p<0.05) reduced: absolute brain weights by 9% (1.58 g vs 1.73 g in controls), absolute left kidney weight by 18% (0.80 g vs 0.97 g in controls), absolute heart weight by 17% (0.92 g vs 1.11 g in controls) - stat. sign. reduced absolute testes weight by 18% (left testis: 1.71 g vs. 2.09 g in controls; right testis: 1.74 g vs 2.11 g in controls) - no stat. sign. differences seen in the relative weights (to body weight) of the testes, brain, kidney or heart - stat. sign (p<0.05) increased relative adrenal weights by 33 – 37.5% (adrenal left: 0.012 g vs. 0.009 g in controls; adrenal right: 0.011 vs. 0.008 g in controls) <p><u>Pathological findings:</u></p> <ul style="list-style-type: none"> - testicular focal tubular atrophy in 3/5 male rats (2/5 in controls, no HCD provided) - inhibition of spermiation (stage IX and X tubules) in 5/5 male rats (2/5 controls, no HCD provided) - small spleen in 2/5 (0/5 in controls) and reduction of parenchyma in the spleen in 5/5 (0/5 in controls) - acanthosis/hyperkeratosis of the stomach in 4/5 males (0/5 in controls) and hyperplasia of fundic mucosa in 5/5 males (0/5 in controls) - acute brain hemorrhage in 1/5 males (2/5 in controls) 	<p>Study Report, 1989</p> <p>REACH registration (ECHA dissemination, [2020])</p> <p>See also Annex I to the CLH-report</p>

²³ Where applicable and unless stated otherwise, the reliability scores of the studies presented in Table 17 are according to the publicly disseminated REACH Registration dossier for EC no. 234-390-0, available at <https://echa.europa.eu/registration-dossier/-/registered-dossier/13523/7/9/2>

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID,
SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC
ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3];
SODIUM PERBORATE [4]

Method, guideline, deviations if any, species, strain, sex, no/group ²³	Test substance, dose levels, duration of exposure	Results	Reference										
		<p>- focal histiocytosis in the lungs in 3/5 males (3/5 in controls) and acute lung hemorrhage 2/5 males (1/5 in controls)</p> <p>Effects observed in females: <u>Clinical signs:</u> - salivation after administration in 4/5 females from day 8 of treatment and temporary piloerection in 1/5 females - no deaths were reported</p> <p><u>Food consumption and body weight:</u> - no stat. sign differences in food consumption (14.3 g vs. 14.6 g in controls) - no stat. sign. differences in body weights (167 g vs. 166.1 g in controls)</p> <p><u>Organ weights:</u> - stat. sign (p<0.05) increased relative liver weight by 10% (4.87 g vs 4.44 g in controls)</p> <p><u>Pathological findings:</u> - inflammation of the liver in 5/5 females - acanthosis/hyperkeratosis of the stomach in 4/5 females (1/5 in controls), hyperplasia of fundic mucosa in 4/5 females (0/5 in controls) and subacute gastritis in 1/5 females (0/5 in controls) - acute brain hemorrhage in 1/5 females (1/5 in controls) - focal histiocytosis in the lungs in 5/5 females (4/5 in controls)</p>											
<i>Boric acid and borates</i>													
<p>Two-year feeding study</p> <p>No guideline specified</p> <p>Rat (Sprague-Dawley) male/female</p> <p>n = 35/sex/dose group with 70/sex/dose group as controls</p>	<p>Test material: boric acid</p> <p>Purity: unknown</p> <p><u>Doses/conc.:</u> 0, 117, 350 and 1170 ppm boron, (eq. 0, 5.9, 17.5 and 58.5 mg B/kg bw/day, respectively)</p> <p><u>Exposure:</u> 24 months, daily in feed.</p>	<p>Testes atrophy was observed at 24 months, as shown below:</p> <table border="1"> <thead> <tr> <th>Dose level (mg B/kg bw/day)</th> <th>0</th> <th>5.9</th> <th>17.5</th> <th>58.5</th> </tr> </thead> <tbody> <tr> <td>No. of animals</td> <td>3/10</td> <td>1/10</td> <td>4/10</td> <td>10/10</td> </tr> </tbody> </table> <p>At 58.5 mg B/kg bw/day, seminiferous tubular degeneration and testicular atrophy were observed at 6, 12 and 24 months of treatment.</p> <p>LOAEL for fertility in rats = 58.5 mg B/kg bw/ day</p> <p>NOAEL for fertility in rats = 17.5 mg B/kg bw/day</p>	Dose level (mg B/kg bw/day)	0	5.9	17.5	58.5	No. of animals	3/10	1/10	4/10	10/10	<p>REACH registration (ECHA dissemination, [2020])</p> <p>Study Report, 1966</p> <p>Weir and Fisher, 1972</p> <p>Weir, 1996a²⁴</p>
Dose level (mg B/kg bw/day)	0	5.9	17.5	58.5									
No. of animals	3/10	1/10	4/10	10/10									
<p>Two-year feeding study</p>	<p>Test material: disodium</p>	<p>Testes atrophy was observed at 24 months, as shown below:</p>	<p>REACH registration</p>										

²⁴ As cited in the RAC Opinions on disodium octaborate anhydrate and disodium octaborate tetrahydrate (2014).

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID, SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3]; SODIUM PERBORATE [4]

Method, guideline, deviations if any, species, strain, sex, no/group ²³	Test substance, dose levels, duration of exposure	Results					Reference
		Dose level (mg B/kg bw/day)	0	5.9	17.5	58.5	
No guideline specified Rat (Sprague-Dawley) male/female n = 35/sex/dose group with 70/sex/dose group as controls	tetraborate tetrahydrate	No. of animals	3/10	1/10	4/10	10/10	(ECHA dissemination, [2020]) Study Report, 1967 Weir and Fisher, 1972 Weir, 1996b ²⁵
	Purity: unknown Doses/conc.: 0, 1030, 3080 and 10300 ppm boron (eq. to 0, 5.9, 17.5 and 58.5 mg B/kg bw/day, respectively) Exposure: 24 months, daily in feed.	LOAEL for fertility in rats = 58.5 mg B/kg bw/ day NOAEL for fertility in rats = 17.5 mg B/kg bw/day					

Table 18: Summary table of human data on adverse effects on sexual function and fertility

Type of data/report	Test substance	Relevant information about the study (as applicable)	Observations	Reference
No data on the effects of per(oxo)borates on human sexual function and fertility were available				

Table 19: Summary table of other studies relevant for toxicity on sexual function and fertility

Type of study/data	Test substance	Relevant information about the study (as applicable)	Observations	Reference
No other studies with per(oxo)borates relevant for investigating sexual function and fertility were available				

10.10.2 Short summary and overall relevance of the provided information on adverse effects on sexual function and fertility

10.10.2.1 Read-across data on PBS-4 from animal studies

In a 28-day limit test (OECD TG 407, 1989), male and female rats (5/sex/dose) were administered sodium perborate tetrahydrate (PBS-4) via oral gavage at 0 and 1000 mg/kg bw/day (equivalent to 0 and 70 mg B/kg bw/day, respectively). According to OECD TG 407, a limit test should be performed if, from assessment of other data, no effects would be expected at a dose of 1000 mg/kg bw/day. A dose-range finding study was performed with 1000 mg/kg bw/day for 23 days. Salivation and reddening of the glandular stomach were seen. According to these findings, the dose level of 1000 mg/kg bw/day was selected for the 28-day repeated dose limit toxicity study.

²⁵ As cited in the RAC Opinions on disodium octaborate anhydrate and disodium octaborate tetrahydrate (2014).

**ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID,
SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC
ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3];
SODIUM PERBORATE [4]**

In the limit test, a 18% stat. sign. decrease in absolute testes weight was reported, while the relative testes weights were not stat. sign. reduced (7.98 g vs 8.09 g in controls). Testicular focal tubular atrophy and inhibition of spermiation was seen in 3/5 and 5/5 rats, respectively, with a high incidence recorded in control rats (2/5 for both effects). The study author considered these effects as spontaneous findings in Wistar rats and therefore not related to treatment, although HCD were not provided. Histological examinations of the testes did not reveal any signs of toxicity. However, testes were fixed with formalin, a method that leads to cellular shrinkage and only allows the detection of major effects. Using more sensitive methods of histopathology, i.e. perfusion with glutaraldehyde/paraformaldehyde and embedding with methacrylate, revealed more subtle effects with boric acid and borate salts (Ku et al. 1993; Treinen and Chapin, 1991).

A statistically significant ($p < 0.05$) reduction in food consumption (by 15%) and body weight (by 16%) were seen in male rats while the food consumption and body weight of female rats were not affected. Statistically significant reduced absolute weights of brain, kidney and heart were reduced by 9%, 18% and 17%, respectively.

Effects such as acanthosis/hyperkeratosis of the stomach and hyperplasia of the fundic mucosa were reported for both male and female rats. Small spleen and reduction of parenchyma in the spleen were seen only in males. Lung effects (acute hemorrhage and focal histiocytosis) and acute brain hemorrhage were reported in both males and females.

As detailed in the EU RAR (2007), the results of the limit test were discussed at the Specialised Experts (SE) meeting²⁶ in October 2004, where it was debated if the reduction in absolute testes weight was a consequence of reduction in body weight gain or a treatment-related effect. The general influence of food uptake and restriction on the weight development of rats based on studies with the same exposure time was taken into account (see Table 20). For comparison, in a study with boric acid, a reduction in body weight gain and absolute testes weight was reported, while no information on relative testes weight was available (Ku et al. 1993). In a study that investigated the effects of food restriction on common toxicity parameters in male rats, the relative testes weights increased, with a 3% reduction in the absolute weight of the testes (Oishi et al. 1979). However, the study performed by Feron et al. (1973) showed reduced relative and absolute testes weight as a consequence of cellulose-rich diet used to prevent the rats from starving.

Table 20: Influence of body weight gain on absolute and relative testes weights (as detailed in the EU RAR, 2007)

	Study Report, 1989	Ku et al. 1993	Oishi et al. 1979	Feron et al. 1973
Species (Strain)	Rat (Wistar)	Rat (F344)	Rat (Wistar)	Rat (Wistar)
Treatment	PBS-4	Boric acid	Food restriction	Increased cellulose in diet (45-70%)
Dose	1000 mg/kg bw (eq. to 70 mg B/kg bw)	9000 ppm (in diet) (eq. to 68 mg B/kg bw)	-	-
Duration of treatment	28 days	30 days (60 and 90 days)	28 days	28 days (and 91 days)

²⁶ The Specialised Experts meeting was previous to the TC C&L meetings (March and November 2005; March 2006) where the classification proposals for perboric acid, sodium salt monohydrate and perboric acid, sodium salt tetrahydrate were discussed and adopted.

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID,
SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC
ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3];
SODIUM PERBORATE [4]

	Study Report, 1989	Ku et al. 1993	Oishi et al. 1979	Feron et al. 1973
Food intake	↓ 15%	↓ 11%	↓ 25 - 30%	-
Reduction in bw gain	15%	16%	approx. 30%	22%
Relative testes weight compared to controls	unchanged	not given	↑ 31%	↓ 13%
Absolute testes weights compared to controls	↓ 18%	↓ approx. 20%	↓ 3%	↓ 25%

The Specialised Experts concluded that the decrease in absolute testes weights seen in the 28-day study with PBS-4 is likely treatment-related, as there is a common view that that brain and testes weights are generally not affected by a reduction in body weight. However, it should be noted that the study also showed stat. sign. reduced brain, heart and kidney weights. Finally, it was stated at the Specialised Experts meeting that reduced testes weights as early signs of testicular toxicity cannot be dismissed in view of the known testicular toxicity of the boric acid and borate salts.

As stated in the Background (section 0 of this CLH-report), the Specialised Experts concluded that the findings of the 28-day repeated dose toxicity study alone are limited and insufficient for the purpose of classification, and that the data on boric acid and borates have to be taken into consideration for read-across. Thus, the classification of sodium per(oxo)borates was based on read-across from boric acid/borates. However, it is not clear to the dossier submitter why the resulting classification of per(oxo)borates was Repr, 2; H361f and not category 1B similar to boric acid. In the current CLH-proposal of PBS-1 the assessment of adverse effects on sexual function and fertility is based on read-across of data from studies of oral exposure to boric acid and borate salts and data from the 28-day repeated dose toxicity study of PBS-4 is considered as supporting evidence in a weight of evidence assessment.

10.10.2.2 Read-across data on boric acid and borate salts from animal studies

The studies with boric acid and borate salts presented in Table 17 above have already been assessed and appointed key studies by the Committee for Risk Assessment (RAC) in 2014 (RAC opinion on boric acid, disodium octaborate anhydrate and disodium octaborate tetrahydrate). It was concluded by RAC that repeated dose toxicity studies and studies investigating reproductive toxicity performed with boric acid and borate salts in several species (mice, rats and dogs) clearly indicated that boron affects the testes, thus impairing fertility. There was no evidence that impaired fertility was secondary to other toxic effects.

Based on the results of a 2-year feeding study performed with boric acid in rats (Study Report, 1966) and supported by a similar study with disodium tetraborate decahydrate (Study Report, 1967), the NOAEL for effects on fertility is 17.5 mg B/kg bw/day, while the LOAEL is 58.5 mg B/kg bw/day.

10.10.2.3 Comparison with data on hydrogen peroxide from animal studies

Available studies on reproductive toxicity of hydrogen peroxide are only described for comparison and to support the read-across hypothesis that it is boric acid that is responsible for the reproductive toxicity and that hydrogen peroxide, also being a degradation product of sodium per(oxo)borates, is not expected to contribute to reproductive toxicity. No guideline studies were available for a complete evaluation of reproductive toxicity of hydrogen peroxide and the available studies do not show any clear effects on sexual function and fertility. However, it is noted (and as also highlighted in the EU RAR of hydrogen peroxide

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID,
SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC
ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3];
SODIUM PERBORATE [4]

(2003)), that the results of the presented studies cannot be considered as conclusive due to their various study design limitations (lack of control groups, low sample size) and very limited reporting. Nevertheless, hydrogen peroxide administration is expected to firstly cause local effects, nutritional disturbances and general toxicity in the tested animals (EU RAR, 2003).

Wales et al. (1959) administered 0.33, 1 or 3% H₂O₂ in drinking water to three groups of 12 male albino mice; the solutions were changed twice weekly. The mice from the high dose group refused to drink and after 5 days were removed from the experiment having lost about 20% of their body weight. The remaining two groups were each divided randomly into four subgroups of 3 animals: (1) two female mice were placed with each male of the subgroup on day 7 and again (with two other females) on day 28 of treatment; (2) and (3) two subgroups of males were placed with females on day 21: the animals in one of the groups continued on hydrogen peroxide, for the other group hydrogen peroxide was replaced with tap water (ensuring no consumption of hydrogen peroxide by the females); (4) the three male mice were killed on day 21 and the epididymal spermatozoa were examined. All female mice mated to treated males became pregnant within a few days and in each case healthy offspring were born in litters of normal size (data not shown). Pregnant mice that continued to consume 1% H₂O₂ in water up until near term showed a delay in parturition compared to dams using tap water (not clear if stat. sign.). No effects were seen on the concentration, morphology and motility of the mouse spermatozoa from the three mice in subgroup 4.

Similarly, three male albino rabbits were administered 0.33, 1 or 3% H₂O₂ in drinking water for 6 weeks, their semen being assessed at weekly intervals. No anomalies were detected in the collected sperm samples. Within the same study, Wales et al. (1959) also demonstrated in an *in vitro* experiment that rabbit semen was more resistant to exogenous hydrogen peroxide (the spermatozoa were not completely immobilised at 3000 ppm H₂O₂) than semen from bull, fowl, dog, ram, mouse and human. Rabbit seminal plasma had a particularly high capacity to decompose hydrogen peroxide, presumably due to a higher catalase content.

In a study conducted by Hankin (1958), three weanling Osborne-Mendel female rats were administered 0.45% H₂O₂ in drinking water for 5 months. After cessation of treatment, they were given tap-water and mated with untreated males. The author reported that normal litters were produced and that long-term treatment with hydrogen peroxide did not have an effect on reproduction in female rats. Six untreated male litter mates were divided in two groups, one receiving 0.45% H₂O₂ and the others tap water, for 9 months. A decrease in average body weight for the male rats administered H₂O₂ (411 g) as compared to the ones on tap water (521 g), was observed. Within 2 weeks after the cessation of treatment, the treated male rats began to gain weight.

A short description of an experimental study investigating the reproductive effects of hydrogen peroxide is enclosed in the EU RAR of hydrogen peroxide (2003). Male and female rats were administered hydrogen peroxide daily by gavage at doses of 1/10-1/5 LD₅₀ (not specified) for 45 days (Antonova et al., 1974; as cited in the EU RAR, 2003). Females from the high dose group showed modifications of the oestrus cycle, while high dose group males showed reduced mobility of spermatozoa (not clear if stat. sign. different than controls), without an effect on the testis weight. In another experiment (not clear if performed by the same authors) male and female rats received daily doses of 0.005, 0.05, 0.5, 5, or 50 mg H₂O₂/kg bw by gavage for 6 months and were mated afterwards. Variations of the oestrus cycle in females were observed during treatment at 0.50 and 50 mg/kg bw. Reduced mobility of spermatozoa in males was observed at 50 mg/kg. No changes were found in the morphology and weight of the testes. Among the high dose females, 3/9 produced litters, compared to 7/9 in the control group. In addition, litter size and bodyweight gain of the offspring of the high dose females were reduced as compared to controls (not clear if stat. sign.). Due to inadequate reporting, the study findings cannot be assessed.

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID, SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3]; SODIUM PERBORATE [4]

10.10.2.4 Read-across from human data on boron compounds

No human data for the assessment of adverse effects of per(oxo)borates on sexual function and fertility were available.

Epidemiological studies investigating the effects of environmental and occupational boron exposure are available in the open literature. The studies published until March 2014 on the potential effects of boron on fertility were discussed in the RAC opinions on boric acid, disodium octaborate anhydrate and disodium octaborate tetrahydrate. The data consist of epidemiological studies of males exposed to B environmentally and/or occupationally. The RAC concluded that the human studies show no clear evidence of adverse effects on male fertility by B. The exposure to B in these studies were well below the LOAELs for fertility reported from studies in animals. RAC pointed out that these epidemiologically studies had several study design limitations and should therefore be regarded as additional information.

Several studies have been published since March 2014, mainly investigating the occupational exposure to boron. In 2018, Duydu et al. (2018a) published a cross-sectional study evaluating the hormone levels and sperm parameters in male workers occupationally exposed to boron in Turkey. The authors found no association between blood B levels and semen parameters or hormone levels (FSH, LH, FSH). The mean blood B level in the extreme exposure group was 0.57 µg/g. An earlier study by the same research group was also negative at a lower maximum exposure level (Duydu et al. 2011). For comparison, Ku et al. (1993) reported mildly inhibited spermiation in a group of rats administered boric acid with mean serum boron level of 6.7 µg/g. The study performed by Duydu et al. (2018a) has been assessed by RAC in the Opinion on barium diboron tetraoxide (2020), where it was concluded that even if the epidemiological data show no clear effects on fertility and sexual function, they are not considered to contradict the effects seen in animal studies. Moreover, there is no evidence that the effects observed in animals are not relevant to humans.

Investigation of Y:X sperm ratio in occupationally exposed workers (Yalcin et al. 2019; Duydu et al. 2019; Robbins et al. 2008)

A recent study assessing the association between boron exposure and Y:X chromosome ratio in men occupationally exposed in a boric acid production zone in Turkey was published (Yalcin et al. 2019). The aim of this study was to either refute or confirm the inverse association between the high level of boron exposure and the decrease in Y:X sperm ratio in men from China, in a similar study conducted by Robbins et al. (2008). The semen samples assessed for the purpose of this recent study were obtained within the scope of an earlier project ("Boron Project – I"; 2008 – 2010) and cryopreserved in liquid nitrogen. The total number of remaining samples was 163, out of which 86 were from workers assigned to the exposed group (i.e. working in the boric acid production facilities) and 77 from workers assigned to the control group (i.e. working in the steam power plant, energy supply unit, demineralised water plant, mechanical workshop etc.). The biological samples were analysed for B content through inductively coupled plasma mass spectrometry, while the Y:X sperm ratio was determined using fluorescence *in situ* hybridisation (FISH).

The mean blood boron concentrations of the exposed workers were stat. sign. higher than the controls (141.55 ± 80.43 vs. 63.56 ± 43.89 ng B/g blood, respectively; p<0.05). Similarly, the semen B levels of the exposed workers were stat. sign. higher than of the control group (1703.42 ± 1895.09 vs. 1127.78 ± 1713.96 ng B/g semen, respectively; p<0.05). These stat. sign. increases in both semen and blood B levels were brought forward by Yalcin and colleagues as an argument to support the high level of daily B exposure (DBE) for the workers assigned in the exposure group. However, no DBE levels for the 86 exposed workers were provided in the study. In the previous work, the exposed group was divided into low, medium and high exposure groups with DBE levels of 7.39 ± 3.97, 11.02 ± 4.61 and 14.45 ± 6.57 mg B/day, respectively (Duydu et al. 2011). Regarding the blood B levels of controls, it should be noted that the previous studies report levels below the limit of quantification (LOQ), i.e. 48.5 ng B/g blood (Duydu et al. 2011), whereas the blood B levels for the control group reported by Yalcin et al. (2019) are above the LOQ, i.e. 63.56 ± 43.89 ng B/g blood (see Table 21 below). The DBE levels seem to correlate with the blood B levels for both controls and exposed Turkish and Chinese workers. However, the blood B levels for controls and exposed

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID, SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3]; SODIUM PERBORATE [4]

groups seem to lead to significantly higher semen B concentrations in the Turkish workers, as compared to blood B levels of the Chinese workers that present approx. 3-fold increased levels (141.55 ± 80.43 vs. 515.4 ± 805.7 ng B/g blood for the exposed Turkish and Chinese workers, respectively; Table 21).

Yalcin and colleagues did not find a stat. sign. correlation (Pearson, $p > 0.05$) between blood/semen B levels and Y:X sperm ratio in workers assigned to the exposed group, and no shift towards female babies at birth was observed (see Table 21). It was thus concluded by the authors that the presented results refute the positive association between high B exposure levels and decreased Y:X sperm ratios, as reported by Robbins et al. (2008).

However, the study conducted by Yalcin et al. (2019) presents several limitations which might have influenced the results. Firstly, even if the workers constituting the control group were not selected from boric acid and borate salts production areas, they were still exposed to B through drinking water from the central cafeteria and/or infirmary of the plant. The high B contamination (9.47 ± 0.18 mg B/L) of these water sources was not anticipated in the planning phase of the study and thus, this “background” exposure led to relatively high exposure of the control group. This is also reflected by the fact that the DBE levels for the Turkish control group were twice as high as for the Chinese control group that was not environmentally exposed (4.68 ± 1.63 vs. 2.3 ± 3.0 mg B/day; Table 25). Secondly, the exposure levels for the workers in the high exposure group were lower than the NOAEL set for male rat fertility. Assuming an average body weight of 70 kg, the high exposure group DBE levels can be converted to 0.2 ± 0.09 mg B/kg bw/day which is considerably lower than the NOAEL of 17.5 mg B/kg bw/day set for male rats.

Table 21: Characteristics of male workers assigned to the control and exposed groups

Number of participants	Mean age \pm SD (years)	Mean duration of employment \pm SD (years)	Mean total daily B exposure \pm SD (mg B/day)	Mean blood B level \pm SD (ng B/g blood)	Mean semen B level \pm SD (ng B/g semen)	Mean Y:X sperm ratio \pm SD (FISH)	Boys at birth (%)
Robbins et al. 2008 (China)							
n = 44 (controls)	31.3 ± 5.4	-	2.3 ± 3.0	45.5 ± 22.5	203.9 ± 105.7	0.99 ± 0.03	76.7
n = 39 (environmentally exposed)	30.0 ± 6.1	-	4.3 ± 3.1	109.11 ± 111.2	297.3 ± 273.0	$0.96^* \pm 0.04$	42.3
n = 63 (occupationally exposed)	31.2 ± 4.4	-	41.2 ± 37.4	515.4 ± 805.7	806.0 ± 612.6	$0.93^* \pm 0.03$	57.7
Yalcin et al. 2019 (Turkey)							
n = 77 (controls, however, environmentally exposed)	42.86 ± 5.06	18.02 ± 6.58	4.68 ± 1.63 [#]	63.56 ± 43.89	1127.78 ± 1713.96	0.99 ± 0.03	48.5
n = 86 (occupationally and environmentally exposed)	42.45 ± 4.61	15.76 ± 7.16	$7.39 \pm 3.97 - 14.45 \pm 6.57$ [#]	141.55 ± 80.43	1703.42 ± 1895.09	0.99 ± 0.02	54

FISH = Fluorescence in situ Hybridisation

* statistically significantly different from controls ($p < 0.05$)

[#] the mean DBE levels were calculated and reported by the same authors in a previous publication (Duydu et al. 2011), where the group of exposed workers was further divided into low (DBE = 7.39 ± 3.97 mg B/day; n = 72), medium (DBE = 11.02 ± 4.61 ; n = 44) and high (DBE = 14.45 ± 6.57 ; n = 39) exposure groups.

**ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID,
SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC
ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3];
SODIUM PERBORATE [4]**

Duydu et al. (2019) further investigated the Y:X chromosome sperm ratio in B-exposed workers from two boron mining facilities located in Bandirma and Bigadic, Turkey. Similarly, the semen samples assessed for the purpose of this study were obtained within the scope of earlier projects, i.e. “Boron Project – I” (2008 – 2010), “Boron project – II” (2014 – 2017), and cryopreserved in liquid nitrogen. A total of 304 biological samples (i.e. blood, semen and urine) were collected and analysed for B content and Y:X sperm ratio using mass spectrometry and FISH, respectively. Based on the blood B content, the workers were assigned into 5 different groups: controls (< 50 ng B/g blood), low exposure (> 50 – 100 ng B/g blood), medium exposure (> 100 – 150 ng B/g blood), high exposure (> 150 – 400 ng B/g blood) and extreme exposure groups (> 400 ng B/g blood) (see Table 22). The measured B semen levels were 36, 21, 12.4, 5.1 and 3 times higher than the blood B levels of the controls, low, medium, high and extreme exposure groups, respectively, which indicates that the male reproductive organs represent an accumulation site for B. Overall, the authors did not find a stat. sign. ($p > 0.05$) association between B exposure and Y:X sperm ratios, the mean Y:X sperm ratios of the different exposure groups were not stat. sign. different in pairwise comparisons ($p > 0.05$), and no B-associated shift in sex ratios at birth towards female offspring was seen. A negative association ($p < 0.05$) between reported pesticide application (information gathered through questionnaires) and Y:X sperm ratio for the total study group was seen.

However, the study presents several limitations that might have impacted the reported results. The different exposure groups were assigned based on blood B concentrations instead of DBE. This is reflected by the very high semen B levels measured in the workers assigned to the control group. The highest individual semen B value attributed to the control group exceeds the highest measured individual value from the extreme exposure group, i.e. 8597 vs. 8086 ng B/g semen, respectively. In addition, the control group was environmentally exposed to B through drinking water. It is important to note the mean semen B levels show a very large variation (e.g. 1598.46 ± 2027.85 ng B/g semen), including in the control group (i.e. 1077.11 ± 1845.34 ng B/g semen), therefore adding an extra layer of difficulty for identifying potential effects. Moreover, based on an average body weight of 70 kg, the extreme DBE values calculated by this study will be 0.64 ± 0.26 mg B/kg bw/day, and the maximum individual DBE (i.e. 106.8 mg B/day) will be converted to 1.52 mg B/kg bw/day. As also indicated above, these values are considerably lower than the LOAEL for fertility in male rats (58.5 mg B/kg bw/day) and the NOAEL for rat fertility (i.e. 17.5 mg B/kg bw/day), set by the RAC (Opinion on boric acid, 2014).

Table 22: Boron concentrations in biological fluids, DBE and other characteristics of male workers assigned to the control and exposed groups of workers

Number of participants	Mean age \pm SD (years)	Mean duration of employment \pm SD (years)	Mean total daily B exposure (DBE) \pm SD (mg B/day)	Mean blood B level \pm SD (ng B/g blood)	Mean semen B level \pm SD (ng B/g semen)	Mean Y:X sperm ratio \pm SD (FISH)	Boys at birth (%)
Duydu et al. 2019 (Turkey)							
n = 38 (controls, environmentally exposed)	42.89 \pm 5.32 (26 – 48)	18.20 \pm 6.49 (2 – 26)	4.57 \pm 1.69 (0.20 – 7.54)	30.00 \pm 10.12 (16.23 – 49.23)	1077.11 \pm 1845.34 (52 – 8597)	0.98 \pm 0.03 (0.85 – 1.02)	53.73
n = 60 (low exposure)	41.50 \pm 6.05 (23 – 49)	15.79 \pm 7.47 (0.17 – 23)	8.32 \pm 5.71 (2.56 – 35.61)	76.00 \pm 15.22 (50.17 – 99.91)	1598.46 \pm 2027.85 (111 – 8615)	0.99 \pm 0.02 (0.89 – 1.04)	45.95
n = 50 (medium exposure)	40.22 \pm 6.09 (27 – 48)	15.74 \pm 7.51 (1 – 25)	14.81 \pm 9.99 (2.56 – 47.18)	122.88 \pm 15.34 (101.28 – 149.84)	1526.93 \pm 1265.36 (189 – 4897)	0.99 \pm 0.02 (0.94 – 1.09)	52.94

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID,
SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC
ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3];
SODIUM PERBORATE [4]

Number of participants	Mean age ± SD (years)	Mean duration of employment ± SD (years)	Mean total daily B exposure (DBE) ± SD (mg B/day)	Mean blood B level ± SD (ng B/g blood)	Mean semen B level ± SD (ng B/g semen)	Mean Y:X sperm ratio ± SD (FISH)	Boys at birth (%)
n = 87 (high exposure)	37.26 ± 7.46 (22 – 53)	9.15 ± 6.42 (0.5 – 23)	23.50 ± 13.94 (3.32 – 55.10)	247.37 ± 71.32 (150.99 – 391.92)	1259.65 ± 1446.11 (100 – 10542)	0.99 ± 0.02 (0.86 – 1.03)	55.63
n = 69 (extreme exposure)	36.61 ± 6.68 (23 – 50)	6.65 ± 4.84 (1 – 26)	44.91 ± 18.32 (7.95 – 106.79)	553.83 ± 149.52 (401.62 – 1099.93)	1643.23 ± 965.44 (188 – 8086)	0.99 ± 0.02 (0.95 – 1.06)	53.57

FISH = Fluorescence in situ Hybridisation

Other studies (Basaran et al. 2019; Bolt et al. 2020)

The DNA damage in lymphocytes, sperm and buccal cells of occupationally (n = 102), occupationally and environmentally (n = 110) exposed male workers from Bandirma and Bigadic, respectively, was analysed through comet and micronucleus assays (Basaran et al. 2019). The biological samples were obtained within the scope of “Boron project – II” (2014 – 2017). As also reported above, based on their blood B levels, the 212 participants were assigned into 5 different exposure groups: very low exposure (< 100 ng B/g blood), low exposure (101 – 150 ng B/g blood), medium exposure (151 – 450 ng B/g blood), high exposure (451 – 650 ng B/g blood) and overexposure groups (> 651 ng B/g blood) (see Table 23 below). The DBE and blood B levels corresponding to the 5 different exposure groups were not given in this article. Demographic information as well as information on potential confounders (alcohol, smoking, pesticide exposure) was gathered through a questionnaire. However, it was not further detailed if these potential confounders may have affected the study results. No stat. sign. increases in DNA damage in blood, sperm and buccal cells were observed between the B-exposed groups. No stat. sign. differences were found for neither alkaline nor neutral comet assay in the sperm cells. No correlations were seen between the measured blood B levels of the 5 different groups and tail intensity values of the sperm samples, lymphocyte samples, frequencies of micronucleus (MN), binucleated (BN), condensed chromatin (CC), karyorrhectic (KHC), karyolytic (KYL), pyknotic (PYC) and nuclear bud (NBUD) cells. Based upon these results, the authors concluded that extreme occupational exposure to B (i.e. > 651 ng b/g blood) does not induce DNA damage in lymphocytes, sperm or buccal cells. These results are in line with those reported previously by the same authors (Duydu et al. 2012; Basaran et al. 2012) and indicate that no statistically significantly increases in DNA-damage or changes on semen parameters were found in the B-exposed Turkish workers.

As also stated in the RAC Opinion on boric acid (2014), the Turkish studies were initially set up based on the assumption that different occupational categories would give groups with quantitatively different exposure to B. However, high B concentrations in drinking water resulted in high exposure also in the controls (without occupational exposure). Therefore, participants were grouped according to blood concentrations of B rather than based on occupational exposure, and it is not clear how well these groups were matched. Moreover, the group sizes for the very low, low and overexposure groups were limited (i.e. n = 12, 17 and 25, respectively), thus leading to low statistical power.

Table 23: Comet assay results in sperm samples, lymphocytes and buccal cells according to the different exposure groups

**ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID,
SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC
ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3];
SODIUM PERBORATE [4]**

Number of participants	Mean tail intensity ± SD in sperm (alkaline comet assay) (%)	Mean tail intensity ± SD in sperm (neutral comet assay) (%)	Mean tail intensity ± SD in lymphocytes (comet assay) (%)	Mean micronucleus frequencies in buccal cells ± SD (micronucleus assay)					
Basaran et al. 2019 (Turkey)									
n = 12 (very low exposure)	5.37 ± 1.63 (3.1 – 8.42)	6.31 ± 1.16 (5.13 – 8.49)	6.0 ± 2.69 (2.82 – 11.95)	3.54 ± 2.73* (1 – 9)					
n = 17 (low exposure)	5.61 ± 1.2 (3.97 – 8.96)	6.09 ± 1.1 (4.22 – 7.81)	7.79 ± 5.18 (1.85 – 24.5)	5.13 ± 4.69 (0 – 19)					
n = 108 (medium exposure)	6.03 ± 4.83 (2.6 – 49.71)	6.23 ± 1.36 (3.95 – 13.68)	7.5 ± 5.34 (1.64 – 27.47)	4.32 ± 3.82 (0 – 19)					
n = 50 (high exposure)	5.55 ± 1.88 (2.81 – 13.73)	6.16 ± 1.26 (4.12 – 9.66)	8.7 ± 7.94 (1.38 – 36.0)	4.56 ± 3.61 (0 – 16)					
n = 25 (extreme exposure)	5.36 ± 1.88 (3.04 – 12.32)	5.71 ± 0.97 (4.24 – 8.4)	5.04 ± 2.26 (0.65 – 10.08)	4.06 ± 2.93* (0 – 10)					
Correlations of blood B levels and genotoxicity parameters									
Correlations between blood B level and:	Sperm DNA damage	Lymphocyte DNA damage	MN	BN	CC	KHC	KYL	PYC	NBUD
Pearson correlations	0.028	-0.024	0.023	-0.052	-0.156*	0.047	-0.045	0.058	0.023

*Statistically significant difference between groups (p<0.05); MN – micronucleus; BN – binucleated; CC – condensed chromatin; KHC – karyorrhectic; KYL – karyolytic; PYC – pyknotic; NBUD – nuclear bud.

A review paper on the effects of boron compounds on human reproduction was recently published (Bolt et al. 2020). The results of several reproductive toxicity studies in humans from Argentina, China and Turkey are detailed, discussed and the measured DBE levels are compared to the NOAELs for fertility and developmental toxicity established in rats (see Table 24 below). Based on these previously published epidemiological studies, Bolt and colleagues state that, compared to the B blood levels at the boron-related NOAELs for male fertility and for developmental toxicity in rats, the blood level means of the highest occupational exposure groups in China and in Turkey are lower by factors of > 4 and > 2, respectively. Part of the persons in the highest B exposure groups in China and in Turkey reach or exceed the experimental B blood levels at the NOAEL for developmental toxicity in rats. Part of the persons in the highest B exposure group in China reach or exceed the experimental B blood levels at the NOAEL for impaired male rat fertility. In this sense, the highest individual blood B level recorded from occupationally exposed workers from China is 3568.9 ng B/g blood, corresponding to a maximum individual DBE of 470 mg B/ day. The latter would thus correspond to a value of 6.7 mg B/kg bw/day if a 70 kg average body weight is assumed, that is considerably lower than the NOAEL for rat fertility of 17.5 mg B/kg bw/day. Moreover, the study conducted by Robbins et al. (2010) presents a series of limitations, such as the influence of different lifestyle factors, co-exposure to other minerals in relatively high concentrations (e.g. Mg) and fertility being assessed through questionnaires/interviews.

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID,
SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC
ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3];
SODIUM PERBORATE [4]

Table 24: Human and experimental exposure to boric acid/borate salts and associated blood boron levels²⁷

Human studies	Estimated DBE (mg/day)	Blood B levels (ng B/ g blood)
Bolt et al. 2020 (review)		
Turkey, ENV - High dose group I (Sayli et al. 1998; Korkmaz et al. 2007)	6.8 (1.8 – 2.3)	-
Argentina, ENV - Total cohort of mothers (Igra et al. 2016)	-	130* (0.73 – 610)*
Turkey, ENV + OCCUP - High exposure group (Tuccar et al. 1998)	14.5 (3.3 – 36)	220 (150 – 450)
Turkey, ENV - High exposure group (women) (Duydu et al. 2018b)	25 (10 – 58)	280 (152 – 980)
USA, OCCUP - High dust exposure group (Culver et al. 1994)	58	260 (up to max. 330)
China, OCCUP - High exposure group (Robbins et al. 2010; Scialli et al. 2010 - review)	37 (2.3 – 470)	500 (20 – 3600)
Turkey, OCCUP - Extreme exposure group (Duydu et al. 2019)	45 (8.0 – 200)	550 (400 – 2000)
NOAEL for male rat fertility (mg/kg bw/day) (Weir et al. 1972)	17.5	2300#
NOAEL for developmental toxicity in rats (mg/kg bw/day) (Price et al. 1996)	9.6	1270

ENV = environmental exposure, OCCUP = occupational exposure;
*Assuming equal distribution of B between serum and blood cells;
#Calculated by Bolt et al. (2020)

Furthermore, Bolt and colleagues state that human B exposures, even in the highest exposed cohorts, are still too low to reach the blood concentrations in order to exert toxic effects on reproduction. Thus, under the most extreme occupational exposure reported, concentrations of B within the human body that are reprotoxic cannot be reached. The authors conclude that based on these epidemiological data, the current categorisation of inorganic boron compounds should be reconsidered.

However, it should be kept in mind that no studies on effects on fertility and sexual function in humans are available at exposure and/or blood B levels corresponding to the animal LOAELs. Assuming a blood density of 1060 kg/m³ and taking into account the uncertainty factors for inter-species and intra-human variability (EFSA 2012), the LOAEL of 58.5 mg B/kg bw/day set for rat fertility would correspond to approx. 7360 ng B/g blood in humans; the highest individual blood B level recorded in human samples was 3568.9 ng B/g blood (Robbins et al. 2010). Furthermore, there are no available data indicating that boron toxicokinetics from animals would not be relevant for humans. Finally, the available epidemiological studies showing no effects on fertility and semen parameters, FSH, LH and testosterone levels at DBE levels that were

²⁷ The experimental studies and some of the epidemiological studies presented in this table were included in the CLH-report for boric acid (2013) and have already been assessed by RAC (RAC Opinion on boric acid, 2014).

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID,
SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC
ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3];
SODIUM PERBORATE [4]

substantially below the LOAELs and even NOAELs from corresponding animal studies, do not contradict the experimental data showing clear effects of impaired fertility in male rats.

Conclusion on human data

The available epidemiological studies did not show clear boron-induced adverse effects on sexual function and fertility. As described above, the studies had several methodological limitations and were designed to mostly investigate male fertility. Other limitations are generally small sample sizes and/or decreased participation rates. It should also be noted that the estimated human exposure levels (DBE) of the high, extreme and overexposure groups in these studies were considerably lower than the NOAELs and LOAELs reported for rat fertility. No studies on effects on fertility and sexual function in humans are available at DBE levels corresponding to the animal LOAELs.

Hence, as was also highlighted by the RAC (Opinions on boric acid (2014), disodium octaborate anhydrate (2014) and disodium octaborate tetraborate (2014)) it is concluded that the available human data on fertility and sexual function do not contradict the animal data. The human data are therefore considered as additional information.

Overall, the available human data do not contradict the experimental data seen across several species (mice, rats and dogs) and give no evidence to support that the effects seen in animals are not relevant for humans.

10.10.3 Comparison with the CLP criteria

PBS-1 has a harmonised classification as Repr. 2; H361f. **A change to the classification is proposed.**

No guideline reproductive toxicity study with PBS-1 was available for the assessment of adverse effects on sexual function and fertility. The 28-day limit test (OECD TG 407; Study report, 1989) performed with PBS-4 in rats showed effects such as decreased absolute testes weight, testicular focal tubular atrophy and inhibition of spermiation at the only administered dose of 1000 mg/kg bw/day (eq. to 70 mg B/kg bw/day), in the absence of any histological signs of toxicity. However, it has to be noted that these effects were seen in the presence of general toxicity (stat. sign. reduced body weight and food consumption) in the exposed group and that the method used for histological examination (fixation of tissues with formalin) led to cellular shrinkage, thus only allowing for the detection of major effects. Due to study design limitations (e.g. only one dose level, few animals) and poor reporting, this study alone is considered insufficient for the purpose of classification. As the common view that per(oxo)borates are expected to have the same effects as boric acid was already expressed in 2005 at the TC C&L meeting (ECBI/60/05 Rev. 3), data from studies of oral exposure to boric acid and borate salts are therefore read-across in order to support the assessment of sexual function and fertility of per(oxo)borates. Their toxicokinetic and toxicological properties after oral exposure are expected to be similar to those of boric acid and borates, on a B-equivalents basis.

The studies performed with boric acid and borate salts have been previously assessed by the RAC (RAC Opinions on boric acid; disodium octaborate anhydrate and disodium octaborate tetrahydrate, 2014 and on barium diboron tetraoxide, 2020). It was concluded by RAC that the repeated dose and reproductive toxicity studies in rats, mice and dogs clearly show that boron impairs fertility through effects on the testes. The observed effects were consistent throughout the different species and there were no indications that impaired fertility was secondary to other toxic effects.

In conclusion, the overall weight of evidence of available information, a large body of evidence from read-across data on animal studies on boric acid and borate salts and supporting evidence from read-across of experimental data on PBS-4 coming from the 28-day limit test, provide clear evidence of an adverse effect on sexual function and fertility in the absence of other toxic effects. Thus, classification of PBS-1 as **Repr. 1B, H360F** is warranted.

Classification as Repr. 1A is not appropriate as it should be based on human data. No human data assessing the reproductive toxicity on sodium per(oxo)borates were available. The available epidemiological data on

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID,
SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC
ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3];
SODIUM PERBORATE [4]

boric acid and borate salts do not provide clear evidence of adverse effects on sexual function and fertility at boron exposure levels that were well below the LOAELs from corresponding animal studies. The overall negative human data do not contradict the animal data, and there is no evidence to indicate that the observed effects in animal studies are not relevant for humans.

Classification in Repr. 2 is not justified since the evidence for adverse effects on sexual function and fertility based on read-across from boric acid, with supporting evidence from read-across data on PBS-4, is considered to be clear and not some evidence. Moreover, the read-across from boric acid is considered robust and appropriate for the endpoint and applicable for PBS-1.

Specific concentration limits for adverse effects on sexual function and fertility

As detailed in the proposal for SCLs for sodium per(oxo)borates drafted by Austria and The Netherlands, the SCLs for fertility of the per(oxo)borates (i.e. 9% for PBS-1 and 14% for PBS-4) were calculated based on the old SCLs for boric acid (i.e. 5.5%) that were set by the approach proposed by BauA (1998) , and corrected for the difference in boron content (ECBI/38/03 Add.17).

Since the per(oxo)borates covered by the present proposal was subject to harmonised classification, new recommendations on how to derive concentration limits for reproductive toxicity have been agreed upon (CLP Guidance, 2017). Section VI.5.1.1.4 of the CLP Guidance (2017) states that “*Several other options for a method for determining SCLs were discussed including a method that was used by the TC C&L in a limited number of cases in the past. This method is based on the limit dose of 1000 mg/kg bw/day, as described in the test guideline OECD 414 and 416. This method would result in an individual SCL for each substance. This would indicate a precision that cannot be expected from standard reproduction studies. Also, this would result in an SCL for most substances and in a GCL for only some substances. Therefore, this method was not considered*”.

Moreover, in 2019, the RAC has concluded on the harmonisation of GCL values of 0.3% w/w for boric acid and six borates that have a harmonised classification as Repr. 1B (RAC Opinion, 2019).

According to the CLP Guidance (2017), concentration limits for effects on sexual function and fertility are derived by calculating the reproductive toxicity dose descriptor, i.e. ED10 (the dose level at which a change of 10% compared to the concurrent control group is observed). It should be noted that, the available data on per(oxo)borates were not robust enough in order to derive the ED10, and thus read-across data on boric acid and borate salts were used. According to the RAC (RAC opinions on boric acid, disodium octaborate anhydrate and disodium octaborate tetrahydrate, 2014), testes atrophy was identified as the most sensitive effect on fertility in rats, based upon a 2-year feeding study with boric acid (Weir 1966, as cited in the CLH-report for boric acid, 2013). There is no reason to reconsider this conclusion based on the human information published since 2014. At the end of the treatment (24 months), the incidence of testicular atrophy was 30%, 10%, 40% and 100% at 0, 5.9, 17.5 and 58.5 mg B/kg bw/day, respectively. Based upon these results, the ED10 would therefore be 17.5 mg B/kg bw/day.

Correcting for the percentage of boron, the ED10 of 17.5 mg B/kg bw/day would correspond to 159 mg PBS-1 (see Table 32). According to section 3.7.2.6.3 of the CLP Guidance (2017), a substance with a $4 < ED10 < 400$ mg/kg bw/day belongs to the medium potency group. None of the modifying factors related to type or severity of effect, data availability, dose-response relationship, mode/mechanism of action, toxicokinetics or bio-accumulation applies for PBS-1.

The **medium potency group with a GCL of 0.3% w/w** should therefore be assigned to PBS-1.

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID,
SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC
ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3];
SODIUM PERBORATE [4]

10.10.4 Adverse effects on development

Table 25: Summary table of animal studies on adverse effects on development

Method, guideline, deviations if any, species, strain, sex, no/group ²⁸	Test substance, dose levels, duration of exposure	Results	Reference
<i>Sodium perborate tetrahydrate (PBS-4)</i>			
<p>OECD TG 414 (Prenatal developmental toxicity study), carried out according to GLP guidelines</p> <p>Rat (Sprague-Dawley), females</p> <p>n = 25/dose group</p> <p>Reliability: 1 (reliable without restriction)</p>	<p>Test material: sodium perborate tetrahydrate (PBS-4)</p> <p>Purity: unknown</p> <p>Vehicle: 1% aqueous methyl cellulose</p> <p><u>Doses:</u> 0, 100, 300 and 1000 mg/kg bw/day (eq. to 0, 7, 21 and 70 mg B/kg bw/day, respectively)</p> <p><u>Exposure:</u> GD 6-15, via oral gavage</p>	<p>NOAEL for maternal toxicity = 100 mg PBS-4/kg bw/day (eq. to 7 mg B/kg bw/day)</p> <p>LOAEL for maternal toxicity (decreased bw, bw gain and food intake) = 300 mg PBS-4/kg bw/day (eq. to 21 B/kg bw/day)</p> <p>NOAEL for developmental toxicity = 100 mg PBS-4/kg bw/day (eq. to 7 mg B/kg bw/day)</p> <p>LOAEL for developmental toxicity (increased post-implantation loss, increased number of resorptions, decreased number of live foetuses, decreased foetal weight) = 300 mg PBS-4/kg bw/day (eq. to 21 B/kg bw/day)</p> <p>Maternal effects:</p> <ul style="list-style-type: none"> - at 300 and 1000 mg /kg bw/day: stat. sign. (p<0.05) reduced bw during GD 15-20, (on GD 20: 369.4 g and 366 g, respectively, vs. 410.9 g in controls) - at 300 and 1000 mg /kg bw/day: stat. sign. (p<0.05) reduced bw gain during GD 1-20 (119.2 g and 110.89 g, respectively, vs. 153.81 g in controls) - the body weight gain excluding gravid uterine wight was stat. sign (p<0.05) decreased only at the mid dose level (67.2g, 59.7 g, 50.9* g and 55.1 g at 0, 100, 300 and 1000 mg/kg bw/day, respectively) - no clinical signs, behavioural changes, deaths or pathological findings were reported at any of the dose levels - 21/25, 20/25, 20/25 and 19/25 dams gravid at 0, 100, 300 and 100 mg /kg bw/day, respectively (2 and 1 dams with complete resorptions at 300 and 1000 mg/kg bw, respectively) <p>Foetal effects:</p> <ul style="list-style-type: none"> - at 1000 mg/kg bw/day stat. sign. (p<0.05) increased number of resorptions/litter, within the HCD range (1.53 vs. 0.43 in controls; HCD: 0.7 ± 1.1) - at 300 and 1000 mg /kg bw/day stat. sign. (p<0.05) decreased live foetus weight (3.28 g and 2.4 g, respectively, vs. 3.69 g in controls; outside of the HCD: 3.7 g ± 0.4) - increased post-implantation loss, stat. sign. (p<0.05) at the high dose level (2.91%, 2.39%, 13.54%, 15.2%* at 0, 100, 300 and 1000 mg/kg bw/day, respectively) - decreased number of live foetuses, stat. sign. (p<0.05) at mid and high dose levels (311, 295, 256*, 242* at 0, 100, 300 and 1000 	<p>Study Report, 1995b</p> <p>EU RAR (2007)</p> <p>See also Annex I to the CLH-report</p>

²⁸ Where applicable and unless stated otherwise, the reliability scores of the studies presented in Table 25 are according to the publicly disseminated REACH Registration dossier for EC no. 234-390-0, available at <https://www.echa.europa.eu/en/web/guest/registration-dossier/-/registered-dossier/13523/7/9/3>

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID,
SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC
ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3];
SODIUM PERBORATE [4]

Method, guideline, deviations if any, species, strain, sex, no/group ²⁸	Test substance, dose levels duration of exposure	Results	Reference
		<p>mg/kg bw/day, respectively)</p> <ul style="list-style-type: none"> - dose-dependently but not stat. sign decreased number of live fetuses/litter (14.8, 14.75, 14.2, 13.4 at 0, 100, 300 and 1000 mg/kg bw/day, respectively; HCD:14.4 ± 3.3) - dose-dependently reduced litter weight, stat. sign. (p<0.05) at the high dose level (54.97, 52.62, 46.49, 32.52* g at 0, 100, 300 and 1000 mg/kg bw/day, respectively) - at 100 mg/kg bw/day external malformations were seen in 6 plurimalformed fetuses: ablepharia (5), acrania (6), exencephaly (6), exophthalmia (3), macroglossia (6), cleft palate (5), cleft lip (2), facial cleft (1) <p>Skeletal and cranial effects:</p> <ul style="list-style-type: none"> - reduced rib XIII (uni- and bilateral) in 0.64%, 0%, 3% and 9%* at 0, 100, 300 and 1000 mg/kg bw/day, respectively - rib XII/XIII in 0.64%, 2%, 0.77% and 11.38%* at 0, 100, 300 and 1000 mg/kg bw/day, respectively - stat. sign. (p<0.05) increased incidences of wavy rib at the mid and high dose levels (1.30%, .70%, 13.20%* and 7.30%* at 0, 100, 300 and 1000 mg/kg bw/day, respectively) - in controls, 1 foetus with scoliosis and bifurcated 8th rib - at 1000 mg/kg bw/day, 2 fetuses from 2 different litters with fused ribs - dose-dependently and stat. sign (p<0.05) increased incidences of supraoccipital incomplete ossification at all dose levels (26.92%, 38.89%*, 45.73%* and 76.42%* at 0, 100, 300 and 1000 mg/kg bw/day, respectively), outside of the HCD range (0 – 35.90%) - dose-dependently and stat. sign (p<0.05) increased incidences of unossified 5th sternbrae at all dose levels (35%, 60.42%*, 70.50%* and 100%* at 0, 100, 300 and 1000 mg/kg bw/day, respectively), outside of the HCD range (19.91 – 51.16%) - dose-dependently and stat. sign (p<0.05) increased incidences of unossified 6th sternbrae at all dose levels (25%, 34%*, 54.20%* and 89.43%* at 0, 100, 300 and 1000 mg/kg bw/day, respectively) - dose-dependently increased incidences of incomplete ossification of 4th sternbrae (7%, 11.11%, 15.50%* and 48.78%* at 0, 100, 300 and 1000 mg/kg bw/day, respectively) <p>Visceral effects:</p> <ul style="list-style-type: none"> - at 1000 mg /kg bw/day only, cardiovascular effects in 5.88% (vascular ring, displaced or double aortic arch, displaced botallus duct), malformations of the eyes in 3.36% (anophthalmia or microphthalmia) and CNS effects (enlarged lateral ventricles of the brain) in 1.68% of the fetuses - stat. sign. (p<0.05) increased incidences of dilated or convoluted ureter at all dose levels (28.40%, 44.82%*, 42%* and 79%* at 0, 100, 300 and 1000 mg/kg bw/day, respectively) - stat. sign. (p<0.05) increased incidences of dilated renal pelvis at all dose levels (4.51%, 17.24%*, 11%* and 38.60%* at 0, 100, 300 	

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID,
SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC
ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3];
SODIUM PERBORATE [4]

Method, guideline, deviations if any, species, strain, sex, no/group ²⁸	Test substance, dose levels duration of exposure	Results	Reference
		and 1000 mg/kg bw/day, respectively) - absence of renal papillae was stat. sign. (p<0.05) increased only at the high dose level (0.64%, 0.70%, 0.78% and 6.72%* at 0, 100, 300 and 1000 mg/kg bw/day, respectively)	

Table 26: Summary table of human data on adverse effects on development

Type of data/report	Test substance	Relevant information about the study (as applicable)	Observations	Reference
Mother-child cohort study (prospective)	Boron environmental exposure via drinking water of pregnant women residing in Northern Argentina	n = 194 mothers 1-3 samples of serum, whole blood and urine was taken during pregnancy. Infant weight, length and head circumference was measured at birth.	Serum B > 80 µg/L were found to be inversely associated with birth length. An increase in the serum B of 100 µg/L in the last trimester was associated with a decrease of 0.9 cm (p<0.05) in new-born length and a decrease of 120g (p<0.05) in new-born weight.	Igra et al. 2016
Mother-child cohort study (prospective, follow-up until 6 months of age)	Boron, environmental exposure via drinking water of pregnant women residing in Northern Argentina	n = 194 mothers, 120 infants Infant urine and whole blood were collected at the two follow-ups after birth (at 3 and 6 months). Infant weight, length and head circumference were measured at the two follow-ups after birth. This study is a follow-up of the same mother-child cohort as was investigated by Igra et al. 2016.	At 0 – 3 months: each doubling of B levels in infant urine was associated with a decrease in bodyweight of 141 g (p<0.05) and a decrease in infant head circumference of 0.39 cm (p<0.05). At 3 – 6 months: each doubling of B in infant urine was associated with a 200 g (p<0.05) in infant weight and decrease of 0.57 cm (p<0.05) in infant length.	Hjelm et al. 2019

Table 27: Summary table of other studies relevant for developmental toxicity

Type of study/data	Test substance	Relevant information about the study (as applicable)	Observations	Reference
No other relevant studies for the assessment of developmental toxicity were available				

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID, SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3]; SODIUM PERBORATE [4]

10.10.5 Short summary and overall relevance of the provided information on adverse effects on development

10.10.5.1 Read-across data on PBS-4 from animal studies

A prenatal developmental toxicity study (OECD TG 414, GLP; Study Report, 1995b) performed in rats with PBS-4 was available in the registration dossier of EC No. 234-390-0 (perboric acid, sodium salt). Female rats (n = 25/dose group) were administered 0, 100, 300 and 1000 mg PBS-4/kg bw/day (eq. to 0, 7, 21 and 70 mg B/kg bw/day, respectively) in 1% aqueous methyl cellulose during GD 6-15, via oral gavage. The dams were scheduled for necropsy and caesarean section on GD 20. No clinical signs, behavioural changes, pathological findings or maternal deaths were reported. Maternal effects consisted of dose-dependently and stat. sign. (p<0.05) reduced bodyweight and bodyweight gain at 300 and 1000 mg/kg bw/day. These effects cannot however be considered as clear signs of maternal toxicity since the reduced weight gain may be related to reduced foetal weights and the resorptions detected. Moreover, no effects can be seen on body weight gain of the females from the lowest and highest dose levels by excluding the gravid uterine weight (see Table 28 below). The NOAEL for maternal toxicity was set by the authors of the study at 100 mg/kg bw/day.

A dose-dependent increase in post-implantation loss that was stat. sign. (p<0.05) at 300 and 1000 mg/kg bw/day was seen. The total number of resorptions per litter was stat. sign. (p<0.05) increased at 1000 mg/kg bw/day and within the HCD range (1.53 vs. 0.43; HCD: 0.7 ± 1.1). A dose-dependent decrease in the number of live foetuses that was stat. sign. (p<0.05) at 300 and 1000 mg/kg bw/day was reported. The number of live foetuses/litter was also dose-dependently but not stat. sign. (p>0.05) decreased, however within the HCD range. Dose-dependent decreases in the live foetal weight (p<0.05 at 300 and 1000 mg/kg bw/day) and litter weight (p<0.05 at 1000 mg/kg bw/day; lower than the HCD foetal weight) were also seen.

According to OECD GD 43, if historical control data are used, the most appropriate of these are from studies conducted in the same laboratory, within a reasonable amount of time prior to the study being interpreted (e.g., ± 2 years) in order to avoid genetic drift in the laboratory animal population, and under the same study conditions (e.g., identical species, strain, source, age, vehicle, route and duration of administration, technical personnel, etc.). In the study report for OECD TG 414 study, it is stated that the historical control data is based on 2146 foetuses during years 1992-1993. Thus, the time prior to the study is appropriate. However, with regards to study conditions (e.g., laboratory, identical species, strain, source, age, vehicle, route and duration of administration, technical personnel, etc) the dossier submitter have no information to enable assessment of the relevance.

At 100 mg/kg bw/day, six foetuses (2% vs. 0% in controls; p<0.05) with external malformations (ablepharia, acrania, exophthalmia, macroglossia, cleft palate, cleft lip and facial cleft) were found. The authors of the study considered this finding as incidental due to the lack of dose-response and since these effects were present only in 2 litters and not at the other dose levels, where different types of malformations were seen. This can also be supported by the fact that with other boron compounds such as boric acid and borates which have very similar developmental effects to sodium per(oxo)borates, these types of external malformations were not seen. Since the malformations seen at the mid and high dose levels are of a different nature, the assumption of a syndrome of genetic origin was proposed and discussed in the EU RAR (2007). However, no information on the mating male was available to support this assumption. These external malformations were not taken into account by the study authors when deriving the NOAEL for developmental effects, i.e. 100 mg/kg bw/day.

Malformations of the cardio-vascular system (displaced or double aortic arch, displaced botallus duct and vascular ring) and of the eyes (anophthalmia or microphthalmia) were seen in 5.88% and 3.36% vs. 0% in controls, respectively, of the foetuses at 1000 mg/kg bw/day (stat. sign; p<0.05; no HCD provided for these specific developmental effects). Effects on the kidneys such as dilated renal pelvis and absence of renal papillae were reported at all dose levels. The CNS effects (enlarged lateral ventricles of the brain) seen at 1000 mg/kg bw/day (1.68% vs. 0% in controls) were considered as visceral anomalies by the authors of the

**ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID,
SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC
ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3];
SODIUM PERBORATE [4]**

study. According to the RAC opinion on boric acid (2014), the enlargement of the lateral ventricles in the brain is considered a common malformation of boric acid administration.

A dose-related effect on the ossification and skeletal system was seen. The reported effects consisted of dose-dependently increased incidences of supraoccipital incomplete ossification, stat. sign. ($p < 0.05$) and outside of the HCD range in all treated groups (26.92%, 38.89%, 45.73% and 76.42% at 0, 100, 300 and 1000 mg/kg bw, respectively; 0 - 35.90% HCD; stat. sign. $p < 0.05$) and incomplete ossification of head and hyoid bone (at all dose levels), pelvic girdle and pubis (at the mid- and high-dose levels) and unossified vertebrae (at the high dose level). The incidences of unossified 5th sternbrae were stat. sign. ($p < 0.05$) and dose-dependently increased and outside of the HCD range in all treated dose groups (60.42%, 70.50% and 100 % at 100, 300 and 1000 mg/kg bw, respectively, vs. 35% in controls; 19.910 – 51.160 HCD; stat. sign. $p < 0.05$). Similarly, the incidences of unossified 6th sternbrae were dose-dependently and stat. sign ($p < 0.05$) increased (34%, 54.20%, 89.43% at 100, 300 and 1000 mg/kg bw, respectively, vs. 25% in controls; no HCD provided). A dose-dependent increase in the incidences of incomplete ossification of the 4th sternbrae was also reported (11.11%, 15.50% and 48.78% at 100, 300 and 1000 mg/kg bw, respectively, vs. 7% in controls; no HCD provided). Wavy ribs were reported in 1.30%, 0.70%, 13.20% and 7.30% of the examined fetuses at 0, 100, 300 and 1000 mg/kg bw, respectively. Rib XII/XIII, reported as a skeletal variation, was seen in 0.64%, 2%, 0.80% and 11.38% of the fetuses at 0, 100, 300 and 1000 mg/kg bw, respectively. Since this effect was not described nor highlighted in the study summary, the significance of this skeletal variation remains unclear. Short rib XIII (uni- or bilateral) was seen in 0.6%, 0%, 3% and 9% of the fetuses at 0, 100, 300 and 1000 mg/kg bw, respectively.

For comparison and in support of the findings in the PNDD study of PBS-4, the RAC has previously concluded that the most sensitive effect on development by boric acid and borates is the increased incidence of agenesis or shortening of rib XIII (RAC opinions on boric acid, disodium octaborate anhydrate and disodium octaborate tetrahydrate, 2014). This effect alongside other dose-dependently increased incidences of skeletal effects were reported in the PNDD study performed with PBS-4. Also, very similar effects for borates and per(oxo)borates can be seen in the craniofacial (effects on the eyes: micro- or anophthalmia), kidney (hypoplasia, hydronephrosis, dilated renal pelvis, absence of renal papillae) and cardiovascular (displaced or double aortic arch) malformations, but also cerebral effects (enlarged lateral ventricles of the brain). Therefore, it can be stated that the embryotoxic effects of PBS-4 are due to the boron moiety, as the malformations observed at the mid and high dose levels are similar to those induced by boric acid and borates. Divergence of effects (i.e. increased foetal lethality) may be explained by differences in administration (oral gavage, feed) and absorption.

Table 28: Results of the prenatal developmental toxicity study (OECD TG 414; GLP) with PBS-4 in rats (Study Report, 1995b; EU RAR, 2007)

	HCD on 2146 foetuses (1992-1993)	Dose levels (mg/kg bw/day)			
		0	100	300	1000
No. of pregnant females	-	21	20	20 ^{&}	19 [#]
No. of litters	-	21	20	18	18
Maternal body weight (g; group mean and gain)					
GD 6	-	288.7	283.6	277.6	282.2
GD 15	-	333.3	329.5	315.8*	314.3*
GD 20	-	410.9	400.3	369.4*	366.0*
GD 0-20, gain	-	153.8	144.5	119.2*	110.9*

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID,
SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC
ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3];
SODIUM PERBORATE [4]

	HCD on 2146 foetuses (1992-1993)	Dose levels (mg/kg bw/day)				
		0	100	300	1000	
GD 0-20 (gain excluding gravid uterine weight)	-	67.2	59.7	50.9*	55.1	
Reproductive parameters						
Gravid uterine weight (g)	-	86.6	84.8	68.3*	55.8*	
No. dams with early resorptions	-	7/21	7/20	7/20	13*/19	
No. dams with late resorptions	-	1/21	0/20	0/20	2/19	
No. of implantations/no. of corpora lutea	-	320/369	301/345	272/332	272*/352	
No. of early resorptions	-	8	7	12	24*	
Total no. of resorptions	-	9	7	16*	29*	
Post-implantation loss (%)	-	2.91	2.39	13.54*	15.20*	
Foetal parameters						
No. of live foetuses	-	311	295	256*	242*	
No. of dead foetuses	-	0	0	0	1	
No. of live foetuses/litter	14.4 ± 3.3	14.80	14.75	14.22	13.44	
No. of resorptions/litter	0.7 ± 1.1	0.43	0.35	0.80	1.53*	
Live foetus weight (g)	3.7 ± 0.4	3.69	3.57	3.28*	2.4*	
Live litter weight (g)	53.9	54.97	52.62	46.49	32.52*	
Placenta weight (g)	0.5 ± 0.08	0.5	0.51	0.48	0.37*	
Malformations, abnormalities and variations as reported by the study authors (Study Report, 1995b)						
No. of foetuses examined for skeletal/visceral	-	156/155	144/145	129/127	123/119	
Malformations (%)	External	0 – 0.120	0	2 ^{*a}	0	
	Skeletal	0	0.64 ^b	0	1.62 ^b	
	Overall visceral, including:	0.020	0	0	9.20 ^{*c}	
	Cardio-vascular effects	-	0	0	5.88 ^{*c}	
	Eye effects	-	0	0	3.36 ^c	
Abnormalities (%)	External	0.115	0	0	0	
	Overall skeletal, including:					
	Wavy rib ^(d)	-	1.30	0.70	13.20*	7.30*
	Supraoccipital incomplete ossification ^(e)	0 – 35.90	26.92	38.89*	45.73*	76.42*
	Overall visceral, including:	0.415	0.64	1.37	1.57	7.56 ^{*f}
	Enlarged lateral ventricles of the brain	-	0	0	0	1.68 ^f
	Absence of renal papillae	-	0.64	0.70	0.78	6.72 ^{*f}

**ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID,
SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC
ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3];
SODIUM PERBORATE [4]**

		HCD on 2146 foetuses (1992-1993)	Dose levels (mg/kg bw/day)			
			0	100	300	1000
Variations (%)	Overall skeletal, including:					
	Reduced rib XIII unilateral (^g)	-	0	0	1.55	4.07
	Reduced rib XIII bilateral (^g)	-	0.64	0	1.55	4.88
	Ribs XIII punctate unilateral (^h)	-	0.64	2.08	0	14.63*
	Ribs XIII punctate bilateral (^h)	-	1.28	1.39	2.33	6.50
	Ribs XII/XIII (i)	-	0.64	2.1	0.78	11.38*
	Ribs XIII/XIV (^l)	-	1.92	0.69	0	0
	Ribs XIV punctate unilateral (^k)	-	1.92	0.69	0	0
	Unossified 5 th sternbrae	19.910 – 51.160	35	60.42*	70.50*	100*
	Unossified 6 th sternbrae	-	25	34	54.20*	89.43*
	Incomplete ossification of 4 th sternbrae	-	7	11.11	15.50*	48.78*
	Overall visceral, including:					
	Dilated or convoluted ureter	-	28.40	44.82*	42*	79*
Dilated renal pelvis	-	4.51	17.24*	11*	38.60*	

[&] Two dams with complete resorptions

[#] One dam with complete resorptions

^{*} Statistically significant effect $p < 0.05$; statistical analysis by Chi-squared and Fischer's exact test or ANOVA parametric or nonparametric, where applicable, compared to controls

^a 6 plurimalformed foetuses (of 295 total foetuses): ablepharia (5), acrania (6), exencephaly (6), exophthalmia (3), macroglossia (6), cleft palate (5), cleft lip (2), facial cleft(1)

^b 1 foetus with scoliosis and bifurcated 8th rib (controls); 2 foetuses of 2 different litters with fused ribs (1000 mg/kg bw/day)

^c 11 foetuses: microphthalmia or anophthalmia (4), vascular ring (2), bilateral hydronephrosis (1), displaced or double aortic arch (3), displaced botallus duct (2), hypoplasia of kidney (1); the 7 foetuses with cardio-vascular effects were from 5 different litters; the 4 foetuses with eye effects were from 3 different litters

^d wavy rib: 2 (from 2 different litters), 1, 17 (from 5 different litters) and 9 (from 3 different litters) foetuses at **0, 100, 300 and 1000 mg/kg bw/day, respectively**

^e Supraoccipital incomplete ossification in 251 foetuses: 42 (from 14 litters), 56 (from 20 litters), 59 (from 15 litters) and 94 (from 16 litters) at 0, 100, 300 and 1000 mg/kg bw/day, respectively

^f 9 foetuses: dilated lateral cerebral ventricles (2 foetuses of the same litter), absence of renal papillae (8 foetuses of 4 different litters), hemorrhagic kidney (1)

^g Reduced rib XIII unilateral in 0, 0, 2 and 5 foetuses at 0, 100, 300 and 1000 mg/kg bw/day, respectively

Reduced rib XIII bilateral in 1, 0, 2 and 6 foetuses at 0, 100, 300 and 1000 mg/kg bw/day, respectively

^h Ribs XIII punctate unilateral in 1, 3, 0 and 18 foetuses at 0, 100, 300 and 1000 mg/kg bw/day, respectively

Ribs XIII punctate bilateral in 2, 2, 3 and 8 at 0, 100, 300 and 1000 mg/kg bw/day, respectively

ⁱ Ribs XII/XIII in 1, 3 (from the same litter), 1 and 14 (from 10 different litters) foetuses at 0, 100, 300 and 1000 mg/kg bw/day, respectively

^j Ribs XIII/XIV in 3, 1, 0 and 0 foetuses at 0, 100, 300 and 1000 mg/kg bw/day, respectively

^k Ribs XIV punctate unilateral in 3, 1, 0 and 0 foetuses at 0, 100, 300 and 1000 mg/kg bw/day, respectively

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID,
SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC
ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3];
SODIUM PERBORATE [4]

10.10.5.2 Human data on boron compounds

No human data for the assessment of adverse effects of per(oxo)borates on development were available. Epidemiological studies available on the potential effects of boron exposure have therefore been included in the weight of evidence assessment for the conclusion on classification and consideration of human relevance. This is justified on the basis of hydrolytic and toxicokinetic behaviour of per(oxo)borates.

Epidemiological studies on possible adverse pregnancy outcomes in female workers, or females environmentally exposed to boron via food or drinking water were not available in 2014, and such data was therefore not discussed in the 2014 RAC opinions on boric acid, disodium octaborate anhydrate and disodium octaborate tetrahydrate.

In 2016, Igra et al. has published a prospective mother-child cohort study investigating environmental exposure of boron through drinking water on pregnant women from Argentina. A statistically significant inverse association was found between serum blood boron levels >80 µg/L and birth length (newborns were 0.7 cm shorter per each 100 µg/L increase in serum boron levels). Moreover, this association was more pronounced (increased by 28%) during the third trimester of pregnancy, when the highest serum boron concentrations were the highest (0.73 – 447 µg/L). However, it cannot be excluded that the observed effects can be the result of a combined exposure to lithium.

In 2018, Duydu et al. (2018b) published a retrospective cohort study investigating birth weights of newborns and pregnancy outcomes of females environmentally exposed to boron via drinking water in Turkey. The study had several limitations (self-reporting, low sample size, boron levels measured only after birth). For comparison, the mean blood boron level at the rat developmental NOAEL (9.6 mg B/kg bw/day) was 1.3 µg B/g blood (Price et al. 1996a, 1997), whereas the mean blood boron concentration in the high exposure group from the epidemiological study was 0.27 µg B/g blood.

These two epidemiological studies have been assessed by RAC in the Opinion on barium diboron tetraoxide (2020). The RAC concluded that even if these studies show no clear effects on development of the offspring, there is no evidence that the effects observed in animals are not relevant to humans.

In 2019, Hjelm et al. have published a follow-up study of the mother-child cohort (n = 194) investigated previously by Igra et al. (2016). This study has not been assessed by RAC previously in the Opinion on barium diboron tetraoxide (2020).

In order to evaluate the potential impact of pre- and post-natal boron exposure on infant growth, samples of maternal drinking water, placenta, urine, whole blood and breast milk were collected. Both maternal and infant samples were analysed for arsenic and lithium that were also present in the drinking water.

Boron concentrations in drinking water ranged between 377 – 16076 µg B/L (median: 5863 µg B/L; n = 114). As shown in Table 29, concentrations of B in maternal serum were similar to those in whole blood (third trimester, GW 28-39), both showing a moderate correlation with concentrations in drinking water (rs = 0.28; p = 0.0001). Maternal blood B levels markedly increased from late pregnancy, GW 33 on average (median value: 140 µg B/L, n = 78), to the first follow-up post-partum (median values: 263 µg B/L, n = 108). A strong correlation between B in cord blood and cord serum was also seen (rs = 0.82). The authors suggested that the high B concentrations in cord serum (median: 196 µg B/L, i.e. just in between the concentration in maternal serum in GW 33 and that at the first follow-up about 50 days post-partum) is indicative of a rapid transfer to the foetus. The correlation of B concentrations in cord blood with those in placenta (rs = 0.73; p < 0.001) was stronger than the correlation with concentrations in maternal blood at GW 33 (rs = 0.41; p < 0.001). Boron concentrations in breast milk (median: 274 µg/L at 0–3 months after delivery) were similar to and strongly correlated with those in maternal serum (median: 266 µg B/L; rs = 0.94). The correlation with arsenic and lithium in breast milk was rs = 0.49 and 0.64, respectively, but there was no association between the breast milk concentrations of boron and those of calcium, magnesium, phosphorous, zinc, iron and selenium (rs > 0.1).

**ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID,
SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC
ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3];
SODIUM PERBORATE [4]**

Median birth weight was 3050 g and 8% of the infants had low birth weight (i.e. < 2500 g). In total, 76% of the infants were exclusively breastfed at the follow-up at 0-3 months and 57% at 3 – 6 months, as reported by the mothers. The correlation between B concentrations in infant urine collected at 0 – 3 months after birth and breast milk became markedly stronger if restricted to infants who were reported to be exclusively breastfed ($r_s = 0.68$; $p < 0.001$). The boron concentrations in urine of infants who were reported to be exclusively breastfed at 0 – 3 months (median: 541 $\mu\text{g B/L}$, $n = 81$) were approx. twice as high as those in the breast milk they received (median: 266 $\mu\text{g/L}$, collected within an hour of the infant urine sampling). An even bigger difference was found for the exclusively breastfed infants at 3 – 6 months (median urine: 1327 $\mu\text{g B/L}$, median breast milk: 293 $\mu\text{g B/L}$, $n = 55$). The authors suggested that the higher B concentrations in urine of the infants that were not exclusively breastfed demonstrate the strong impact of water intake on infant boron exposure; this was particularly evident at 3–6 months, when fewer infants were exclusively breastfed.

The authors used two cross-sectional analysis models, adjusting for infant age only (Model A) and for infant age and several other parameters, including lithium and arsenic concentrations in maternal blood and urine during pregnancy (Model B), for both follow-up periods (Table 29). A significant inverse association of B in infant urine with infant weight, at 0 – 3 months was observed (Model A). A non-stat. sign. tendency of shorter infants at higher B concentrations in cord blood was noticed after the 0 – 3 months follow-up (Model B; $p = 0.08$). At 0 – 3 months, adjusting for additional covariates (Model B) gave rise to a stronger inverse association of urinary B and infant body weight, and also the inverse association with head circumference became stat. significant ($p < 0.05$). Each 2-fold increase of B levels in infant urine was associated with a decrease in bodyweight of 141 g and a decrease in infant head circumference of 0.39 cm. Neither arsenic, nor lithium in infant urine was significant in the models. At the 3 – 6 months follow-up, each 2-fold increase of B concentrations in infant urine was associated with a decrease of 200 g in infant weight and a decrease of 0.57 cm in infant length (Model B).

The study had a high participation rate (88%) and a prospective design with measurements of the infants at birth and two follow-ups during the first 6 months, but a small sample size. A limitation is the exposure to other metals, such as lithium, of the infants that also received drinking water. The concentrations of lithium were correlated with those of boron in the exposure biomarkers, and all exposures were lower in exclusively breastfed infants than in those also given drinking water. However, the measures of exposure to lithium (and arsenic) were generally not significant in the used statistical models (with and without metal adjustments). Previous studies correlated high altitude with low birth weight. Hjelm and colleagues underlined that even if the current study was performed in the Andes at 3100 – 4070 m above sea level, most of the mothers were of indigenous origin. The ancestors of these women lived in villages situated at high altitude in the Andes and this has resulted in adaptation to high altitude, including reproductive fitness.

In conclusion, the results of the study conducted by Hjelm et al. (2019) show a strong correlation between B in maternal serum and breast milk which indicates that exposure to B in early infancy was inversely associated with infant weight, length and head circumference during the first 6 months of life. These results are in line with the previously published findings of the same research group, showing that maternal serum B concentrations during pregnancy were associated with impaired foetal growth in the same mother-child cohort (Igra et al. 2016).

Table 29: Boron exposure markers prenatally and in early infancy

Perinatal exposure markers		Median (range) boron concentrations ($\mu\text{g/L}$)
Hjelm et al. 2019 (Argentina)		
Prenatal exposure markers	Maternal serum (last trimester)	134 (30 – 447)

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID,
SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC
ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3];
SODIUM PERBORATE [4]

Perinatal exposure markers		Median (range) boron concentrations (µg/L)
Hjelm et al. 2019 (Argentina)		
(n = 78)	Maternal whole blood (last trimester)	140 (27 – 332)
	Placenta (µg/kg)	133 (1.1 – 605)
	Cord blood serum	196 (69 – 658)
	Cord whole blood	177 (29 – 600)
First follow-up (0 – 3 months after birth; n = 108)	Maternal serum	266 (47 – 624)
	Maternal whole blood	263 (66 – 750)
	Breast milk	274 (46 – 786)
	Infant urine*	689 (105 – 9200)
Second follow-up (3 – months after birth; n = 93)	Breast milk	293 (65 – 1386)
	Infant whole blood	127 (37 – 1351)
	Infant urine*	1784 (389 – 15068)

*Adjusted to mean osmolality (122 and 223 mOsm/kg at 0 – 3 and 3 – 6 months, respectively).

Table 30: Early life boron exposure and infant anthropometry (multivariable-adjusted linear regression analysis) as published by Hjelm et al. (2019)

Exposure as boron concentration (µg/L)	Infant outcomes					
	Weight (g)/log ₂ B (µg/L) (95% CI)	P-value	Length (cm) /log ₂ B (µg/L) (95% CI)	P-value	Head circumference (cm) /log ₂ B (µg/L) (95% CI)	P-value
First follow-up (0 – 3 months)						
Maternal serum blood (last trimester)	n = 140/138		n = 140/131		n = 136/121	
Model A ^a	-29 (-108;51)	0.477	-0,19 (-0.50; 0.12)	0.221	-0.05 (-0.23; 0.12)	0.545
Model B ^b	-30 (-100; 41)	0.405	-0.23 (-0.50;0.05)	0.103	-0.06 (-0.25; 0.12)	0.509
Cord blood	n = 92/83		n = 92/80		n = 90/71	
Model A ^a	-63 (-234; 108)	0.464	-0.46 (-1.0; 0.13)	0.126	0.06 (-0.35; 0.47)	0.765
Model B ^b	-77 (-223; 69)	0.297	-0.52 (-1.1; 0.07)	0.082	-0.16 (-0.56; 0.25)	0.447
Infant urine (0 – 3 months)	n = 113/112		n = 113/109		n = 113/100	
Model A ^a	-83 (-158; -8.1)	0.030	0.04 (-0.26; 0.34)	0.798	-0.01 (-0.20; 0.19)	0.943
Model B ^b	-141 (-240; -42)	0.006	-0.07 (-0.53; 0.40)	0.773	-0.39 (-0.74; -0.04)	0.028
Second follow-up (3 – 6 months)						
Infant urine (0 – 3 months)	n = 111/109/109		n = 111/106/106		n = 106/93/93	
Model A ^a	-94 (-197; 8.5)	0.072	- 0.00 (-0.31; 0.31)	0.988	-0.04 (-0.22; 0.14)	0.665
Model B ^c	-200 (-377; -23)	0.027	-0.57 (-1.1; -0.03)	0.040	-0.30 (-0.64; 0.04)	0.083

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID,
SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC
ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3];
SODIUM PERBORATE [4]

Exposure as boron concentration (µg/L)	Infant outcomes					
	Weight (g)/log ₂ B (µg/L) (95% CI)	p-value	Length (cm) /log ₂ B (µg/L) (95% CI)	p-value	Head circumference (cm) /log ₂ B (µg/L) (95% CI)	p-value
Model C ^d	-176 (-343; -8.9)	0.039	-0.66 (-1.2; -0.11)	0.019	-0.23 (-0.52; 0.06)	0.125
Infant urine (3 – 6 months)	n = 112/107		n = 112/101		n = 112/94	
Model A ^a	-111 (-229; 6.0)	0.063	-0.34 (-0.70; 0.01)	0.059	-0.12 (-0.31; 0.08)	0.231
Model B ^c	60 (-154; 273)	0.580	-0.48 (-1.2; 0.26)	0.202	-0.21 (-0.62; 0.19)	0.304
Infant whole blood (3 – 6 months)	n = 106/92		n = 106/87		n = 106/82	
Model A ^a	-51 (-180; 78)	0.436	-0.12 (-0.50; 0.26)	0.528	-0.12 (-0.32; 0.07)	0.217
Model B ^c	-34 (-190; 123)	0.667	-0.10 (-0.60; 0.40)	0.694	-0.14 (-0.43; 0.15)	0.330

a Adjusted for infant age (days).

b Adjusted for infant age, birth weight, length, head circumference, sex, mothers height (cm), exclusively breastfed (yes/no) and lithium concentrations (log₂ µg/L) in maternal whole blood during pregnancy or infant urine, and arsenic concentrations (log₂ µg/L) in maternal urine during pregnancy or infant urine.

c Adjusted for infant age, birth weight, length, head circumference, sex, mothers height (cm), exclusively breastfed (yes/no) at time of exposure measurement, lithium concentrations (log₂ µg/L) in infant urine and arsenic concentrations (log₂ µg/L) in infant urine.

d As Model B^c, but adjusted for weight, length or head circumference at 0 – 3 months instead of at birth.

Conclusion on human data

The human data on developmental effects of boron should be seen as additional information for the assessment of human relevance of the observed developmental toxicity of PBS-4 in animal studies in a weight of evidence assessment.

The retrospective study (Duydu et al. 2018b) reports no adverse effects on development at exposure levels that were well below the NOAEL for developmental effects in rats. The blood B levels for the women in the highest exposure group (mean value of 274.6 ng B/g blood, highest individual value was 957.7 ng B/g blood) were below those corresponding to the NOAEL for developmental effects in rats (i.e. 9.6 mg B/kg bw/day corresponding to 1270 ng B/g blood; Price et al. 1997). This study presents several limitations, mainly associated with the retrospective study design and small sample size.

The prospective study conducted by Igra et al. (2016) detected a dose-dependent influence on birth size at B exposure levels (that were below the NOAEL for developmental effects in animal studies) but it could not be excluded that the results were influenced by co-exposure to lithium. The follow-up results of the same mother-child cohort published by the same research group provides the first evidence that exposure to B during early infancy (via breast milk and drinking water) may have a negative effect on post-natal growth up to 6 months of age (Hjelm et al. 2019). The lithium concentrations correlated with those of B in the assessed exposure biomarkers. However, it should be noted that adjusting for Li and As concentrations in maternal whole blood and infant urine resulted in a stronger inverse association of urinary B and infant body weight, the inverse association with infant head circumference becoming stat. significant at the first follow-up.

Assuming a blood density of 1060 g/L, the highest individual maternal serum B concentration of 624 µg/L measured at the first follow-up, would result in 589 ng B/g blood. This value is below the level of 1270 ng B/g blood that corresponds to the NOAEL for developmental effects in rats. However, the two prospective studies are the first to show developmental effects of perinatal environmental B exposure.

Overall, the available human data on boron do not contradict the experimental data coming from studies performed with per(oxo)borates in rats and give no evidence to support that the effects seen in animals are not relevant for humans. Moreover, the same conclusion was stated in RAC opinions (2014 and 2020) on

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID,
SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC
ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3];
SODIUM PERBORATE [4]

boric acid and borate salts where experimental data across several species (mice, rats and rabbits) are available.

10.10.6 Comparison with the CLP criteria

PBS-1 has a harmonised classification as Repr. 1B; H360D based on one PNDT study of PBS-4 in rat. **No change to the classification is proposed.**

There is clear evidence of structural abnormalities, death of the organism and retarded growth based on read-across from PBS-4. Classification in Repr. 1B, H360D is therefore warranted. Moreover, the recorded effects are relevant for humans, and are not considered to be secondary to maternal toxicity. Although not included in the previous decision on classification by the TC C&L, available data on boric acid could also be considered in the weight of evidence since read-across from boric acid to per(oxo) borates for developmental toxicity is appropriate. In the current proposal human data on boron were included to assess human relevance and the available data give no evidence to support that the effects seen in animals are not relevant for humans.

Classification in Repr. 1A, H360D is not justified since there is no human data demonstrating that per(oxo)borates have adverse effect on human fetal development. There is also no human data on boron that demonstrates clear evidence of adverse effect on human fetal development.

Classification in Repr. 2 is not justified since the evidence for developmental toxicity from existing experimental data on PBS-4 is considered to be clear and not some evidence of developmental toxicity.

Specific concentration limits for adverse effects on the development of the offspring

As detailed in the proposal for SCLs for sodium per(oxo)borates drafted by Austria and The Netherlands, the classification was based on the developmental effects seen at 300 and 1000 mg/kg bw/day in the OECD TG PNDT study with PBS-4 (ECBI/38/03 Add.17). While it was acknowledged that PBS-4 induced similar types of malformations on rat fetuses as boric acid and borates, it was not clearly stated if the classification was solely based on the observed malformations or on the total weight of evidence of developmental effects.

The current SCLs for adverse effects on development of the per(oxo)borates (i.e. $6.5\% \leq C < 9\%$) included in that proposal were calculated using the approach proposed by BauA (1998) based on the limit dose of 1000 mg/kg bw/day as described in the OECD TG 414, and using the NOAEL for developmental effects (i.e. 100 mg/kg bw/day) set by the authors of the PNDT study with PBS-4. This yielded an SCL of 10% for PBS-4 that was further used to calculate the SCL for PBS-1, taking into account the molecular weights of both per(oxo)borates and thus, yielding a value of 6.5% for PBS-1 (ECBI/38/03 Add.17).

Since the per(oxo)borates covered by the present proposal was subject to harmonised classification, new recommendations on how to derive concentration limits for reproductive toxicity have been agreed upon (CLP Guidance, 2017). Section VI.5.1.1.4 of the CLP Guidance (2017) states that “*Several other options for a method for determining SCLs were discussed including a method that was used by the TC C&L in a limited number of cases in the past. This method is based on the limit dose of 1000 mg/kg bw/day, as described in the test guideline OECD 414 and 416. This method would result in an individual SCL for each substance. This would indicate a precision that cannot be expected from standard reproduction studies. Also, this would result in an SCL for most substances and in a GCL for only some substances. Therefore, this method was not considered*”.

In 2019, the RAC has removed the SCLs calculated based on the old method and concluded on the harmonisation of GCL values to 0.3% w/w for boric acid and six sodium borates that have a harmonised classification as Repr. 1B.

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID,
SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC
ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3];
SODIUM PERBORATE [4]

In the available PNDT study with PBS-4, developmental effects such as skeletal, eye, CNS and cardiovascular malformations typical for boron-exposure were seen. Other developmental effects such as increased resorptions and post-implantation loss, decreased number of live foetuses, decreased foetal and litter weights were also reported. As the incidences of typical boron-exposure malformations are low, it is not possible to derive an ED10: skeletal (short rib XIII in 0.6%, 0%, 3% and 9% of the foetuses at 0, 100, 300 and 1000 mg/kg bw, respectively), eye (anophthalmia and microphthalmia seen only at 1000 mg/kg bw/day in 3.36% of the foetuses), CNS (enlarged lateral ventricles of the brain seen only at 1000 mg/kg bw/day in 1.68 of the foetuses) and cardio-vascular (seen only at 1000 mg/kg bw/day in 5.88% of the foetuses) malformations.

Thus, the LOAEL for developmental effects should be used for setting the SCLs, as according to the CLP Guidance (2017). The LOAEL for developmental effects in the PNDT study with PBS-4 is 300 mg/kg bw/day (eq. to 21 mg B/kg bw/day). Since the ED10 (LOAEL) is ≥ 4 mg/kg bw/day and ≤ 400 mg/kg bw/day (Table 3.14 of the CLP guidance) the medium potency group with a GCL of 0.3% w/w would therefore be assigned to PBS-4 (and consequently to PBS-1, correcting for B-content).

It is worth noting that a difference between effects seen in developmental studies performed with boric acid and borates and the PNDT study performed with PBS-4 is increased foetal lethality. This effect can also be used for ED10 derivation, as death of the developing organism is one of the major manifestations of developmental toxicity. On a boron-equivalent basis, there is little difference between using the LOAEL or post-implantation loss for ED10 derivation (21 mg B/kg bw/day vs. 20.2 mg B/kg bw/day, respectively). For the purpose of transparency, it can be noted that linear interpolation between the doses for the other developmental effects that allow for ED10 derivation, including post-implantation loss, gives rise to ED10-values for PBS-4 which also are ≥ 4 mg/kg bw/day and ≤ 400 mg/kg bw/day. Not only the lowest ED10 but all ED10-values are within the range for the medium potency group (Table 31).

Table 31: Determination of ED10-values based on developmental effects of PBS-4

Developmental effects	Dose levels (mg PBS-4/kg bw/day)				ED10 (linear interpolation of available doses)		Allocation of potency group*
	0	100	300	1000	(mg PBS- 4/kg bw/day)	mg B/kg bw/day	
Live foetus weight (g)	3.69	3.57	3.28	2.4	127.5	9	Medium, GCL of 0.3%
Litter weight (g)	54.97	52.62	46.49	32.52	197.2	13.8	Medium, GCL of 0.3%
Post-implantation loss (%)	2.91	2.39	13.54	15.2	288.8	20.2	Medium, GCL of 0.3%
LOAEL for developmental effects					300	21	Medium, GCL of 0.3%

*According to Table 3.14 of the CLP Guidance (2017)

In accordance with the CLP Guidance (Section 3.7.2.6.5.), modifying factors should be considered when assigning the final potency group. None of the modifying factors related to type or severity of effect, data availability, dose-response relationship, mode/mechanism of action, toxicokinetics or bio-accumulation applies for the sodium per(oxo)borates.

Therefore, PBS-4 should be assigned to the medium potency group with a GCL of 0.3% w/w. Correcting for the percentage of boron (calculations are available in Table 32), the LOAEL of 21 mg B/kg bw/day would correspond to 191 mg PBS-1/kg bw/day. Thus, PBS-1 falls within the range of the **medium potency group for adverse effects on development, for which the GCL of 0.3% w/w should apply.**

10.10.7 Adverse effects on or via lactation

No data for the assessment of adverse effects on or via lactation for per(oxo)borates were available.

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID, SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3]; SODIUM PERBORATE [4]

Since boric acid is an *in vivo* degradation product of per(oxo)borates, read-across of data from boric acid and borates is used. A recent epidemiological study found a strong correlation between B in maternal serum (266 µg/L) and breast milk (274 µg/L), indicating that there is no regulation of B in the mammary gland, but possible transfer by passive diffusion (Hjelm et al. 2019). Due to rapid excretion of B in the urine, the B levels of maternal serum and breast milk were reported to be only a fraction (approx. 5%) of those measured in the drinking water (5800 µg/L). The authors found that B exposure (via breast milk and drinking water) had a continuous effect on infant growth (up to 6 months of age), being associated with stat. sign. decreases in infant weight and length. In addition, boron compounds have been found in human breast milk (BfR, 2005), with reported (background) concentrations of approximately 4 µg B/L (Hunt et al. 2005, as reported in WHO, 2009) and in an experiment where 1 – 13 g of boric acid was given to lactating women, levels between 10 – 285 mg B/L were found in milk (Moseman, 1994).

However, it is not possible to distinguish between prenatal and postnatal exposure and the available data are not sufficient to conclude that boron is present in potentially toxic levels in breast milk.

Therefore, classification of PBS-1 for adverse effects on or via lactation is not warranted.

10.10.8 Conclusion on classification and labelling for reproductive toxicity

Based on a total weight of evidence (read-across data from PBS-4 and read-across data from boric acid and sodium borates), classification in category 1B for adverse effects on sexual function and fertility (**Repr. 1B; H360F**) for PBS-1 (Index No. 005-019-00-8, 005-019-01-5, 005-017-00-7, 005-017-01-4) is considered appropriate.

Moreover, PBS-1 (Index No. 005-019-00-8, 005-019-01-5, 005-017-00-7, 005-017-01-4) has a harmonised classification in category 1B for adverse effects on the development of the offspring (**Repr. 1B; H360D**). No change to the classification is proposed.

Withdrawal of the specific concentration limits is warranted and therefore the **GCLs of 0.3%** apply for both adverse effects on sexual function and fertility, and for adverse effects on the development of the offspring (see Table 32 below).

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID, SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3]; SODIUM PERBORATE [4]

Table 32: Derivation of ED10 values and concentration limits for PBS-1 based on boron content

Substance name	Molecular formula	EC No.	CAS No.	Molecular weight (g/mol)	Conversion factor for equivalent dose of boron (B)*	ED10 fertility**, corrected for B content (mg/kg bw/day)	LOAEL for development***, corrected for B content (mg/kg bw/day)	Proposed GCL fertility (% w/w)	Proposed GCL development (% w/w)
perboric acid, sodium salt [1] perboric acid, sodium salt, monohydrate [2] perboric acid (HBO(O ₂)), sodium salt, monohydrate; [3] sodium perborate [4]	B ₂ H ₄ O ₈ Na ₂	234-390-0 [1] 234-390-0 [2] 239-172-9 [4]	11138-47-9 [1] 12040-72-1 [2] 10332-33-9 [3] 15120-21-5 [4]	199.6	0.11	17.5/0.11 = 159	21/0.11 = 191	0.3	0.3

* Molecular weight of boron is 10.81 g/mol.

** Based on read-across from boric acid and borate salts, for which the LOAEL for effects on sexual function and fertility was set at 17.5 mg B/kg bw/day.

*** Based on the LOAEL for developmental effects of 300 mg PBS-4 /kg bw/day (eq. to 21 mg B/kg bw/day), from an OECD TG 414 study performed in rats.

RAC evaluation of reproductive toxicity

Adverse effects on sexual function and fertility

A change to classification from Repr. 2; H361f to Repr. 1B; H360F is proposed by the DS.

There are no studies available on adverse effects on sexual function and fertility for PBS-1. Read-across to data from PBS-4, boric acid and borates is proposed. Adverse effects on male fertility were the main findings in those studies.

The majority of the available epidemiological studies for boron have been previously assessed in the RAC opinions for boric acid, disodium octaborate anhydrate and disodium octaborate tetrahydrate (2014). The DS concluded based on these studies and recent available studies that although no clear boron-induced adverse effects on fertility and sexual function were shown, these data do not contradict the animal data. The DS provided data on hydrogen peroxide for comparison and to support the read-across hypothesis that boric acid, not hydrogen peroxide, is responsible for the reproductive toxicity.

The DS derived an ED₁₀ of 159 mg PBS-1/kg bw/d, based on an ED₁₀ of 17.5 mg B/kg bw/d for testes atrophy. This results in an ED₁₀ in the medium potency group ($4 < \text{ED}_{10} < 400$ mg/kg bw/d) with a generic concentration limit (GCL) of 0.3 % w/w.

Developmental effects

The DS proposes no change in the current harmonised classification of Repr. 1B; H360D for PBS-1. However, a change of the current SCLs into the GCL is proposed.

No developmental studies are available for PBS-1 and therefore read-across to PBS-4 is proposed. A reliable and GLP-compliant oral prenatal developmental toxicity study (PNDT; OECD TG 414) is available for PBS-4. For developmental toxicity, a NOAEL and LOAEL of 100 and 300 mg/kg bw/d are derived (respectively), based on increased post-implantation loss and resorptions, and decreased foetal body weight and number of live foetuses.

RAC has previously assessed epidemiological data on developmental effects upon occupational and environmental exposure to boron. In two recent prospective studies an inverse association on birth size and a possible negative effect on postnatal growth were found. In contrast, no boron-mediated effects on pregnancy outcomes were noted in another retrospective study. According to the DS, these human data are additional information for the assessment of human relevance of the developmental toxicity observed in animal studies and do not contradict these data.

The DS proposes replacing the SCLs for the GCL of 0.3 % w/w. PBS-1 falls in the medium potency group, established on an ED₁₀ (LOAEL) of 191 mg PBS-1/kg bw/d.

Effects on or via lactation

The DS does not propose classification for adverse effects on or via lactation. No relevant data are available for per(oxo)borates on adverse effects on or via lactation.

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID, SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3]; SODIUM PERBORATE [4]

Comments received during consultation

Two comments on toxicity to reproduction were submitted, both by MSCAs. Both supported the DS proposal for classification for Repr. 1B; H360FD and classification in the medium potency group. The other MSCA derived other ED₁₀ values for development than the DS. The DS acknowledged there was a mistake and added a corrected table of ED₁₀ values in the response to comments.

Assessment and comparison with the classification criteria

Adverse effects on sexual function and fertility

No reproduction toxicity studies are available for PBS-1. Read-across to PBS-4, boric acid and borate salts is therefore proposed.

In a repeated dose 28-day oral toxicity limit test (OECD TG 407, GLP) Wistar rats (n = 5/sex/group) were exposed to 0 or 1000 mg/kg bw/d PBS-4 (> 98 % purity) via oral gavage. The following was reported:

- clinical signs (salivation, temporary piloerection),
- reduced body weight (-16 %) and food consumption in males
- changes in organ weights in males (absolute: e.g. kidney, heart, testes; relative: adrenal glands) and females (only relative liver weight) and
- testicular focal tubular atrophy and inhibition of spermiation.

Clear evidence of adverse effects on male fertility, in addition to general toxicity, was thus demonstrated. RAC agrees that reduced testes weight here was substance related and is likely an early sign of testicular toxicity as also induced by boric acid and borate salts.

The DS noted that in a Specialised Experts meeting in 2004, experts concluded that changes in testicular weight were likely attributed to substance exposure and not to reduced body weight. However, it was also concluded these findings on male fertility alone were limited and not sufficient for classification. In general, repeated dose toxicity studies are less sensitive to detect adverse effects on fertility than reproductive toxicity studies due to the limited number of animals per group. This leads to a low statistical power to detect such adverse effects. This is especially true for this study and the fact only one dose group was included (limit test). Further, no information on the severity of the effects is provided. RAC notes that the weak evidence in the 28-day limit test study with PBS-4 might be due to the short duration, as in the study with boric acid, effects started after 2 weeks but worsened until weeks 6-9.²⁹ All in all, the repeated dose toxicity study is regarded as supportive evidence for adverse effects on male fertility.

²⁹ <https://echa.europa.eu/documents/10162/19507471-2f49-9564-d788-0452b1e124ab>

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID, SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3]; SODIUM PERBORATE [4]

RAC agrees read-across to boric acid is justified, based on hydrolysis, and similar toxicokinetics and toxicological profile. DS described two relevant studies with boric acid and disodium tetraborate decahydrate. Histopathological changes in the testes (testes atrophy and seminiferous tubular degeneration) have been demonstrated upon exposure to boric acid or disodium tetraborate decahydrate (purity unknown; 0, 5.9, 17.5 and 58.5 mg B/kg bw/d) in two-year feeding studies (no guideline specified) in Sprague-Dawley rats (n = 35/sex/dose group with 70/sex/dose group as controls), as previously assessed by RAC. In addition, shorter oestrous cycles, reduced sperm motility and spermatozoa concentration have been noted due to exposure in boric acid in mice, rats and dogs. Adverse effects on sexual function and fertility in males and females, due to exposure boric acid and borate salts, resulting in impaired fertility have thus been noted in multiple studies and species. Further studies with boric acid were described in other RAC opinions⁶ leading to classification as Category 1B for fertility based on alterations to the male reproductive system and impaired fertility in several species.

RAC notes that the DS refers to disodium tetraborate tetrahydrate in Table 17 of the CLH report but to disodium tetraborate decahydrate in section 10.10.2.2. RAC referred to disodium tetraborate decahydrate in the opinions on disodium octaborate anhydrate and tetrahydrate cited by the DS. Hence, RAC refers to disodium tetraborate decahydrate in this opinion as well.

For hydrogen peroxide, no guideline studies are available, and the available non-guideline studies have several limitations. Adverse effects on fertility and sexual function (e.g. variations of the oestrus cycle and reduced mobility of spermatozoa) were seen upon exposure to hydrogen peroxide. However, effects of hydrogen peroxide are mainly local and resulting in general toxicity. Altogether, data on adverse effects on fertility and sexual function are not considered conclusive due to various study limitations.

Effects of environmental and occupational exposure to boron have been studied in multiple epidemiological studies. RAC previously concluded that no clear evidence of boron-induced adverse effects on male fertility was present. Newer studies focussing on occupational exposure to boron do not demonstrate adverse effects on male fertility and sexual function. Researchers have found a statistically significant higher boron level in semen of high-exposed workers compared to the control group. However, several limitations (e.g. assignment of group based on blood boron concentrations, high exposure to boron also in control group drinking water, low statistical power) might have impacted study results. Epidemiological studies thus do not show clear evidence for adverse effects on fertility and sexual function related to boron exposure. Besides study limitations, estimated (daily) exposure levels to boron in humans are considerably lower compared to NOAELs and LOAELs for adverse effects on fertility and sexual function in animal studies. Thus, epidemiological data on fertility and sexual function do not contradict animal data.

Conclusion

For PBS-1, read-across to boric acid and borate salts is justified. Clear evidence of adverse effects on male fertility (testes atrophy and seminiferous tubular degeneration in

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID, SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3]; SODIUM PERBORATE [4]

rats) is available for boric acid and disodium tetraborate tetrahydrate, which RAC previously has assessed. The effects on testes in the available repeated dose toxicity study with read-across substance PBS-4 is regarded as supportive evidence for adverse effects on male fertility. These effects on testes induced by per(oxo)borates are likely caused via formation of boric acid and not by hydrogen peroxide.

Adverse effects on the testes in rats seen in absence of other toxicity are relevant to humans. RAC agrees with the DS that the adjustment of the classification for Repr. from Category 2 to Category 1B on adverse effects on sexual function and fertility is warranted for PBS-1.

Developmental effects

No developmental toxicity studies are available for PBS-1, but a PNDT study (OECD TG 414) is available for PBS-4. In this study, female rats (n = 25/group) were exposed to 0, 100, 300 and 1000 mg PBS-4 (purity unknown)/kg bw/d on Gestational Day 6 to 15 via oral gavage. No clinical signs, behavioural changes, pathological findings or maternal deaths were noted. Body weight and body weight gain were statistically significantly reduced in dams exposed to 300 (including and excluding gravid uterine weight) and 1000 (only including gravid uterine weight) mg/kg bw/d. Number of resorptions and post-implantation loss increased, while number of live foetuses and foetal body weight (-11 to -35 %) decreased at ≥ 300 mg/kg bw/d. In addition, increased incidence of skeletal abnormalities and variations (at ≥ 300 mg/kg bw/d; e.g. wavy rib, unossified or incomplete ossification sternebrae), renal and ureter abnormalities and variations (at 300 or 1000 mg/kg bw/d; e.g. absence renal papillae, dilated renal pelvis), and cardiovascular malformations (at 1000 mg/kg bw/d) were observed.

Adverse effects on development were noted in absence of maternal toxicity. Maternal body weight gain excluding gravid uterine weight was statistically significantly reduced in the mid-dose group and not in other dose groups. Decreased maternal body weight (gain) was likely intrauterine, as a result of resorptions, post-implantation loss and reduced foetal body weight. The main adverse effects on development considered in this study are increased number of resorptions and post-implantation loss, and decreased number of live foetuses and foetal body weight.

For boric acid, adverse effects on development at the lowest LOAEL (13.3 mg B/ kg bw/d) available included reduced mean foetal body weight per litter, shortening of the 13th rib and wavy rib (Price et al., 1996, a follow-up study of Heindel et al., 1992). In addition, cardiovascular malformations, enlargement of lateral ventricles in the brain and agenesis were noted.³⁰ A clear overlap of adverse effects of development can be seen in the PNDT study for PBS-4 and other studies available for boric acid.

Human data available for possible boron-induced adverse effects on development have been evaluated by RAC in opinions regarding boric acid, disodium octaborate anhydrate and disodium octaborate tetrahydrate. Since then, new prospective mother-child cohort studies were published. Two prospective studies have been published investigating

³⁰ Opinion of boric acid, diboron trioxide etc. <https://echa.europa.eu/documents/10162/584263da-199c-f86f-9b73-422a4f22f1c3>

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID, SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3]; SODIUM PERBORATE [4]

environmental exposure to boron in a mother-child cohort in Argentina (Igra et al., 2016; Hjelm et al., 2019). A dose-dependent effect on birth size and a possible negative effect on postnatal growth up to 6 months of age were shown due to exposure to boron but an adverse effect due to combined exposure to lithium cannot be excluded. On the other hand, no boron-mediated effects on pregnancy outcomes were noted in a retrospective study in a female cohort in Turkey (Duydu et al., 2018b). RAC agrees with the DS that these studies are additional evidence for adverse effects on development for per(oxo)borates.

Conclusion

Adverse effects on development (resorptions, post-implantation loss, reduced number of live foetuses and foetal body weight) in absence of maternal toxicity were demonstrated for PBS-4 in a PNDT study. This study is regarded as key study for PBS-1, based on read-across to PBS-4. In addition, supportive evidence is found in developmental toxicity studies for boric acid, such as by Price et al. (1996) and Heindel et al. (1992). Markedly increased incidence of agenesis of rib XIII was observed from 58 mg B/kg bw/d. The equivalent dose of PBS-1 (527 mg/kg bw/d) would probably not cause excessive maternal toxicity. Epidemiological studies on boron are also supportive.

Classification of Repr. 1B; H360D is justified for PBS-1. RAC agrees with the DS that no change to the current classification is necessary.

Effects on or via lactation

No studies are available for per(oxo)borates on adverse effects on or via lactation. Studies are available for boric acid and borate salts, where diffusion of boron from maternal serum to breast milk was shown in humans. Development was affected in humans due to boron exposure. However, prenatal and postnatal exposure cannot be separated.

Potential mode-of-action

There are no data presented in the CLH dossier on the mode-of-action of borates for the induction of adverse effects on male fertility and development. Available epidemiological studies for boron are considered as supportive evidence that adverse effects on development in rats are relevant to humans.

Specific concentration limits

Adverse effects on sexual function and fertility

The DS derived a ED₁₀ value of 159 mg/kg bw/d based on a ED₁₀ of 17.5 mg B/kg bw/d for testes atrophy from the 2-year feeding study with boric acid, as cited in the CLH report for boric acid (see Table 3 below). This ED₁₀ value is within the limits of the medium potency group (4 to 400 mg/kg bw/d) for the GCL, and thus a SCL is not justified.

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID,
SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC
ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3];
SODIUM PERBORATE [4]

Table 3: ED₁₀ value for adverse effects on sexual function and fertility (Weir, 1966)

	Dose levels (mg B/kg bw/d)				ED ₁₀ (mg B/kg bw/d)	ED ₁₀ fertility (mg kg PBS-1/kg bw/d) corrected for B content	Allocation of potency group
	0	5.9	17.5	58.5			
Testes atrophy (incidence)	3/10	1/10	4/10	10/10	17.5	17.5/0.11 = 159	Medium, GCL of 0.3 %

Developmental effects

An ED₁₀ of 191 mg/kg bw/d is derived for PBS-1, based on a LOAEL for developmental toxicity of 300 mg/kg bw/d for PBS-4 and within the limits of the medium potency group (4 to 400 mg/kg bw/d) for the GCL. As noted by the DS, ED₁₀ values based on developmental effects individually for PBS-4 (e.g. post-implantation loss, reduced foetal body weight and litter weight) and converted values based on boron content for PBS-1 are also within the limits of the medium potency group (see Table 4 below). Alternatively, the lowest LOAEL (13.3 mg B/kg bw/d) available for boric acid as presented by Price et al. (1996), equivalent to 121 mg PBS-1/kg bw/d, can be used. This converted value is also within the limits of the medium potency group (see Table 4 below).

Table 4: ED₁₀ values for developmental effects as provided by the DS in the RCOM and by RAC (2019)

	Dose levels (mg PBS-4/kg bw/d)				ED ₁₀ *			Allocation of potency group
	0	100	300	1000	mg PBS-4/kg bw/d	mg B/kg bw/d	mg PBS-1/kg bw/d	
Live foetus weight (g)	3.69	3.57	3.28	2.4	127.5 271.7	9 19	173	Medium, GCL of 0.3 %
Litter weight (g)	54.97	52.62	46.49	32.52	197.2 202.7	13.8 14.2	129	Medium, GCL of 0.3 %
Post-implantation loss (%)	2.91	2.39	13.54	15.2	288.8	20.2	184	Medium, GCL of 0.3 %
LOAEL (PBS-4) for developmental effects					300	21	191	Medium, GCL of 0.3 %
LOAEL (boric acid) for developmental effects (Price et al., 1996)					-	13.3	121	Medium, GCL of 0.3 %

*adapted by DS after comments in the consultation (numbers in red colour are the agreed changes compared to the original CLH-report).

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID, SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3]; SODIUM PERBORATE [4]

Overall conclusion

There is some evidence for reproductive toxicity of boron in humans, and this data can be used for PBS-1 based on read-across. However, these data are not sufficient for classification. Therefore, Category 1A is not warranted.

Adverse effects on male fertility (testes atrophy and seminiferous tubular degeneration) were observed in animal studies based on read-across to PBS-4, boric acid and borate salts. Death of the organism and retarded growth observed for PBS-4 in animals are clear evidence of adverse effects on development and used for read-across. These adverse effects are not considered secondary to general toxicity and are considered relevant for humans. RAC concludes that Category 1B is warranted for sexual function and fertility and on development, in agreement with the classifications proposed by the DS. RAC supports the DS proposal for no classification on effects on or via lactation.

Together this results in classification Repr.1B; H360FD without any specific concentration limit.

Inclusion of a Note

The DS proposed inclusion of a specific note to apply additivity for boron compounds that exert their reproductive toxicity through the same toxic entity (boric acid/borate ion): "Classification of mixtures is necessary if the sum of boron compounds that are classified as Repr. 1A/1B in the mixture as placed on the market is ≥ 0.3 %."

The Commission is currently discussing a text for a note (note 11³¹), to be assigned to boron compounds for classification of mixtures as reproductive toxicant based on the additivity approach which applies to substances whose hazard is due to the presence or formation of a common molecular entity (i.e., boric acid in this case).

Since the reproductive toxicity of PBS-1 is due to its hydrolytic product boric acid, RAC considers that additivity is also applicable to PBS-1.

10.11 Specific target organ toxicity-single exposure

Hazard class not assessed in this CLH-proposal.

10.12 Specific target organ toxicity-repeated exposure

Hazard class not assessed in this CLH-proposal.

10.13 Aspiration hazard

Hazard class not assessed in this CLH-proposal.

³¹ Note 11: The classification of mixtures as reproductive toxicant is necessary if the sum of the concentrations of individual boron compounds that are classified as reproductive toxicant in the mixture as placed on the market is ≥ 0.3 %.

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID,
SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC
ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3];
SODIUM PERBORATE [4]

11 EVALUATION OF ENVIRONMENTAL HAZARDS

Not assessed in this CLH-proposal.

12 EVALUATION OF ADDITIONAL HAZARDS

Not assessed in this CLH-proposal.

13 ADDITIONAL LABELLING

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID, SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3]; SODIUM PERBORATE [4]

References

Annex XV report on sodium perborate; perboric acid, sodium salt, 2014.

<https://www.echa.europa.eu/documents/10162/979d24d4-427f-684a-f6c8-c2cb3959242c>

Antonova, V.I., Salmina, Z.A., Latkina, L.L., Bukina, A.P. and Mishina, N.E. (1974). Argumentation hygienique de la concentration limite admissible en peroxyde dehydrogene dans les reservoirs d'eau. [Russian, French translation]. *Gig i Sanit* 10, 20–22.

ATSDR Report on boron (2010).

<https://www.atsdr.cdc.gov/toxprofiles/tp.asp?id=453&tid=80>

BAuA (1998). Concentration limits for substances classified as toxic to reproduction/developmental toxicity in preparations, Bundesanstalt für Arbeitsschutz und Arbeitsmedizin ECBI/19/95 add 18.

Başaran, N., Duydu, Y., Bolt, H.M. (2012). Reproductive toxicity in boron exposed workers in Bandirma, Turkey. *Journal of Trace Elements in Medicine and Biology* 26, 165– 167.

Başaran, N., Duydu, Y., Üstündağ, A., Taner, G., Aydın, S., Anlar, H. G., Yalçın, C. Ö., Bacanlı, M., Aydos, K., Atabekoglu, C.S., Golka, K., Ickstadt, K., Scwerdtle, T., Werner, M., Meyer, S. and Bolt, M. (2019). Evaluation of the DNA damage in lymphocytes, sperm and buccal cells of workers under environmental and occupational boron exposure conditions. *Mutation Research/Genetic Toxicology and Environmental Mutagenesis*, 843, 33-39.

BfR (Bundesinstitut für Risikobewertung) (2005). Addition of boric acid or borax to food supplements. Health Assessment No 005/2006, 16 November 2005.

Bolt, H. M., Başaran, N., & Duydu, Y. (2020). Effects of boron compounds on human reproduction. *Archives of toxicology*, 94(3), 717-724.

Cain, W. S., Jalowayski, A. A., Kleinman, M., Lee, N. S., Lee, B. R., Ahn, B. H. and Culver, B. D. (2004). Sensory and associated reactions to mineral dusts: sodium borate, calcium oxide, and calcium sulfate. *Journal of occupational and environmental hygiene*, 1(4), 222-236.

Cain, W. S., Jalowayski, A. A., Schmidt, R., Kleinman, M., Magruder, K., Lee, K. C. and Culver, B. D. (2008). Chemesthetic responses to airborne mineral dusts: boric acid compared to alkaline materials. *International archives of occupational and environmental health*, 81(3), 337-345.

Carrondo, M.A., Skapski, A.C. (1978). Refinement of the X-ray crystal structure of the industrial bleaching agent disodium tetrahydroxo-di-μ-peroxo-diborate hexahydrate, Na₂[B₂(O₂)₂(OH)₄]₆H₂O. *Acta Cryst.* 34, 3551–3554.

Chance, B., Sies, H., Boveris, A. (1979). Hydroperoxide metabolism in mammalian organs. *Physiological Reviews* 59, 527-605.

CLH report on boric acid (2013).

<https://www.echa.europa.eu/documents/10162/ee39f026-9d2d-28f7-5d90-63a424112162>

CLP Guidance Document on the application of the CLP criteria (2017).

https://echa.europa.eu/documents/10162/23036412/clp_en.pdf/58b5dc6d-ac2a-4910-9702-e9e1f5051cc5

Dill, H. (1977). Blood boron levels in patients using buffered sodium peroxyborate monohydrate mouthwash three times daily for four weeks.

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID, SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3]; SODIUM PERBORATE [4]

Duydu, Y., Başaran, N., Üstündağ, A., Aydın, S., Ündeğer, Ü., Ataman, O. Y. and Golka, K. (2011). Reproductive toxicity parameters and biological monitoring in occupationally and environmentally boron-exposed persons in Bandırma, Turkey. *Archives of toxicology*, 85(6), 589-600.

Duydu, Y., Başaran, N., Üstündağ, A., Aydın, S., Ündeğer, Ü., Ataman, O. Y., Aydos, K., Düker Y., Ickstadt K., Waltrup B.S., Golka K. and Bolt, H. M. (2012). Assessment of DNA integrity (COMET assay) in sperm cells of boron-exposed workers. *Archives of toxicology*, 86(1), 27-35.

Duydu, Y., Başaran, N., Aydın, S., Üstündağ, A., Yalçın, C. Ö., Anlar, H. G., and Ickstadt, K. (2018a). Evaluation of FSH, LH, testosterone levels and semen parameters in male boron workers under extreme exposure conditions. *Archives of toxicology*, 92(10), 3051-3059.

Duydu, Y., Başaran, N., Üstündağ, A., Aydın, S., Yalçın, C. Ö., Anlar, H. G. and Ickstadt, K. (2018b). Birth weights of newborns and pregnancy outcomes of environmentally boron-exposed females in Turkey. *Archives of toxicology*, 92(8), 2475-2485.

Duydu, Y., Başaran, N., Yalçın, C. Ö., Üstündağ, A., Aydın, S., Anlar, H. G., Bacanlı, M., Aydos, K., Atabekoglu, C.S., Golka, K., Ickstadt, K., Scwerdtle, T., Werner, M., Meyer, S. and Bolt, H. M. (2019). Boron-exposed male workers in Turkey: no change in sperm Y: X chromosome ratio and in offspring's sex ratio. *Archives of toxicology*, 93(3), 743-751.

ECBI/38/03 Add. 15 (2006). Clarification of Annex I entries for sodium perborate hydrates.

ECBI/38/03 Add.17 (2006). Draft proposal for specific concentration limits for sodium perborate.

ECBI/55/05 (2005). Draft Summary Record of the meeting of the Technical Committee C&L on the Classification and Labelling of Dangerous Substances.

ECBI/60/05 Rev. 3 (2005). Draft Summary Record of the meeting of the Technical Committee C&L on the Health Effects of new Substances, Pesticides, Biocides, Existing Chemicals and General Issues.

ECBI/90/06 Rev. 8 (2006). Summary Record of the meeting of the Technical Committee C&L on the Health Effects of New Substances, Pesticides, biocides, Existing Chemicals and General Issues.

Edwall, L., Karlen, B. and Rosen, A. (1979). Absorption of boron after mouthwash treatment with Bocosept. *Eur. J. Clin. Pharmacol.* 15, 417-420.

EFSA (2012). Scientific Opinion. Guidance on selected default values to be used by the EFSA Scientific Committee, Scientific Panels and Units in the absence of actual measured data. <https://efsa.onlinelibrary.wiley.com/doi/pdfdirect/10.2903/j.efsa.2012.2579?download=true>

EU RAR (2003). European Risk Assessment Report on hydrogen peroxide (CAS 7722-84-1). European Chemicals Bureau. <https://echa.europa.eu/documents/10162/a6f76a0e-fe32-4121-9d9d-b06d9d5f6852>

EU RAR (2007). European Risk Assessment Report on perboric acid, sodium salt (CAS 11138-47-9). European Chemicals Bureau. https://echa.europa.eu/documents/10162/6434698/orats_final_rar_perboricacid_sodiumsalt_en.pdf

Feron, V. J., De Groot, A. P., Spanjers, M. T., & Til, H. P. (1973). An evaluation of the criterion "organ weight" under conditions of growth retardation. *Food and cosmetics toxicology*, 11(1), 85-94.

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID, SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3]; SODIUM PERBORATE [4]

Flanagan, J., Griffith, W.P., Powell, R.D., West, A.P. (1989). Vibrational spectra of alkali metal peroxoborate. *Spectrochim*, 45, 951–955.

Grootveld, M., Lynch, E., Page, G., Chan, W., Percival, B., Anagnostaki, E., Mylona, V., Bordin-Aykroyd, S. and Grootveld, K. L. (2020). Potential Advantages of Peroxoborates and Their Ester Adducts Over Hydrogen Peroxide as Therapeutic Agents in Oral Healthcare Products: Chemical/Biochemical Reactivity Considerations In Vitro, Ex Vivo And In Vivo. *Dentistry Journal*, 8(3), 89.

Hankin, L. (1958). Hydrogen peroxide, ingestion and the growth of rats. *Nature* 181, 1453.

HERA Report (2002). Human & Environmental Risk Assessment on ingredients of European household cleaning products: Perboric acid, sodium salt, mono and tetrahydrate (CAS 11138-47-9, 10332-33-9, 10486-00-7).
<https://www.heraproject.com/files/7-F-04HERA%20sodium%20perborate%20full%20web%20wd.pdf>

HERA Report (2005). Human & Environmental Risk Assessment on ingredients of household cleaning products: Hydrogen Peroxide (CAS 7722-84-1).
https://www.heraproject.com/files/36-F-05-Shor_H2O2_version1.pdf

Hjelm, C., Harari, F., & Vahter, M. (2019). Pre-and postnatal environmental boron exposure and infant growth: Results from a mother-child cohort in northern Argentina. *Environmental research*, 171, 60-68.

Hunt, C.D., Butte, N.F., Johnson, L.K. (2005). Boron concentrations in milk from mothers of exclusively breast-fed healthy full-term infants are stable during the first four months of lactation. *Journal of Nutrition*, 135(10), 2383–2386.

Igra, A.M., Harari, F., Lu, Y., Casimiro, E. and Vahter, M. (2016). Boron exposure through drinking water during pregnancy and birth size. *Environ Int.*, 95, 54-60.

Ito, A., Naito, M. and Watanabe, H. (1981a). Implication of chemical carcinogenesis in the experimental animal. [Japanese, English translation]. Annual Report of Hiroshima University Research Institute of Nuclear Medicine and Biology 22, 147-158.

Ito, A., Watanabe, H. and Naito, M. (1981b). Prevalence of Gastric Erosions and Duodenal Tumors with a Continuous Oral Administration of Hydrogen Peroxide in C57BL/6J Mice. Study Report. Research Institute for Nuclear Medicine and Biology, Department of Cancer Research, Hiroshima.

Kondrashov, V.A. (1977). Evaluation of the toxicity of hydrogen peroxide vapors for inhalation and percutaneous exposures. [Russian, English translation]. *Gig. Tr. Prof. Zabol.* 21, 22-25.

Ku, W. W., Chapin, R. E., Wine, R. N. and Gladen, B. C. (1993). Testicular toxicity of boric acid (BA): relationship of dose to lesion development and recovery in the F344 rat. *Reproductive toxicology*, 7(4), 305-319.

Makino, N., Mochizuki, Y., Bannai, S. and Sugita, Y. (1994). Kinetic studies on the removal of extracellular hydrogen peroxide by cultured fibroblasts. *J. Biol. Chem.* 269, 1020-1025.

Moseman, R.F. (1994). Chemical disposition of boron in animals and humans. *Environmental Health Perspectives*, 102(7), 113–117.

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID, SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3]; SODIUM PERBORATE [4]

Mulinos, M. G., Higgins, G. K., & Christakis, G. J. (1952). On the toxicity of sodium perborate. *Journal of the Society of Cosmetic Chemists*, 3, 297-302.

Murray, F. J. (1998). A comparative review of the pharmacokinetics of boric acid in rodents and humans. *Biological trace element research*, 66(1-3), 331-341.

OECD TG 403 (2009). Guideline for the testing of chemicals for acute inhalation toxicity. https://www.oecd-ilibrary.org/environment/test-no-403-acute-inhalation-toxicity_9789264070608-en

OECD TG 433 (2018). Guideline for testing of chemicals for acute inhalation toxicity: fixed concentration procedure. https://www.oecd-ilibrary.org/environment/test-no-433-acute-inhalation-toxicity-fixed-concentration-procedure_9789264284166-en

Osihi, S., Oishi, H., Hiranga, K. (1979). The effect of food restriction for 4 weeks on common toxicity parameters in male rats. *Toxicol. Appl. Pharmacol.* 47, 15-22.

Price, C. J., Strong, P. L., Marr, M. C., Myers, C. B. and Murray, F. J. (1996a). Developmental toxicity NOAEL and postnatal recovery in rats fed boric acid during gestation. *Fundamental and applied toxicology*, 32(2), 179-193.

Price, C. J., Strong, P. L., Murray, F. J., & Goldberg, M. M. (1997). Blood boron concentrations in pregnant rats fed boric acid throughout gestation. *Reproductive Toxicology*, 11(6), 833-842.

RAC opinion on boric acid (2014). <https://www.echa.europa.eu/documents/10162/4db9bc68-844e-c557-8914-ab491743d471>

RAC opinion on disodium octaborate anhydrate (2014). <https://www.echa.europa.eu/documents/10162/7d740d8c-5cd5-872b-5da2-e549983a9ff9>

RAC opinion disodium octaborate tetrahydrate (2014). <https://www.echa.europa.eu/documents/10162/658b802c-1ca3-663e-4bd4-437369d715de>

RAC Opinion on boric acid, diboron trioxide, tetraboron disodium heptaoxide hydrate, disodium tetraborate anhydrous, orthoboric acid sodium salt, disodium tetraborate decahydrate and disodium tetraborate pentahydrate (2019). <https://www.echa.europa.eu/documents/10162/584263da-199c-f86f-9b73-422a4f22f1c3>

RAC Opinion on barium diboron tetraoxide (2020). <https://www.echa.europa.eu/documents/10162/19507471-2f49-9564-d788-0452b1e124ab>

Riihimäki, V., Toppila, A., Piirilä, P., Kuosma, E., Pfäffli, P. and Tuomela, P. (2002). Respiratory health in aseptic packaging with hydrogen peroxide. A report of two cases. *J. Occup. Health* 44, 433-438.

Robbins, W. A., Wei, F., Elashoff, D. A., Wu, G., Xun, L., & Jia, J. (2008). Y: X sperm ratio in boron-exposed men. *Journal of andrology*, 29(1), 115-121.

Robbins, W. A., Xun, L., Jia, J., Kennedy, N., Elashoff, D. A., & Ping, L. (2010). Chronic boron exposure and human semen parameters. *Reproductive Toxicology*, 29(2), 184-190.

SCCS Opinion on sodium perborate and perboric acid (2010). https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_146.pdf

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID, SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3]; SODIUM PERBORATE [4]

Silajev, A.A., (1984). Experimental bases of MAC for sodium perborate workplace air. Gig. Trud. Prof. Zabol, 28, 44.

Spector, A. and Garner, W.H. (1981). Hydrogen peroxide and human cataract. Exp. Eye Res. 33, 670-681.

Study report (1966). Two-year dietary feeding study with boric acid in rats. REACH Registration dossier for boric acid, publicly available at <https://www.echa.europa.eu/sv/web/guest/registration-dossier/-/registered-dossier/15472/1>, accessed 27th of October, 2020.

Study report (1967). Two-year dietary feeding study with boric acid in rats. REACH Registration dossier for boric acid, publicly available at <https://www.echa.europa.eu/sv/web/guest/registration-dossier/-/registered-dossier/15472/1>, accessed 27th of October, 2020.

Study Report (1981). Acute oral toxicity study with hydrogen peroxide 60% in rats. REACH Registration dossier for hydrogen peroxide, EC No. 231-765-0, publicly available at <https://echa.europa.eu/registration-dossier/-/registered-dossier/15701/7/3/2>, accessed 26th of October, 2020.

Study Report (1982). Acute dermal toxicity of hydrogen peroxide in rabbits. REACH Registration dossier for hydrogen peroxide, EC No. 231-765-0, publicly available at <https://echa.europa.eu/registration-dossier/-/registered-dossier/15701/7/3/4>, accessed 27th of October, 2020.

Study Report (1987a). Acute oral toxicity of sodium perborate monohydrate in rats. REACH Registration dossier for perboric acid, sodium salt, EC No. 234-390-0, publicly available at <https://www.echa.europa.eu/en/web/guest/registration-dossier/-/registered-dossier/13523/7/3/2/?documentUUID=e0667f3b-ec06-4e50-b620-33bf3ad71e94>, accessed 26th of October, 2020.

Study Report (1987b). Acute dermal toxicity of sodium perborate monohydrate in rabbits. REACH Registration dossier for perboric acid, sodium salt, EC No. 234-390-0, publicly available at <https://www.echa.europa.eu/en/web/guest/registration-dossier/-/registered-dossier/13523/7/3/4>, accessed 26th of October, 2020.

Study Report (1987c). Acute inhalation toxicity of sodium perborate tetrahydrate in rats. REACH Registration dossier for perboric acid, sodium salt, EC No. 234-390-0, publicly available at <https://www.echa.europa.eu/en/web/guest/registration-dossier/-/registered-dossier/13523/7/3/3>, accessed 26th of October, 2020.

Study report (1988). Acute oral toxicity of sodium perborate monohydrate in rats. REACH Registration dossier for perboric acid, sodium salt, EC No. 234-390-0, publicly available at <https://www.echa.europa.eu/en/web/guest/registration-dossier/-/registered-dossier/13523/7/3/2>, accessed 26th of October, 2020.

Study Report (1989). Repeated dose 28-day toxicity study with sodium perborate tetrahydrate in rats. REACH Registration dossier for perboric acid, sodium salt, EC No. 234-390-0, publicly available at <https://www.echa.europa.eu/en/web/guest/registration-dossier/-/registered-dossier/13523/7/9/2>, accessed 26th of October, 2020.

Study Report (1990). Acute oral toxicity study of hydrogen peroxide 10% in rats. REACH Registration dossier for hydrogen peroxide, EC No. 231-765-0, publicly available at <https://echa.europa.eu/registration-dossier/-/registered-dossier/15701/7/3/4>, accessed 27th of October, 2020.

Study Report (1990b). Acute inhalation toxicity study of hydrogen peroxide 50% in rats. REACH Registration dossier for hydrogen peroxide, EC No. 231-765-0, publicly available at

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID, SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3]; SODIUM PERBORATE [4]

<https://echa.europa.eu/registration-dossier/-/registered-dossier/15701/7/3/4>, accessed 27th of October, 2020.

Study Report (1995a). Acute inhalation toxicity study of hydrogen peroxide 50% in mice. REACH Registration dossier for hydrogen peroxide, EC No. 231-765-0, publicly available at <https://echa.europa.eu/registration-dossier/-/registered-dossier/15701/7/3/4>, accessed 27th of October, 2020.

Study Report (1995b). Prenatal developmental toxicity study with sodium perborate tetrahydrate in rats. REACH Registration dossier for perboric acid, sodium salt, EC No. 234-390-0, publicly available at <https://www.echa.europa.eu/en/web/guest/registration-dossier/-/registered-dossier/13523/7/9/3>, accessed 28th of October, 2020.

Study report (1996). Acute oral toxicity study with hydrogen peroxide 70% in rats. REACH Registration dossier for hydrogen peroxide, EC No. 231-765-0, publicly available at <https://echa.europa.eu/registration-dossier/-/registered-dossier/15701/7/3/2>, accessed 27th of October, 2020.

Takayama, S. (1980). Report on a Carcinogenicity Study. Research Group, Ministry of Health and Welfare, Japan. Cancer Institute of Japan, Foundation for Cancer Research, Tokyo.

Treinen, K. A., and Chapin, R. E. (1991). Development of testicular lesions in F344 rats after treatment with boric acid. *Toxicology and applied pharmacology*, 107(2), 325-335.

Bertsch-Frank, B., Engel, D., Kleinschmit, P., Lehmann, T., Panster, P., Steiner, N. and Jacobi, S. (1991). Peroxo compounds, inorganic. Ullmann's encyclopedia of industrial chemistry, Revised subsequent edition, 177-197.

Urschel, Jr. H.C. (1967). Progress in cardiovascular surgery. Cardiovascular effects of hydrogen peroxide: current status. *Prog. Cardiovasc. Surg. (Dis. Chest.)* 51, 180-192.

Varma, S.D. and Devamanoharan, P.S. (1991). Hydrogen peroxide in human blood. *Free Rad. Res. Comm.* 14, 125-131.

Wales, R.G., White, I.G. and Lamond, D.R. (1959). The spermicidal activity of hydrogen peroxide *in vitro* and *in vivo*. *J. Endocrin.* 18, 236-244.

Watt, B. E., Proudfoot, A. T., & Vale, J. A. (2004). Hydrogen peroxide poisoning. *Toxicological reviews*, 23(1), 51-57.

Weir RJ and Fisher RS, 1972. Toxicologic studies on borax and boric acid. *Toxicology and Applied Pharmacology* 23: 351 – 364. As summarised in the publicly disseminated REACH Registration for boric acid, <https://www.echa.europa.eu/sv/web/guest/registration-dossier/-/registered-dossier/15472/1>.

Weir RJ (1966). Three-generation reproductive study - rats. Boric acid. Final Report. Testing laboratory: Hazleton Laboratories Inc. Report no. TX-66-16.

WHO (World Health Organization) (2009). Boron in Drinking-water. Background document for development of WHO Guidelines for Drinking-water Quality. World Health Organization, Geneva, Switzerland. 28 pp. http://whqlibdoc.who.int/hq/2009/WHO_HSE_WSH_09.01_2_eng.pdf

Williams, M.D., Leigh, J.S. and Chance, B. (1982). Hydrogen peroxide in human breath and its probable role in spontaneous breath luminescence. *Ann. NY Acad. Sci.* 386, 478-483.

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON PERBORIC ACID,
SODIUM SALT [1]; PERBORIC ACID, SODIUM SALT, MONOHYDRATE [2]; PERBORIC
ACID (HBO(O₂)), SODIUM SALT, MONOHYDRATE; SODIUM PEROXOBORATE [3];
SODIUM PERBORATE [4]

Yalçın, C. Ö., Üstündağ, A., & Duydu, Y. (2019). Is There an Association Between Extreme Levels of Boron Exposure and Decrease in Y: X Sperm Ratio in Men? Results of an Epidemiological Study. *Turkish Journal of Pharmaceutical Sciences*, 16(1), 96.

14 ANNEXES

Annex I to the CLH-report.

Annex I to the CLH report

Proposal for Harmonised Classification and Labelling

**Based on Regulation (EC) No 1272/2008 (CLP Regulation),
Annex VI, Part 2**

International Chemical Identification:

**perboric acid, sodium salt [1]; perboric acid, sodium salt, monohydrate [2];
perboric acid (HBO(O₂)), sodium salt, monohydrate; sodium peroxoborate [3];
sodium perborate [4]**

EC Number: 234-390-0 [1]; 234-390-0 [2]; 239-172-9 [4]

CAS Number: 11138-47-9 [1]; 12040-72-1 [2]; 10332-33-9 [3]; 15120-21-5 [4]

Index Number: 005-019-00-8; 005-019-01-5; 005-017-00-7; 005-017-01-4

Contact details for dossier submitter:

Swedish Chemicals Agency
Esplanaden 3A, P.O Box 2
SE-172 13 Sundbyberg, Sweden
kemi@kemi.se
+46 8 519 41 100

Version number: 1

Date: 2021-04-01

CONTENTS

1 PHYSICAL HAZARDS

2 HEALTH HAZARDS

2.1 ACUTE TOXICITY - ORAL ROUTE

2.1.1 *Animal data*

2.1.1.1 [Study 1] Acute oral toxicity study with PBS-1 in rats (EPA OPP 81-1, GLP)

2.2 ACUTE TOXICITY - DERMAL ROUTE

2.2.1 *Animal data*

2.2.1.1 [Study 1] Acute dermal toxicity study in rats with PBS-1 (OECD TG 402, non-GLP)

2.3 ACUTE TOXICITY - INHALATION ROUTE

2.3.1 *Animal data*

2.3.1.1 [Study 1] Acute inhalation toxicity study with PBS-4 in rats (non-guideline, GLP)

2.4 SKIN CORROSION/IRRITATION

2.5 SERIOUS EYE DAMAGE/EYE IRRITATION

2.6 RESPIRATORY SENSITISATION 7

2.7 SKIN SENSITISATION

2.8 GERM CELL MUTAGENICITY

2.9 CARCINOGENICITY

2.10 REPRODUCTIVE TOXICITY

2.10.1 *Animal data*

2.10.1.1 Adverse effects on sexual function and fertility

2.10.1.2 Adverse effects on the development of the offspring

2.10.2 *Human data*

2.10.2.1 Adverse effects on sexual function and fertility

2.10.2.2 Adverse effects on the development of the offspring

2.11 SPECIFIC TARGET ORGAN TOXICITY – SINGLE EXPOSURE

2.12 SPECIFIC TARGET ORGAN TOXICITY – REPEATED EXPOSURE

2.13 ASPIRATION HAZARD⁴

3 ENVIRONMENTAL HAZARDS

1 PHYSICAL HAZARDS

Not assessed in this CLH-proposal.

2 HEALTH HAZARDS

Acute toxicity

2.1 Acute toxicity - oral route

2.1.1 Animal data

2.1.1.1 [Study 1] Acute oral toxicity study with PBS-1 in rats (EPA OPP 81-1, GLP).

Study reference:

Study report (1988). Acute oral toxicity of sodium perborate monohydrate in rats.

Detailed study summary and results:

Test type

Acute oral toxicity of sodium perborate monohydrate in rats according to US EPA 099 81-1, GLP-compliant.

Test substance

- Sodium perborate monohydrate
- Degree of purity: unknown

Test animals

- Species/strain/sex: rat/Spargue-Dawley/males and females
- No. of animals per sex per dose: 5/sex/dose group

Administration/exposure

- Mode of administration : oral (gavage)
- Doses/concentration levels: 500, 1000 and 2000 mg/kg bw
- Post exposure observation period: 14 days

Results and reliability

- LD50 males: 1300 mg/kg bw
- LD50 females: 890 mg/kg bw
- LD50 males/females: 1120 mg/kg bw

Dose (mg/kg)	Lethality M	Lethality F
500	0/5	0/5
1000	1/5 (on day 1)	3/5 (1/5 on day 1 and 2/5 on day 2)
2000	5/5 (3/5 on day 0 and 2/5 on day 1)	5/5 (on day 0)

Estimated Oral LD50*: Male - 1.30 g/kg of body weight
 95% Confidence Limits of 0.85 to 1.99 g/kg
 Female - 0.89 g/kg of body weight
 95% Confidence Limits of 0.53 to 1.51 g/kg
 Combined Sexes - 1.12 g/kg of body weight
 95% Confidence Limits of 0.77 to 1.63 g/kg

Mortality Summary (Number of Deaths)

Dose Level (g/kg)	Hours		Days								Total		
	0 - 4		1	2	3	4	5	6	7-14	M	F	Both	
	M	F	M F	M F	M F	M F	M F	M F	M F	M	F	Both	
0.5	0	0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0/5	0/5	0/10
1.0	0	0	1 1	0 2	0 0	0 0	0 0	0 0	0 0	0 0	1/5	3/5	4/10
()	3	5	2 -	- -	- -	- -	- -	- -	- -	- -	5/5	5/5	10/10

Average Body Weights (g)

	Dose Level (g/kg)	Average Body Weights (g)		
		Initial	Day 7	Terminal
Male	0.5	269	348	392
	1.0	292	361	427
	2.0	275	---	---
Female	0.5	225	247	259
	1.0	213	247	256
	2.0	228	---	---

CLINICAL SIGNS
(No. of Animals Affected)

	Hours			Days													
	1.0	2.5	4.0	1	2	3	4	5	6	7	8	9	10	11	12	13	14
Males (0.50 g/kg)																	
Appeared Normal	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
Females (0.50 g/kg)																	
Appeared Normal	4	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
Diarrhea	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Males (1.0 g/kg)																	
Appeared Normal	1	0	0	0	2	3	4	4	4	4	4	4	4	4	4	4	4
Mydriasis	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Hypoactivity	1	5	5	5	1	1	0	0	0	0	0	0	0	0	0	0	0
Excessive salivation	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Possible respiratory congestion	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Ataxia	0	3	5	1	0	0	0	0	0	0	0	0	0	0	0	0	0
Diarrhea	0	0	3	1	0	0	0	0	0	0	0	0	0	0	0	0	0
Red-stained face	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
Yellow-stained genital region	0	0	0	2	1	0	0	0	0	0	0	0	0	0	0	0	0
Death	0	0	0	1*	0	0	0	0	0	0	0	0	0	0	0	0	0
Females (1.0 g/kg)																	
Appeared Normal	0	0	0	0	0	0	1	1	1	1	2	2	2	2	2	2	2
Hypoactivity	5	5	5	4	2	2	1	1	1	0	0	0	0	0	0	0	0
Ataxia	4	5	5	3	1	0	0	0	0	0	0	0	0	0	0	0	0
Mydriasis	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Possible respiratory congestion	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Diarrhea	0	4	4	3	0	0	0	0	0	0	0	0	0	0	0	0	0
Lacrimation	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Yellow-stained genital region	0	1	1	3	2	1	1	1	1	1	0	0	0	0	0	0	0
Red-stained face	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
Death	0	0	0	1	2	0	0	0	0	0	0	0	0	0	0	0	0

* - Found dead at p.m. mortality check.

CLINICAL SIGNS (continued)
(No. of Animals Affected)

	Hours			Days													
	1.0	2.5	4.0	1	2	3	4	5	6	7	8	9	10	11	12	13	14
Males (2.0 g/kg)																	
Appeared Normal	2	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-
Hypoactivity	3	4	2	0	-	-	-	-	-	-	-	-	-	-	-	-	-
Ataxia	0	4	2	0	-	-	-	-	-	-	-	-	-	-	-	-	-
Pain reflex absent	0	1	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-
Diarrhea	0	2	2	0	-	-	-	-	-	-	-	-	-	-	-	-	-
Lacrimation	0	1	1	0	-	-	-	-	-	-	-	-	-	-	-	-	-
Tremors	0	0	1	0	-	-	-	-	-	-	-	-	-	-	-	-	-
Death	0	1	2	2	-	-	-	-	-	-	-	-	-	-	-	-	-
Females (2.0 g/kg)																	
Appeared Normal	5	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Hypoactivity	0	1	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Ataxia	0	1	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Diarrhea	0	2	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Prostration	0	1	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pain reflex absent	0	1	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Lacrimation	0	1	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Death	0	3	2	-	-	-	-	-	-	-	-	-	-	-	-	-	-

PATHOLOGY

Dose Level: 0.50 g/kg of body weight

Animal Number	Sex	Test Day		Necropsy Comments
		Died	Sacrificed	
C03087	M	-	14	No visible lesions.
C03083	M	-	14	No visible lesions.
C03084	M	-	14	No visible lesions.
C03100	M	-	14	No visible lesions.
C03098	M	-	14	No visible lesions.
C03297	F	-	14	No visible lesions.
C03280	F	-	14	No visible lesions.
C03275	F	-	14	No visible lesions.
C03271	F	-	14	No visible lesions.
C03277	F	-	14	Alopecia of entire inguinal region.

PATHOLOGY (continued)

Dose Level: 1.0 g/kg of body weight

Animal Number	Sex	Test Day		Necropsy Comments
		Died	Sacrificed	
C03150	M	1	-	Testes cannibalized.
C03153	M	-	14	No visible lesions.
C03148	M	-	14	No visible lesions.
C03090	M	-	14	Kidney (right) - enlarged pelvis.
C03126	M	-	14	No visible lesions.
C03252	F	1	-	No visible lesions.
C03254	F	2	-	No visible lesions.
C03255	F	2	-	No visible lesions.
C03251	F	-	14	No visible lesions.
C03253	F	-	14	No visible lesions.

PATHOLOGY (continued)

Dose Level: 2.0 g/kg of body weight

Animal Number	Sex	Test Day		Necropsy Comments
		Died	Sacrificed	
C03118	M	0	-	Entire gastrointestinal (GI) tract - filled with clear fluid and air; stomach - very distended with air or gas, walls are thickened, and mucosa is stained yellow, red and brown.
C03115	M	0	-	Stomach - very distended with air or gas, walls are thickened, and mucosa is stained brown, tan and red.
C03119	M	1	-	Stomach - very distended and glandular mucosa is stained red, tan and brown.
C03117	M	0	-	Stomach - very distended with air or gas, walls are thickened, and glandular mucosa is stained yellow, tan and red.
C03086	M	1	-	Stomach - very distended and glandular mucosa is stained red, tan and brown.

PATHOLOGY (continued)

Dose Level: 2.0 g/kg of body weight (continued)

Animal Number	Sex	Test Day		Necropsy Comments
		Died	Sacrificed	
C03300	F	0	-	Entire GI tract - filled with air and clear fluid; stomach - very distended with air or gas, walls are thickened, and glandular mucosa is stained yellow, tan and red.
C03292	F	0	-	Entire GI tract - filled with clear fluid; stomach - very distended, walls are thickened, and glandular mucosa is stained white, tan and red; kidney (bilateral) - enlarged pelvis.
C03295	F	0	-	Entire GI tract - filled with clear fluid; stomach - contains tan semi-fluid, is very distended with gas or air, walls are thickened, and mucosa is stained tan and red.
C03294	F	0	-	Stomach - contains white semi-fluid, walls are thickened, and mucosa is stained tan and red; cecum - contains brown, mucoid semi-fluid.
C03293	F	0	-	Stomach - very distended with air or gas, walls are thickened, and glandular mucosa is stained yellow, tan and red.

2.2 Acute toxicity - dermal route

2.2.1 Animal data

2.2.1.1 [Study 1] Acute dermal toxicity study in rats with PBS-1 (OECD TG 402, non-GLP).

Study reference:

Study Report (1987c). Acute dermal toxicity of sodium perborate monohydrate in rabbits.

Detailed study summary and results:

Test type

Acute dermal toxicity (OECD TG 402, non-GLP).

Test substance

- Sodium perborate monohydrate (PBS-1)
- Degree of purity: unknown

Test animals

- Species/strain/sex: rabbit/New Zealand White/males and females

- No. of animals per sex per dose: 5/sex

Administration/exposure

- Mode of administration: Occlusive dermal application
- Duration of test/exposure period: Single dermal dose, 24 h exposure
- Doses/concentration levels: 2000 mg/kg bw
- Post exposure observation period: 14 days

Results and reliability

- LD₅₀ > 2000 mg/kg bw
- The acute dermal toxicity study (OECD TG 402) performed in rabbits with sodium perborate monohydrate established an LD₅₀ > 2000 mg/kg bw. Clinical signs such as diarrhoea, few faeces, yellow nasal discharge and anogenital soiling were reported. One male rabbit died on day 13 post-treatment revealing abnormalities of the gastrointestinal tract, spleen, liver and lung. On day 1 post-treatment, 2/9 surviving rabbits showed skin irritation, which decreased in severity during the 14-day observation period, and distended intestines at the necropsy evaluation. No statistically significant effects on body weight were recorded.

2.3 Acute toxicity - inhalation route

2.3.1 Animal data

2.3.1.1 [Study 1] Acute inhalation toxicity study with PBS-4 in rats (non-guideline, GLP).

Study reference:

Study report (1987d). Acute inhalation toxicity of sodium perborate tetrahydrate in rats.

Detailed study summary and results:

Test type

Acute inhalation toxicity of sodium perborate tetrahydrate in rats, standard acute method, similar to OECD TG 403; GLP-compliant. Data concerning macroscopic or histopathological examinations not reported.

Test substance

- Sodium perborate tetrahydrate (PBS-4)
- CAS No. 10486-00-7
- Degree of purity: 98.6%
- Impurities (or a note that the impurities do not affect the classification)
- Batch number: 16.703 (Haskell Lab.)
- MMAD: 3.3 – 4.2 µm (dust)

Test animals

- Species/strain/sex: rats/ CrI:CD BR/males
- No. of animals per sex per dose: 6/dose group
- Age and weight at the study initiation: 8 weeks, 230 – 290 g

Administration/exposure

- Type of inhalation exposure: nose-only
- Duration of test/exposure period: 4 hours

- Doses/concentration levels: 0.16, 0.48, 1.10 and 2.90 mg/L
- Post exposure observation period: 14 days
- Statistical methods: LC 50 was calculated separately by Probit Analysis.

**Characterization of Sodium Perborate Tetrahydrate Atmospheres
and Associated Rat Mortality**

<u>Concentration (mg/m³)</u>			<u>% Particles < 10 um AD^a</u>	<u>MMD(um)^b</u>	<u>Mortality (# deaths/# exposed)</u>
<u>Mean</u>	<u>S.D.</u>	<u>Range</u>			
160	23	140 - 210	94	3.3	0/6
480	130	280 - 640	94	3.5	1/6
1100	240	720 - 1500	93	3.5	3/6
2900	1500	870 - 4900	86	4.2	5/6

^a Percent by weight of particles with aerodynamic diameter (AD) less than 10 um.
^b Mass median aerodynamic diameter.

Results

- LC50 value : 1.16 mg/L
- All deaths occurred within 24 hours.
- Clinical signs: During or immediately following exposure, rats from all groups exhibited gasping, red nasal discharge, and compound-covered faeces. Rats from the ≥ 480 mg/m³ groups also exhibited laboured breathing.
- Body weight: Rats typically had slight to severe (up to 18 % of initial body weight) weight losses within 24 hours of exposure.
- Pathology: no data.

**Characterization of Sodium Perborate Tetrahydrate Atmospheres
and Associated Rat Mortality**

<u>Concentration (mg/m³)</u>			<u>% Particles < 10 um AD^a</u>	<u>MMD(um)^b</u>	<u>Mortality (# deaths/# exposed)</u>
<u>Mean</u>	<u>S.D.</u>	<u>Range</u>			
160	23	140 - 210	94	3.3	0/6
480	130	280 - 640	94	3.5	1/6
1100	240	720 - 1500	93	3.5	3/6
2900	1500	870 - 4900	86	4.2	5/6

^a Percent by weight of particles with aerodynamic diameter (AD) less than 10 um.
^b Mass median aerodynamic diameter.

2.4 Skin corrosion/irritation

Not assessed in this CLH-proposal.

2.5 Serious eye damage/eye irritation

Not assessed in this CLH-proposal.

2.6 Respiratory sensitisation

Not assessed in this CLH-proposal.

2.7 Skin sensitisation

Not assessed in this CLH-proposal.

2.8 Germ cell mutagenicity

Not assessed in this CLH-proposal.

2.9 Carcinogenicity

Not assessed in this CLH-proposal.

2.10 Reproductive toxicity

2.10.1 Animal data

2.10.1.1 Adverse effects on sexual function and fertility

2.10.1.1.1 [Study 1] 28-day repeated dose toxicity study in rats administered PBS-4 (OECD TG 407, Limit test; GLP).

Study reference:

Study report (1989). Sodium perborate tetrahydrate 4-week oral toxicity study after repeated administration in rats. Unpublished report.

Detailed study summary and results:

Test type

Repeated dose 28-day oral toxicity study in rats, according to OECD TG 407, GLP-compliant.

Only one dose level – limit test.

Test substance

- Sodium perborate tetrahydrate (PBS-4)
- CAS No. 10486-00-7
- Degree of purity - >98%

Test animals

- Species/strain/sex – rat/WISW (SPFCpb)/males and females
- No. of animals per sex per dose – 5/sex

- Age and weight at the study initiation – 7 weeks; males: 139-173 g; females: 108-131 g

Administration/exposure

- route of administration – oral (gavage)
- duration and frequency of test/exposure period – once daily, 7 days/week for 4 weeks
- doses/concentration levels, rationale for dose level selection – 1000 mg/kg bw/day; dose rationale based on a dose finding study
- control group – 1% aqueous tylose suspension
- test substance concentration of the vehicle suspension – 215 mg/L

Description of test design:

- CAGE SIDE OBSERVATIONS: 1 - 2 times daily incl. observations for mortality
- DETAILED CLINICAL OBSERVATIONS: Daily check for clinical signs (behavioural changes, first occurrence, progress, intensity and duration of signs of toxicity). Prior to study start and at termination: testing of reflexes (pain, pinna and corneal reflexes) as well as examinations of eyes, teeth, or hearing.
- BODY WEIGHT: once weekly, starting with pre-study period.
- FOOD CONSUMPTION: once weekly
- FOOD EFFICIENCY: No data
- WATER CONSUMPTION: No data
- OPHTHALMOSCOPIC EXAMINATION: prior to study start and at termination in all animals
- HAEMATOLOGY: during week 4 in all animals
Anaesthetic used for blood collection: CO₂ anaesthesia. Parameters examined: RBC, Hct, Hb, WBC, MCH, MCHC, MCV, thrombocytes (platelets) and differential leucocyte count
- CLINICAL CHEMISTRY: during week 4 in all animals
Parameters examined: Alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, BUN, Ca, Cl, CHE, CK, creatinine, gamma-glutamyltransferase, glucose, inorganic phosphorus, K, Na, total bilirubin, total cholesterol, total protein, triglycerides
- URINALYSIS: during week 4 in all animals
Parameters examined: bilirubin, glucose, haemoglobin, ketones, leucocytes, nitrite, osmolality, pH-value, protein, urobilinogen and microscopic sediment examination in animals whose urine state showed pathological changes in leucocytes, protein, or haemoglobin.
- GROSS PATHOLOGY: all animals
- HISTOPATHOLOGY: adrenal glands, bone (sternum), bone marrow smears, brain, caecum, colon, duodenum, heart, ileum, jejunum, kidneys, liver, lungs, ovaries, rectum, skin, spleen, stomach, testes.
- STATISTICS: Dunnett or Steel-test.

Results and discussion

- Clinical symptoms: The only clinical symptom observed in almost all treated rats was salivation, in males also of reddish colour. One male additionally performed stilted gait, sunken sides and piloerection. During the last 4 days of treatment piloerection was observed in two additional animals. Mortality did not occur during the study.

- Food consumption and body weight: The food consumption as well as the body weight gain were reduced in males after start of administration. The difference reached about 15% in week 4 for both parameters. Females were not affected.
- Clinical pathology: Slight decreases were present in treated animals of both sexes in red blood cell count, haemoglobin content and hematocrit. The value of mean corpuscular haemoglobin concentration was slightly increased, white blood cell count and absolute lymphocyte count were decreased only in males. The number of platelets was slightly elevated in both males and females. Reduction of absolute lymphocyte number with corresponding decrease in white blood cell count was also present in females but without statistical significance.
- Clinical chemistry: slight but statistically significantly decreased values were found for alkaline phosphatase, total protein and cholinesterase in both sexes. The serum levels of bilirubin, inorganic phosphorus and potassium were increased in males only.
- Urinalysis: no alterations were present.
- Organ weights: the absolute weights of hearts, brains, kidneys and testes were reduced in males only. The relative weight (to body weight) of these organs were not affected. Slight increases were noticed in the relative weight of adrenals in males and livers in females.
- Necropsy: reduction of spleen size in 2 treated males.
- Histopathology: test substance-related findings in the spleen in males only, and in the stomach in males and females. Mild general reduction of splenic parenchyma in males without specific findings. The gastric changes consist of minimal to slight acanthosis and hyperkeratosis in the forestomach, slight to moderate hyperplasia of fundic mucosa, especially of the gastric pits.

ORGAN/BODY WEIGHT RATIOS SUMMARY
 Week 5 (Main-Group)
 MALES

		GROUP 1 CONTROL	GROUP 2 1000
B.- Weight (GRAM)	MEAN	249	206 *
	ST.DEV.	7	29
	T STAT	---	-3.18
	MINIMUM	243	180
	MAXIMUM	260	251
	N	5	5
Brain (%)	MEAN	0.70	0.77
	ST.DEV.	0.02	0.08
	T STAT	---	2.26
	MINIMUM	0.68	0.67
	MAXIMUM	0.72	0.85
	N	5	5
Heart (%)	MEAN	0.45	0.45
	ST.DEV.	0.05	0.04
	T STAT	---	0.10
	MINIMUM	0.40	0.40
	MAXIMUM	0.51	0.50
	N	5	5
Liver (%)	MEAN	4.42	4.17
	ST.DEV.	0.69	0.25
	T STAT	---	-0.77
	MINIMUM	3.95	3.90
	MAXIMUM	5.61	4.50
	N	5	5
Kidney l. (%)	MEAN	0.39	0.39
	ST.DEV.	0.03	0.02
	T STAT	---	-0.27
	MINIMUM	0.36	0.37
	MAXIMUM	0.42	0.41
	N	5	5
Kidney r. (%)	MEAN	0.37	0.39
	ST.DEV.	0.03	0.03
	T STAT	---	1.36
	MINIMUM	0.35	0.36
	MAXIMUM	0.41	0.43
	N	5	5
Adrenal l. (%)	MEAN	0.009	0.012 *
	ST.DEV.	0.001	0.002
	T STAT	---	2.64
	MINIMUM	0.008	0.010
	MAXIMUM	0.011	0.014
	N	5	5
Adrenal r. (%)	MEAN	0.008	0.011 **
	ST.DEV.	0.001	0.001
	T STAT	---	3.82
	MINIMUM	0.006	0.009
	MAXIMUM	0.009	0.012
	N	5	5
Testis l. (%)	MEAN	0.84	0.84
	ST.DEV.	0.03	0.07
	T STAT	---	0.00
	MINIMUM	0.80	0.78
	MAXIMUM	0.87	0.94
	N	5	5
Testis r. (%)	MEAN	0.85	0.85
	ST.DEV.	0.04	0.08
	T STAT	---	0.07
	MINIMUM	0.80	0.76
	MAXIMUM	0.90	0.95
	N	5	5

* / ** : Dunnett-Test based on pooled variance significant at 5% (*) or 1% (**) level

ORGAN/BODY WEIGHT RATIOS SUMMARY
 Week 5 (Main-Group)
 FEMALES

		GROUP 1 CONTROL	GROUP 2 1000
B.- Weight (GRAM)	MEAN	157	159
	ST.DEV.	12	9
	T STAT	---	0.36
	MINIMUM	142	150
	MAXIMUM	171	172
	N	5	5
Brain (%)	MEAN	1.02	0.99
	ST.DEV.	0.10	0.09
	T STAT	---	-0.43
	MINIMUM	0.90	0.88
	MAXIMUM	1.13	1.12
	N	5	5
Heart (%)	MEAN	0.50	0.49
	ST.DEV.	0.06	0.02
	T STAT	---	-0.34
	MINIMUM	0.45	0.46
	MAXIMUM	0.59	0.51
	N	5	5
Liver (%)	MEAN	4.44	4.87 *
	ST.DEV.	0.27	0.26
	T STAT	---	2.56
	MINIMUM	4.18	4.51
	MAXIMUM	4.88	5.12
	N	5	5
Kidney l. (%)	MEAN	0.38	0.39
	ST.DEV.	0.03	0.04
	T STAT	---	0.41
	MINIMUM	0.34	0.36
	MAXIMUM	0.41	0.43
	N	5	5
Kidney r. (%)	MEAN	0.39	0.39
	ST.DEV.	0.04	0.03
	T STAT	---	0.20
	MINIMUM	0.35	0.36
	MAXIMUM	0.43	0.43
	N	5	5
Adrenal l. (%)	MEAN	0.018	0.020
	ST.DEV.	0.004	0.002
	T STAT	---	1.22
	MINIMUM	0.016	0.017
	MAXIMUM	0.024	0.022
	N	5	5
Adrenal r. (%)	MEAN	0.018	0.017
	ST.DEV.	0.004	0.004
	T STAT	---	-0.24
	MINIMUM	0.015	0.012
	MAXIMUM	0.024	0.022
	N	5	5
Ovar l. (%)	MEAN	0.036	0.030
	ST.DEV.	0.010	0.004
	T STAT	---	-1.33
	MINIMUM	0.029	0.023
	MAXIMUM	0.054	0.034
	N	5	5
Ovar r. (%)	MEAN	0.036	0.033
	ST.DEV.	0.004	0.004
	T STAT	---	-1.22
	MINIMUM	0.031	0.026
	MAXIMUM	0.041	0.037
	N	5	5

* / ** : Dunnett-Test based on pooled variance significant at 5% (*) or 1% (**) level

NUMBER OF ANIMALS WITH MICROSCOPIC FINDINGS BY ORGAN/GROUP/SEX
STATUS AT NECROPSY: K0

ORGAN/FINDING	DOSE GROUP: SEX: NO. ANIMALS:	01		02	
		M	F	M	F
LIVER	NO. EXAM.:	5	5	5	5
- Mononucl.c.inf. foc.		1	4	2	5
- Small inflammat.foci		3	5		4
KIDNEYS	NO. EXAM.:	5	5	5	5
- Pelvic dilatation			1		
- Basophilic tubules		1		2	1
- Hyaline casts					1
- Mononucl.c.inf. foc.		1	1		2
- Nephritis interstit.		1		1	
HEART	NO. EXAM.:	5	5	5	5
- Mononucl.c.inf. foc.		1	1	2	2
- Arteritis		1			
- Fibrosis subendocard			1		
SPLEEN	NO. EXAM.:	5	5	5	5
- Increas.hematopoies.					1
- Reduction parenchyma				5	
LUNGS	NO. EXAM.:	5	5	5	5
- Hemorrhage acute		1		2	
- Histiocytosis focal		3	4	3	5
STOMACH	NO. EXAM.:	5	5	5	5
- Hemorrhage acute				1	
- Cyst(s) mucosal			1		
- Akanthos./Hyperkerat			1	4	4
- Hyperplasia fund.muc				5	4
- Gastritis subacute					1
BRAIN	NO. EXAM.:	5	5	5	5
- Hemorrhage acute		2	1	1	1

2.10.1.1.2 [Study 2] Two-year feeding study with boric acid in rats

Study reference:

Study report (1966d). Two-year dietary feeding study with boric acid in rats. REACH Registration dossier for boric acid, publicly available at <https://www.echa.europa.eu/sv/web/guest/registration-dossier/-/registered-dossier/15472/1>.

Study report (1967). Two-year dietary feeding study with boric acid in rats. REACH Registration dossier for boric acid, publicly available at <https://www.echa.europa.eu/sv/web/guest/registration-dossier/-/registered-dossier/15472/1>.

Guideline:

- No guideline followed for 90-day oral repeated dose toxicity studies.
No guideline specified for the reproductive toxicity study, but conforms to the standard three-generation, 2 litters per generation multi-generation studies normally used at the time.

Reliability :

- Klimisch 2: reliable with restrictions (reliability according to the CLH dossier of boric acid, assessed by RAC in 2013)

Species /strain: Rat, Sprague-Dawley (male/female), Beagle dogs (male/female)

Test material:

- Boric acid or borax
- Purity: unknown

Materials and methods:

1. 90-day oral repeated dose toxicity study in rats and dogs (Study 1 and 2)

Male and female rats per group were placed for a period of 90 days on dietary concentrations of borax or boric acid at 52.5, 175, 525, 1750 and 5250 ppm as boron equivalent added with thorough mixing to the basal diet on a w/w basis. In addition, five young male and five female beagle dogs per group were placed for a period of 90 days on dietary concentrations of borax or boric acid at 17.5, 175 and 1750 ppm as boron equivalent added to the laboratory diet. In both studies all animals were individually caged.

Route of administration: oral, feed

Exposure: 90 days

Doses / Concentrations:

- in rats: 0, 52.5, 175, 525, 1750 and 5250 ppm boron, equivalent to 0, 4.7, 15.7, 47.2, 157.5 and 472.5 mg B/kg

bw/day, respectively

- in dogs: 0, 17.5, 175, and 1750 ppm boron, equivalent to 0, 0.4, 4.3 and 43.7 mg B/kg bw/day, respectively

No. of animals: 10 rats/sex/dose group and 5 dogs/sex/dose group

Body weights: Body weights and food consumption were measured at weekly intervals.

Clinical observations: Hematologic studies included packed cell volume, hemoglobin, erythrocyte count, total and differential leukocyte counts on all dogs initially, at 2 and 4 wk and at termination. Biochemical studies including blood urea nitrogen, blood sugar, serum glutamic-oxaloacetic transaminase and serum glutamic-pyruvic transaminase were performed at the same time. Urine samples were analyzed for specific gravity, pH, protein, sugar, bilirubin, acetone and sediment at similar intervals. Survivors were sacrificed after 90 days on the diet.

Necropsy evaluation: the weights of brain, thyroid, liver, spleen, kidney, adrenals and testes were recorded. The tissues preserved in buffered formalin and studied histopathologically were brain, pituitary, thyroids, lung, heart, liver, spleen, kidneys, adrenals, pancreas, small and large intestines, urinary bladder, testes, ovary (for rat only), bone and bone marrow.

Statistics: Numerical deviation from the control observations were evaluated by conventional statistical tests using $P < 0.05$ as the fiducial limit (Snedecor, 1956).

2. Reproductive toxicity study (Study 3)

Prior to initiation of the first breeding phase, the male and female rats were maintained in individual cages and fed their respective diets for 14 wk. After the 14 wk feeding period, 1 male and 2 females were placed in each breeding cage. At 24 hr after birth, the litters were reduced to a maximum of 8 progeny to be raised. The first filial generation (F1A) was carried through weaning and discarded. The parental generation (P1) was rebred to produce their second litter (F1B). At the time of weaning, 16 females and 8 males each from the control and test groups were selected at random and designated the second parental generation (P2) for continuation of the reproduction study. These animals were bred to produce the F2A and F2B litters as before. The F2B litter became the P3 generation and were bred to produce the F3A and F3B litters.

Route of administration: oral, feed

Exposure: from the beginning of the study (14 weeks pre-mating exposure) until sacrifice of parents P1, and from weaning until sacrifice of the F1- and F2-generations

Doses / Concentrations: 0, 117, 350 and 1170 ppm boron, equivalent to 0, 5.9, 17.5 and 58.5 mg B/kg bw/day

No. of animals: 8 males/dose group and 16 females/dose group

Body weights: Body weight and food consumption were recorded weekly.

Necropsy evaluation: With the exception of the P1, P2 and P3, control and test groups, necropsies were performed on all rats.

Statistics: Numerical deviation from the control observations were evaluated by conventional statistical tests using $P < 0.05$ as the fiducial limit (Snedecor, 1956).

3. Two-year feeding study with boric acid in rats (Study 4)

The control group of 70 male and 70 female weanling rats (Sprague-Dawley strain) received the basal diet. Test groups of 35 male and 35 female weanling rats each received a diet containing borax or boric acid at 117, 350 and 1170 ppm as boron equivalent, for a period of 2 yr. All animals were individually housed and provided with free access to the diet and drinking water.

Route of administration: oral, feed

Exposure: 2 years

Doses / Concentrations: 0, 117, 350 and 1170 ppm boron, equivalent to 0, 5.9, 17.5 and 58.5 mg B/kg bw/day

No. of animals: 70/sex/dose group for controls and 35/sex/dose group for the treatment

Body weights: Data on body weight, food consumption and toxic signs were recorded regularly (interval not specified).

Clinical parameters: Biochemical studies and urine analyses (as described in study 1 above) were carried out on all dogs at similar intervals. Pooled urine samples from 5 rats each were analyzed at 6, 18 and 24 mo. Samples of blood for hematologic studies were taken from representative rats in each group at seven intervals during the 2 yr feeding period.

Organ weights: Organ weights (organs involved were described in study 1 above) were recorded and organ weight/body weight ratios were calculated.

Histopathology examination: Sections of tissues involved (as described in Study 1 above) were examined for histopathologic alteration.

Necropsy evaluation: Five rats of both sexes from each group at 6 and 12 mo, and all survivors at 2 yr were sacrificed and necropsied.

Statistics: Numerical deviation from the control observations were evaluated by conventional statistical tests using $P < 0.05$ as the fiducial limit (Snedecor, 1956).

Results:

1. 90-day oral repeated dose toxicity study in rats and dogs (Study 1 and 2)

• Rats

Clinical observations: the physical appearance of the rats receiving either borax or boric acid at levels at and below 525 ppm boron were generally comparable to those of the controls throughout the study. Rats fed 1750 and 5250 ppm of boron as borax or boric acid had a rapid respiration, inflamed eyes, swollen paws, and desquamated skin on the paws and tails. These animals appeared excited when handled. All males had a shrunken scrotum during the last weeks of the study.

Mortality: One rat each at 52.5 and 1750 ppm of boron (in borax) died during the study. At 5250 ppm of boron, both borax and boric acid killed all rats within 3 to 6 wk.

Feed consumption: Growth and food utilization efficiency were significantly reduced for males fed borax at 1750 ppm boron content and for both males and females at 5250 ppm boron. Boric acid at 525 ppm (or less) as boron equivalent did not affect the growth, food consumption and food efficiency. At 1750 ppm boron levels, boric acid reduced growth and food consumption in both males and females.

Organ weights: Borax at 52.5 ppm as boron equivalent caused an increase in the weight of brain, spleen, kidneys and ovaries in female rats, while boric acid at the same level caused an increase in liver weight; no changes of organ weights occurred in male rats. Increase in kidney weight was observed in males fed borax at 175 ppm boron content.

Rats which received either borax or boric acid at 525 ppm of boron showed organ weights comparable to those of the controls. Male rats fed boron compounds at 1750 ppm boron content had a significant decrease in body weight and the weights of liver, spleen, kidneys and testes; borax at this level also caused a reduction in brain weight, while boric acid lowered adrenal weight.

Table: Changes in body weights in male rats administered 1750 ppm boron

	Control	Borax	Boric acid
Body	477 ± 31	215 + 90 ^b	268 ± 44 ^b
Brain	2.13 ± 0.17	1.86 ± 0.11 ^b	1.97 ± 0.15
Thyroids	0.019 ± 0.004	0.015 ± 0.002	0.016 ± 0.004
Liver	16.85 ± 1.35	7.04 ± 1.42 ^b	7.41 ± 1.61 ^b
Spleen	0.78 ± 0.12	0.34 ± 0.09 ^b	0.40 ± 0.11 ^b
Kidneys	3.08 ± 0.34	1.92 ± 0.32 ^b	1.89 ± 0.33 ^b
Adrenals	0.046 ± 0.006	0.039 ± 0.008	0.037 ± 0.009 ^b
Testes	3.50 ± 0.26	0.79 ± 0.17 ^b	0.83 ± 0.11 ^b

^a All values are expressed as mean ± SD for 9 rats. All lower levels are comparable to controls.

^b Significantly lower than control, $p < 0.05$.

Female rats which received the same dose levels of either borax or boric acid had decreases in body weight and weights of liver, spleen and ovaries; in addition, boric acid caused a fall in adrenal weight.

Table: Changes in body weights in female rats administered 1750 ppm boron

	Control	Borax	Boric acid
Body	247 ± 21	222 ± 28 ^b	216 ± 28 ^b
Brain	1.91 ± 0.09	1.91 ± 0.13	1.91 ± 0.17
Thyroids	0.015 ± 0.003	0.015 ± 0.003	0.018 ± 0.006
Liver	7.90 ± 1.20	6.40 ± 1.46 ^b	6.38 ± 1.16 ^b
Spleen	0.52 ± 0.12	0.39 ± 0.11 ^b	0.38 ± 0.06 ^b
Kidneys	1.88 ± 0.15	1.75 ± 0.28	1.73 ± 0.19
Adrenals	0.05 ± 0.01	0.040 ± 0.009 ^b	0.047 ± 0.007
Ovaries	0.124 ± 0.02	0.071 ± 0.025 ^b	0.090 ± 0.030 ^b

^a All values are expressed as mean ± SD for 9 rats. All lower levels are comparable to controls.

^b Significantly lower than control, $p < 0.05$.

An increase in brain/body weight ratio occurred in female rats fed borax at 52.5 ppm, while boric acid at the same dose level was accompanied by a decrease in brain/body weight ratio in male rats. Borax caused an increase in kidney/body weight ratio at 525 ppm. Both boron compounds, when fed to rats at 1750 ppm, caused increases in brain, thyroids and adrenal/body weight ratios in the males.

Table: Changes in body weight: body weight ratios (%) for male rats administered 1750 ppm boron

	Control	Borax	Boric acid
Brain	0.447 ± 0.003	0.81 ± 0.20 ^c	0.75 ± 0.11 ^c
Thyroids	0.814 ± 0.002	0.007 ± 0.002 ^c	0.006 ± 0.002 ^c
Liver	3.54 ± 0.27	2.96 ± 0.23 ^b	2.77 ± 0.34 ^b
Spleen	0.17 ± 0.02	0.14 ± 0.02	0.15 ± 0.04
Kidneys	0.65 ± 0.08	0.81 ± 0.08 ^c	0.71 ± 0.09
Adrenals	0.010 ± 0.001	0.015 ± 0.002 ^c	0.014 ± 0.003 ^c
Testes	0.73 ± 0.06	0.34 ± 0.04 ^b	0.32 ± 0.07 ^b

^a All values are expressed as mean ± SD for 9 rats. All lower levels are comparable to controls.

^b Significantly lower than control, $p < 0.05$.

^c Significantly higher than controls, $p < 0.05$.

In addition to these findings, borax also increased kidney/body weight ratio. There was an increase in brain/body weight ratios in female rats receiving either borax or boric acid at 1750 ppm boron content.

Table: Changes in organ weight: body weight ratios (%) for female rats administered 1750 ppm boron

	Control	Borax	Boric acid
Brain	0.78 ± 0.07	0.90 ± 0.12 ^c	0.90 ± 0.14 ^c
Thyroids	0.006 ± 0.001	0.007 ± 0.001	0.008 ± 0.003 ^c
Liver	3.19 ± 0.21	3.06 ± 0.26	2.95 ± 0.22 ^b
Spleen	0.20 ± 0.03	0.18 ± 0.03	0.18 ± 0.04
Kidneys	0.75 ± 0.05	0.79 ± 0.06	0.81 ± 0.05
Adrenals	0.022 ± 0.002	0.019 ± 0.005	0.022 ± 0.002
Ovaries	0.05 ± 0.01	0.034 ± 0.010 ^b	0.042 ± 0.013

^a All values are expressed as mean ± SD for 9 rats. All lower levels are comparable to controls.

^b Significantly lower than control, $p < 0.05$.

^c Significantly higher than control, $p < 0.05$.

Furthermore, borax decreased ovaries/body weight ratio: boric acid increased thyroids and decreased liver/body weight ratios. There were no changes of organ/brain weight ratios in the rats fed either borax or boric acid at 52.5, 175 and 525 ppm as boron equivalent. Both borax and boric acid at 1750 ppm boron content caused decreases in liver, spleen, kidneys and testes/brain weight ratios in male rats.

Table: Organ: brain weight ratios (%) for male rats administered 1750 ppm boron

	Control	Borax	Boric acid
Thyroids	0.88 ± 0.22	0.81 ± 0.16	0.79 ± 0.21
Liver	795 ± 68	378 ± 72 ^b	373 ± 58 ^b
Spleen	37.0 ± 5.0	18.0 ± 4.0 ^b	20.0 ± 5.0 ^b
Kidneys	146 ± 20	103 ± 16 ^b	95.2 ± 11.1 ^b
Adrenals	2.2 ± 0.3	2.1 ± 0.4	1.9 ± 0.4
Testes	165 ± 14	42.4 ± 7.7 ^b	42.4 ± 5.8 ^b

^a All values are expressed as mean ± SD for 9 rats. All lower levels are comparable to controls.

^b Significantly lower than control, $p < 0.05$.

Female rats receiving boron compounds at the Furthermore, borax at 1750 ppm boron content also caused a decrease

in adrenals/brain weight ratio in female rats.

Necropsy examination: Necropsies performed on the animals that died (one each from 52.5 and 1750 ppm boron levels of borax and all rats at 5250 ppm boron level of borax and boric acid) showed congestion of liver and kidneys,

bright red lungs and in several animals a swollen appearance of the brain, small gonads and a thickened pancreas. Microscopic examination of the tissues revealed complete atrophy of testes in all males fed either borax or boric acid

at 1750 ppm as boron equivalent, partial atrophy in 4 males at 525 ppm of borax and in 1 at 525 ppm of boric acid. Spermatogenic arrest was found in 1 male at 525 ppm of borax. The adrenals of the majority of the males and several

females at 1750 ppm boron equivalent of borax revealed a slight to moderate increase in lipid content and the size of

the cells in the zona reticularis; the adrenals of 4 males at 1750 ppm boron content of boric acid had similar changes

but to a lesser degree.

• Dogs

Clinical observations: dogs, with one exception, fed both borax and boric acid at 17.5, 175 and 1750 ppm as boron equivalent were essentially normal in appearance, behavior, elimination, body weights and food consumption.

Mortality: One male dog at 1750 ppm level of boron as borax died of diarrhea on day 68 of the study and showed congested kidneys and severe congestion of the mucosa of small and large intestines.

Clinical parameters: Hematologic, biochemical and urine values were within normal limits except for 2 male and 3 female dogs in the high borax level group (1750 ppm boron content). These animals had decreased packed cell volume and hemoglobin values during the study.

Organ weights: The spleen/body weight ratio in male dogs at 17.5 ppm level of boron as borax was significantly lower than that of the controls. At 175 ppm boron content, as boric acid, a decrease in testes/body weight ratio was observed. Both borax and boric acid caused significant decreases in thyroids and testes/body weight ratios in dogs at 1750 ppm boron content.

Table: Mean body weights, organ weights and organ:body weight ratios (%) of male and female dogs administered 1750 ppm boron

	Control		Borax		Boric acid	
	Weight	Ratio	Weight	Ratio	Weight	Ratio
Male						
Body weight	8.5 ± 1.9		9.3 ± 0.8		8.6 ± 1.0	
Thyroids	0.77 ± 0.14	0.009 ± 0.001	0.59 ± 0.13	0.006 ± 0.001 ^b	0.48 ± 0.18	0.006 ± 0.002 ^b
Testes	1.72 ± 3.3	0.20 ± 0.03	9.6 ± 3.4	0.10 ± 0.03 ^b	10.5 ± 1.5	0.12 ± 0.02 ^b
Female						
Body weight	6.2 ± 2.0		7.7 ± 1.2		9.0 ± 2.3	
Brain	68.7 ± 7.1	1.1 ± 0.4	80.3 ± 3.1 ^c	1.10 ± 0.15	72.3 ± 2.7	0.85 ± 0.23
Liver	190.0 ± 47.0	2.8 ± 0.5	257 ± 47	3.3 ± 0.5	345 ± 49	4.1 ± 1.2 ^c

^a All numbers are expressed as mean ± SD for four male and five female dogs. All lower levels are comparable to controls.

^b Significantly lower than control at $p < 0.05$

^c Significantly higher than control at $p < 0.05$.

Other organs including spleen, liver, kidneys and adrenals were found to be within normal limits. Neither borax nor boric acid at 17.5 and 175 ppm boron content levels produced any changes in organ weights and organ/body weight ratios in female dogs. Increases in brain/body weight ratio and liver/body weight ratio occurred in dogs fed 1750 ppm boron content levels of borax and boric acid, respectively.

Histopathology examination: No histologic alterations were seen in dogs fed 175 ppm (or less) of boron in boric acid. Both borax and boric acid at the 1750 ppm boron level produced severe testicular atrophy in all male dogs. Degeneration of the spermatogenic epithelium was generally complete. Red blood cell destruction, as indicated by the presence of hemosiderin in the reticular cells of the liver and spleen and the proximal tubules of the kidney, was somewhat greater in the animals that received borax than in those that received boric acid. The thyroid gland of the borax treated males presented a slightly greater proportion of solid epithelial nests and minute follicles than was found in the control animals. In the adrenal gland, the zona reticularis was consistently increased in width in borax fed dogs and only in boric acid treated female dogs. The high level of boric acid (1750 ppm boron content) also increased the width of the zona glomerulosa in the adrenals of the female dogs. The zona fasciculata was, in general, somewhat decreased in width. The thyroids of the two females were infiltrated by lymphoid tissue, and one was rather markedly atrophied.

2. Reproductive toxicity study (Study 3)

There were no adverse effects on the reproduction of rats receiving a diet containing either borax or boric acid at 117 and 350 ppm as boron equivalent. Litter size, weights of progeny and appearance were normal compared with those of the controls. The overall fertility indices for the two test compounds at levels of 177 and 350 ppm boron were significantly higher than those of the controls. Live birth indices were within normal limits in the test groups.

Table: Fertility indices for F1, F2 and F3 filial generations of rats (5.9 and 17.5 mg B/kg bw/day administered as boric acid or borax)

Index	Control	5.9 mg B/kg bw/day	17.5 mg B/kg bw/day	Control	5.9 mg B/kg bw/day	17.5 mg B/kg bw/day	
Borax							
Fertility index ^a	P1-F1A			P1-F1B			
	62.5	68.8	75	60	62.5	75	
	P2-F2A			P2-F2B			
	81.3	81.3	100	80	75	93.8	
	P3-F3A			P3-F3B			
	68.8	87.5	100 ^b	68.8	87.5	100 ^b	
	Boric acid						
	P1-F1A			P1-F1B			
	62.5	87.5	81.3	60	87.5	75	
	P2-F2A			P2-F2B			
	81.3	93.8	93.8	80	93.8	93.8	
	P3-F3A			P3-F3B			
68.8	100 ^b	87.5	68.8	93.8	93.8		

^a Fertility index: number of pregnancies/number of matings x 100.

^b Significantly higher than controls.

Histopathological examination: No gross abnormalities were observed in the organs examined from either parents or weanlings. Evidence was also found of decreased ovulation in the majority of the ovaries examined from the same level females sacrificed following the reproduction study (data not shown).

Mating: The high level test groups fed both borax and boric acid at 1170 ppm as boron equivalent were found to be sterile. An attempt to obtain litters by mating the treated females with the males fed only the basal diet was not successful. Microscopic examination revealed the lack of viable sperm in the atrophied testes of all males at the 1170 ppm boron equivalent level of both borax and boric acid.

For all filial generations (i.e. F1, F2 and F3), for both low- and mid-dose groups, the litter size, weights of progeny and appearance were not statistically significantly different from controls (data not shown). No other information on maternal toxicity is reported.

At 58.5 mg/kg bw/day there were no offspring produced from P1 animals.

Table: Live birth indices for F1, F2 and F3 filial generations of rats (5.9 and 17.5 mg B/kg bw/day administered as boric acid or borax)

Index	Control	5.9 mg B/kg bw/day	17.5 mg B/kg bw/day	Control	5.9 mg B/kg bw/day	17.5 mg B/kg bw/day	
Borax							
Live birth index ^a	P1-F1A			P1-F1B			
	98.4	98.4	100	99.1	99.2	99.4	
	P2-F2A			P2-F2B			
	97.8	99.4	96.9	98.6	92.4	98.8	
	P3-F3A			P3-F3B			
	100	100	99.4	100	100	100	
	Boric acid						
	P1-F1A			P1-F1B			
	98.4	96	97.2	99.1	99.4	100	
	P2-F2A			P2-F2B			
97.8	100	99.4	98.6	99.4	97.9		
P3-F3A			P3-F3B				
100	99.5	97.9	100	99	98.8		

^a Live birth index = number of pups born alive/number of born pups x 100.

3. Two-year feeding study in rats (Study 4)

Clinical observations: The appearance and behavior of the rats fed both borax and boric acid at 117 and 350 ppm as boron equivalent in the diets were generally comparable with those of the controls. The following gross signs were observed among the rats at the highest level (1170 ppm boron content): coarse hair coats, scaly tails, a hunched position, swelling and desquamation of the pads of the paws, abnormally long toenails, shrunken appearance of the scrotum of the males, inflamed eyelids and bloody discharge of the eyes. Onset of these signs was at the beginning of the second month. They became more frequent and pronounced by the end of the first year, but remained relatively unchanged during the second year.

Feed consumption: Both borax and boric acid at 1170 ppm as boron equivalent lowered food consumption during the first 13 wk and suppressed growth in rats throughout the 2 yr study.

Clinical parameters: Low packed cell volume and hemoglobin values found at many intervals during the study are considered to be significant in male and female rats fed borax at 1170 ppm as boron equivalent, and in female rats which received the same level of boric acid. Biochemical values and urine analyses were found to be within normal limits in rats which received different levels of both boron compounds.

Organ weights: The testes weights and testes/body weight ratios were significantly lower, whereas the brain and thyroid/body weight ratios were significantly higher than those of the controls (data not shown).

Histopathology examination: There were no histologic alterations in the organs of rats fed either borax or boric acid at 117 and 350 ppm levels as boron equivalent for 2 yr. Atrophic testes were found in all males receiving 1170 ppm boron in both borax and boric acid at 6, 12 and 24 mo. Microscopic examination revealed atrophied seminiferous epithelium and decreased tubular size in the testes.

Table: Testes atrophy was observed at 24 months

Dose level (mg B/kg bw/day)	0	5.9	17.5	58.5
No. of animals	3/10	1/10	4/10	10/10

Conclusion

Rats exposed to the high dose of 336 mg/kg bw boric acid (corresponding to a level of 58.5 mg B/kg bw) were sterile. Microscopic examination of the atrophied testes of all males in this group showed no viable sperm. The authors also reported evidence of decreased ovulation in about half of the ovaries examined from the females exposed to 58.5 mg B/kg bw and only 1/16 matings produced a litter from these high dose females when mated with control male animals. There were no adverse effects on reproduction reported at exposures of 34 and 100 mg/kg bw boric acid (5.9 and 17.5 mg B/kg bw). The authors reported no adverse effects on fertility, lactation, litter size, progeny weight or appearance in rats exposed to either 5.9 or 17.5 mg B/kg bw. Also, no gross abnormalities were observed in the organs examined from either parents or weanlings from these dose groups.

2.10.1.2 Adverse effects on the development of the offspring

2.10.1.2.1 [Study 1] Prenatal developmental toxicity study with PBS-4 in rats (OECD TG 414, GLP).

Study reference:

Study report (1995). Sodium perborate tetrahydrate: teratogenesis study in rats by oral route. Unpublished report.

Detailed study summary and results:

Test type

Prenatal developmental toxicity study in rats, according to OECD TG 414, GLP-compliant, no deviations.

Test substance

- Sodium perborate tetrahydrate (PBS-4)
- CAS No. 10486-00-7
- Degree of purity – unknown
- Batch number – CONFIDENTIAL

Test animals

- Species/strain/sex – rat/Crl:CD (SD) BR/females
- No. of animals per sex per dose – 25 females/dose group
- Age and weight at the study initiation – approx. 11 weeks old, 200-225 g at receipt.

Administration/exposure

- route of administration – oral (gavage)
- duration and frequency of test/exposure period – daily from day 6 through day 15 of pregnancy (GD 6 – 15)
- doses/concentration levels, rationale for dose level selection - The dosages had been established in accordance with the Sponsor and on the basis of the results of the preliminary teratogenesis study (results of the preliminary study not available).

Group 1	1 % Methylcellulose 400 cps aqueous solution as control article
Group 2	100 mg/kg/day of PBS-4
Group 3	300 mg/kg/day of PBS-4
Group 4	1000 mg/kg/day of PBS-4

Administration volume - 10 mL/kg/day, calculated for each animal on the basis of the last body weight recorded.

- test substance formulation/diet preparation, achieved concentration, stability and homogeneity of the preparation:

Results show that formulates at the concentrations of 10 and 200 mg/ml are stable up to 2 hours if stored at room temperature. All formulates were stored accordingly. Formulates proved also homogeneous if kept magnetically stirred. Concentration checks were performed according to the method provided by the Sponsor, twice during the experiment.

Date of sampling	Concentration mg/ml		
	Expected	Observed	%Δ
February, 1995	10	9.868	- 1.32
	30	30.396	+ 1.32
	100	100.000	0
March, 1995	10	9.668	- 3.32
	30	30.204	+ 0.68
	100	98.687	- 1.31

Values were rounded off at the last decimal. Percent differences were calculated before rounding off.

Description of test design:

- details on mating procedure

At the start of the mating period, the cages of males were alternated in close proximity with the cages of females. Every evening (4 evenings/week) the 2 females of each cage were mated with one sexually mature male for 16 hours at a time. Every morning, a vaginal smear was taken with a metal loop from each female and examined at the microscope, to ascertain copulation. The day on which the presence of spermatozoa was found was considered day 0 of pregnancy for that female.

- parameters assessed for P and F1

CLINICAL SIGNS AND BEHAVIOR

The rats were observed daily for physical appearance, behavior and clinical signs. Any deviation from the norm was recorded. During the treatment period, the animals were observed for any possible reaction to the treatment.

MORTALITY

The female rats found dead would have been subjected to autopsy to detect the cause of death. Corpora lutea and implantations would have been counted, whenever possible. The organs with gross alterations would have been fixed in formalin for histologic examination, if necessary.

ABORTION

The female rats presenting signs of abortion (vaginal bleeding) would have been left alive and autopsied at day 20 of gestation. Implantations would have been counted, whenever possible.

BODYWEIGHT

The dams were weighed on days 0, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 18, 20 of gestation.

FOOD CONSUMPTION

The leftover amounts of the weighed food was recorded on days 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 18 and 20 of pregnancy in order to calculate the mean food consumption in g/animal/day.

PARAMETERS INVESTIGATED

On day 20 of gestation, the dams were killed by cervical dislocation after preliminary CO₂ anesthesia. A gross pathology examination was performed with special emphasis to the gastro-intestinal tract, stomach, intestine (duodenum, jejunum, ileum, cecum, colon, rectum) and organs with gross alterations were fixed in formalin for histologic examination. The following parameters were recorded:

- gravid uterus weight
- number of corpora lutea
- number of implantations
- number of resorptions - early: only placenta visible; late : placenta and embryo visible
- number and sex of viable fetuses
- number and sex of dead fetuses (fetuses without spontaneous movements and breathing)
- individual fetus weight
- individual placental weight

A gross external examination was performed on all fetuses immediately.

The externally malformed fetuses were fixed in order not to lose the evidence of malformation.

Half of the fetuses per litter were cleared and examined for skeletal malformations, anomalies and variants.

The remaining half of the fetuses were preserved in Bouin's fluid for examination by the Wilson technique.

As far as possible, the distribution per litter for examination by clearing or by Wilson's technique was equal by sex.

The observations were classified as follows:

- malformations: rare and/or usually lethal (such as hydrocephaly, thoracocele, acephalia, amelia, phocomelia, celosomia etc.)
- anomalies: more frequent and not lethal (such as reduced cranial ossification, hemorrhages etc.)
- variants: common in the control populations and often definable only in terms of continuous variable gradients: i.e. poor ossification of sternbrae, pubis or other.

The uteri of apparently non-pregnant females were stained using the method of Salewski and examined for the presence of early resorption sites.

DATA EVALUATION AND STATISTICAL ANALYSIS

All raw data were recorded on appropriate forms bound in numbered registers, and the numerical data were stored and processed by a computer system. The fertility index was expressed as the percent ratio between the number of females having evident signs of pregnancy with respect to the number of females that had positive vaginal smears. The mean body weight of each group including the maternal weight excluding gravid uterus was calculated from the weight of the gravid females. Calculation was also made of maternal body weight excluding gravid uterus. Absolute body weight gain was calculated at the different scheduled times and on day 6 of gestation (1st day of treatment). The mean food consumption of each group was calculated at different days in order to have the mean daily food consumption. Litter weight, mean fetal weight and placental weight were calculated from individual fetal or placental weights. Fetal losses were subdivided into pre-and post-implantation and were counted per litter.

Group mean values were calculated from individual data in two ways:

- Mean A: calculated on all the surviving females having evident signs of pregnancy including those that presented 100% post-implantation losses.
- Mean B: calculated only on those females with viable fetuses at term.

The external, visceral and skeletal malformations, anomalies and variants found are presented in tables and described for each litter. The malformations found in the dead fetuses were presented only in the Appendices. The expression "normal values" refers to data culled from our laboratory experience. Data recorded from observations were expressed both as individual and as group mean values ($M. \pm S.D.$). Frequencies were expressed both as absolute and as percent values. The following tests were used for the purpose of comparing treated and control groups: To compare frequencies, the heterogeneity test (CHI square $2 \times N$) and Fisher's exact test were applied. The Trend test was also applied. The probability of Trend test was recorded alongside the groups under the word "TREND". All these tests were one-tailed.

Results and discussion

Maternal effects:

- Clinical signs and mortality – no clinical signs or behavioural changes and no mortality were observed at any dose level in the dams.
- Body weight and body weight gain in dams - dose-dependently and stat. sign. ($p < 0.05$) reduced bodyweight and bodyweight gain at 300 and 1000 mg/kg bw/day.
- Significantly lower mean daily food consumption was observed, in comparison with the control group, in the 1000 mg/kg/day group on days 8, 9 and 10 of gestation, in the 300 mg/kg/day group on days 9, 14, 16 and 20 of gestation and in the 100 mg/kg/day group only on day 9 of gestation. A significantly lower mean daily food consumption was observed also during the interval days 0-6 of gestation in the 300 mg/kg/day group. This finding was considered incidental since the treatment starts on day 6 of gestation.
- Autopsy done on females did not show any pathological finding.

TABLE 6. - Observation on gravid females (p. 1)

Dose (mg/kg/day)	Gr# 1 0	Gr# 2 100	Gr# 3 300	Gr# 4 1000	TREND (P)
Gravid at term	21	20	20	19	
With res. visible at Salewski	0/21 0.00%	0/20 0.00%	2/20 10.00%	1/19 5.26%	>0.05
With early resorptions	7/21 33.33%	7/20 35.00%	7/20 35.00%	* 68.42%	.0058
With late resorptions	1/21 4.76%	0/20 0.00%	0/20 0.00%	2/19 10.53%	>0.05
With resorptions	8/21 38.10%	7/20 35.00%	9/20 45.00%	* 73.68%	.0041
With only resorptions	0/21 0.00%	0/20 0.00%	2/20 10.00%	1/19 5.26%	>0.05
With dead fetuses	0/21 0.00%	0/20 0.00%	0/20 0.00%	1/19 5.26%	.0428
With only viable fetuses	13/21 61.90%	13/20 65.00%	11/20 55.00%	* 26.32%	.0041

TABLE 7. - Frequencies per group (p. 1)

Mean "A"	Gr# 1	Gr# 2	Gr# 3	Gr# 4	TREND
Dose (mg/kg/day)	0	100	300	1000	(P)
No. of females	21	20	20	19	
Corpora lutea	369	345	332	352	
Implantations	320/369 86.72%	301/345 87.25%	272/332 81.93%	272/352 77.27%	*** .0001
Res. visible at Salewski	0/320 0.00%	0/301 0.00%	4/272 1.47%	3/272 1.10%	* .0313
Early resorptions	8/320 2.50%	7/301 2.33%	12/272 4.41%	24/272 8.82%	*** .0001
Late resorptions	1/320 .31%	0/301 0.00%	0/272 0.00%	2/272 .74%	>0.05
Total no. of resorptions	9/320 2.81%	7/301 2.33%	16/272 5.88%	29/272 10.66%	* *** .0001
Dead fetuses	0/320 0.00%	0/301 0.00%	0/272 0.00%	1/272 .37%	.0410
Live fetuses	311/320 97.19%	295/301 98.01%	256/272 94.12%	242/272 88.97%	* *** .0001
Live male fetuses	155/311 49.84%	156/295 52.88%	119/256 46.48%	122/242 50.41%	>0.05
Live female fetuses	156	139	137	120	

TABLE 8. - Values per litter (p. 1)					
(Mean, S.D., n)					
Mean "A"	Gr# 1	Gr# 2	Gr# 3	Gr# 4	ANOVA
Dose (mg/kg/day)	0	100	300	1000	
-----	-----	-----	-----	-----	N ***
Gravid uterus wt(g)	86.64 20.890 (21)	84.77 11.462 (20)	68.29 23.904 (20)	55.77 16.363 (19)	
Corpora lutea(no.)	17.57 2.874 (21)	17.25 2.468 (20)	16.60 3.789 (20)	18.53 3.454 (19)	P
Res. visible at Salewski ..(no.)	.00 .000 (21)	.00 .000 (20)	.20 .696 (20)	.16 .688 (19)	N
Early resorptions(no.)	.38 .590 (21)	.35 .489 (20)	.60 .883 (20)	1.26 1.240 (19)	P *
Late resorptions(no.)	.05 .218 (21)	.00 .000 (20)	.00 .000 (20)	.11 .315 (19)	N
Total no. of resorptions ..(no.)	.43 .598 (21)	.35 .489 (20)	.80 1.005 (20)	1.53 1.307 (19)	P **
Live fetuses(no.)	14.81 3.124 (21)	14.75 2.197 (20)	12.80 5.258 (20)	12.74 4.293 (19)	P

ANOVA - "P" = Parametric / "N" = Non Parametric / "-" = Not processed

Foetal effects:

- Body weight: Dose-dependent decreases in the live foetal weight ($p < 0.05$ at 300 and 1000 mg/kg bw/day) and litter weight ($p < 0.05$ at 1000 mg/kg bw/day; lower than the HCD foetal weight) were also seen.
- Malformations: Six externally malformed fetuses with ablepharia, acrania, exencephaly and/or with macroglossia, cleft palate, cleft lip and facial cleft were found in two litters of the 100 mg/kg/day group: four in one litter and two in the other one.
No externally malformed fetus was found at the two highest dosages. The skeletal examination showed the following malformed fetuses:
 - one with scoliosis in litter no. 12 of the control group;
 - 2 with fused ribs at 1000 mg/kg/day: one in litter no. 78 and one in litter 84.

A significantly higher frequency of skeletal anomalies was found at 1000 mg/kg/day. When the statistical analysis was done district by district significance levels were found again at 1000 and also at 300 mg/kg/day for various incomplete ossifications and wavy ribs. At 100 mg/kg/day the supraoccipital incomplete ossification was statistically significant. However this significant value (38.89%) was over the upper limit of the colony data (0%-35.90%).

The number of fetuses with skeletal variants was similar in all the experimental groups. As for the skeletal variants examined district by district significance levels were reached at 1000 mg/kg/day. At 300 mg/kg/day significance levels were reached for the 5th and the 6th sternbrae unossified and for the 4th sternbra incomplete ossification. At 100 mg/kg/day the only statistical significance was related to the 5th sternbra unossified.

However the value (60.42%) was over the upper limit of the range of the historical data (15.91% - 51.16%).

The visceral examination showed the following malformed fetuses at the 1000 mg/kg/day group:

- one in litter no. 76 with monolateral microphthalmia; one with vascular ring in litter no. 78;
- one with bilateral hydronephrosis in litter no. 84;
- two in litter no. 85: one with displaced aortic arch and displaced Botallus duct (Ductus arteriosus) and one with monolateral hypoplasia of the kidney;
- two in litter no. 91: one with monolateral microphthalmia and one with bilateral anophthalmia; one with vascular ring in litter no. 94;
- one with displaced aortic arch and displaced Botallus duct (Ductus arteriosus) in litter no. 96;
- one with monolateral microphthalmia in litter no. 97;
- one with double aortic arch in litter no. 100.

The plurimalformed fetuses found in 2 litters at 100 mg/kg/day were considered incidental, since these kinds of malformations were not present at the highest dosages and since they were present only in 2 litters.

	HCD on 2146 foetuses (1992-1993)	Dose levels (mg/kg bw/day)			
		0	100	300	1000
No. of pregnant females	-	21	20	20 ^{&}	19 [#]
No. of litters	-	21	20	18	18
Maternal body weight (g; group mean and gain)					
GD 6	-	288.7	283.6	277.6	282.2
GD 15	-	333.3	329.5	315.8*	314.3*
GD 20	-	410.9	400.3	369.4*	366.0*
GD 0-20, gain	-	153.8	144.5	119.2*	110.9*
GD 0-20 (gain excluding gravid uterine weight)	-	67.2	59.7	50.9*	55.1
Reproductive parameters					
Gravid uterine weight (g)	-	86.6	84.8	68.3*	55.8*
No. dams with early resorptions	-	7/21	7/20	7/20	13*/19
No. dams with late resorptions	-	1/21	0/20	0/20	2/19
No. of implantations/no. of corpora lutea	-	320/369	301/345	272/332	272*/352
No. of early resorptions	-	8	7	12	24*
Total no. of resorptions	-	9	7	16*	29*
Post-implantation loss (%)	-	2.91	2.39	13.54*	15.20*
Foetal parameters					
No. of live foetuses	-	311	295	256*	242*
No. of dead foetuses	-	0	0	0	1

	HCD on 2146 foetuses (1992-1993)	Dose levels (mg/kg bw/day)				
		0	100	300	1000	
No. of live foetuses/litter	14.4 ± 3.3	14.80	14.75	14.22	13.44	
No. of resorptions/litter	0.7 ± 1.1	0.43	0.35	0.80	1.53*	
Live foetus weight (g)	3.7 ± 0.4	3.69	3.57	3.28*	2.4*	
Live litter weight (g)	53.9	54.97	52.62	46.49	32.52*	
Placenta weight (g)	0.5 ± 0.08	0.5	0.51	0.48	0.37*	
Malformations, abnormalities and variations as reported by the study authors (Study Report, 1995b)						
No. of foetuses examined for skeletal/visceral	-	156/155	144/145	129/127	123/119	
Malformations (%)	External	0 – 0.120	0	2* ^a	0	0
	Skeletal	0	0.64 ^b	0	0	1.62 ^b
	Overall visceral, including:	0.020	0	0	0	9.20* ^c
	Cardio-vascular effects	-	0	0	0	5.88* ^c
	Eye effects	-	0	0	0	3.36 ^c
Abnormalities (%)	External	0.115	0	0	0	0
	Overall skeletal, including:					
	Wavy rib (^d)	-	1.30	0.70	13.20*	7.30*
	Supraoccipital incomplete ossification (^e)	0 – 35.90	26.92	38.89*	45.73*	76.42*
	Overall visceral, including:	0.415	0.64	1.37	1.57	7.56* ^f
	Enlarged lateral ventricles of the brain	-	0	0	0	1.68 ^f
	Absence of renal papillae	-	0.64	0.70	0.78	6.72* ^f
Variations (%)	Overall skeletal, including:					
	Reduced rib XIII unilateral (^g)	-	0	0	1.55	4.07
	Reduced rib XIII bilateral (^g)	-	0.64	0	1.55	4.88
	Ribs XIII punctate unilateral (^h)	-	0.64	2.08	0	14.63*
	Ribs XIII punctate bilateral (^h)	-	1.28	1.39	2.33	6.50
	Ribs XII/XIII (i)	-	0.64	2.1	0.78	11.38*
	Ribs XIII/XIV (^l)	-	1.92	0.69	0	0
	Ribs XIV punctate unilateral (^h)	-	1.92	0.69	0	0
	Unossified 5 th sternbrae	19.910 – 51.160	35	60.42*	70.50*	100*
	Unossified 6 th sternbrae	-	25	34	54.20*	89.43*
	Incomplete	-	7	11.11	15.50*	48.78*

	HCD on 2146 foetuses (1992-1993)	Dose levels (mg/kg bw/day)			
		0	100	300	1000
ossification of 4 th sternbrae					
Overall visceral, including:					
Dilated or convoluted ureter	-	28.40	44.82*	42*	79*
Dilated renal pelvis	-	4.51	17.24*	11*	38.60*

& Two dams with complete resorptions

One dam with complete resorptions

* Statistically significant effect $p < 0.05$; statistical analysis by Chi-squared and Fischer's exact test or ANOVA parametric or nonparametric, where applicable, compared to controls

^a 6 plurimalformed foetuses (of 295 total foetuses): ablepharia (5), acrania (6), exencephaly (6), exophthalmia (3), macroglossia (6), cleft palate (5), cleft lip (2), facial cleft(1)

^b 1 foetus with scoliosis and bifurcated 8th rib (controls); 2 foetuses of 2 different litters with fused ribs (1000 mg/kg bw/day)

^c 11 foetuses: microphthalmia or anophthalmia (4), vascular ring (2), bilateral hydronephrosis (1), displaced or double aortic arch (3), displaced botallus duct (2), hypoplasia of kidney (1); the 7 foetuses with cardio-vascular effects were from 5 different litters; the 4 foetuses with eye effects were from 3 different litters

^d wavy rib: 2 (from 2 different litters), 1, 17 (from 5 different litters) and 9 (from 3 different litters) foetuses at **0, 100, 300 and 1000 mg/kg bw/day, respectively**

^e Supraoccipital incomplete ossification in 251 foetuses: 42 (from 14 litters), 56 (from 20 litters), 59 (from 15 litters) and 94 (from 16 litters) at 0, 100, 300 and 1000 mg/kg bw/day, respectively

^f 9 foetuses: dilated lateral cerebral ventricles (2 foetuses of the same litter), absence of renal papillae (8 foetuses of 4 different litters), hemorrhagic kidney (1)

^g Reduced rib XIII unilateral in 0, 0, 2 and 5 foetuses at 0, 100, 300 and 1000 mg/kg bw/day, respectively

Reduced rib XIII bilateral in 1, 0, 2 and 6 foetuses at 0, 100, 300 and 1000 mg/kg bw/day, respectively

^h Ribs XIII punctate unilateral in 1, 3, 0 and 18 foetuses at 0, 100, 300 and 1000 mg/kg bw/day, respectively

Ribs XIII punctate bilateral in 2, 2, 3 and 8 at 0, 100, 300 and 1000 mg/kg bw/day, respectively

ⁱ Ribs XII/XIII in 1, 3 (from the same litter), 1 and 14 (from 10 different litters) foetuses at 0, 100, 300 and 1000 mg/kg bw/day, respectively

^j Ribs XIII/XIV in 3, 1, 0 and 0 foetuses at 0, 100, 300 and 1000 mg/kg bw/day, respectively

^k Ribs XIV punctate unilateral in 3, 1, 0 and 0 foetuses at 0, 100, 300 and 1000 mg/kg bw/day, respectively

TABLE 9. - Observation on fetuses (p. 1)

Dose (mg/kg/day)	Gr# 1 0	Gr# 2 100	Gr# 3 300	Gr# 4 1000	TREND (P)
-----	-----	-----	-----	-----	
Viable fetuses	311	295	256	242	
Skeletally examined fetuses	156	144	129	123	
Wilson's examined fetuses	155	145	127	119	
With external malformations	0/311 0.00%	* 6/295 2.03%	0/256 0.00%	0/242 0.00%	>0.05
With skeletal malformations	1/156 .64%	0/144 0.00%	0/129 0.00%	2/123 1.63%	>0.05
With visceral malf. (Wilson's)	0/155 0.00%	0/145 0.00%	0/127 0.00%	*** 11/119 9.24%	.0001
With external anomalies	0/311 0.00%	0/295 0.00%	0/256 0.00%	0/242 0.00%	>0.05
With skeletal anomalies	92/156 58.97%	89/144 61.81%	84/129 65.12%	*** 117/123 95.12%	.0001
With visceral anom. (Wilson's)	1/155 .65%	2/145 1.38%	2/127 1.57%	*** 11/119 9.24%	.0001
With skeletal variants	153/156 98.08%	143/144 99.31%	129/129 100.00%	123/123 100.00%	>0.05
With visceral var. (Wilson's)	28/155 18.06%	*** 53/145 36.55%	** 43/127 33.86%	*** 66/119 55.46%	.0001

TABLE 10. - Observation on fetuses (p. 1)
(Mean, S.D., no. of litters)

Dose (mg/kg/day)	Gr# 1	Gr# 2	Gr# 3	Gr# 4	ANOVA
	0	100	300	1000	
With external malf.(no.)	.00 .000 (21)	.30 .979 (20)	.00 .000 (18)	.00 .000 (18)	N
With external anomalies ... (no.)	.00 .000 (21)	.00 .000 (20)	.00 .000 (18)	.00 .000 (18)	-
With skeletal malf.(no.)	.05 .218 (21)	.00 .000 (20)	.00 .000 (18)	.11 .323 (18)	N
With skeletal anomalies ... (no.)	4.38 2.397 (21)	4.45 2.212 (20)	4.67 2.425 (18)	** 6.50 1.917 (18)	N *
With skeletal variants(no.)	7.29 1.554 (21)	7.15 1.496 (20)	7.17 1.425 (18)	6.83 1.505 (18)	N
With visc.malf.(Wilson's) .(no.)	.00 .000 (21)	.00 .000 (20)	.00 .000 (18)	*** .61 .698 (18)	N ***
With visc.anom.(Wilson's) .(no.)	.05 .218 (21)	.10 .308 (20)	.11 .323 (18)	* .61 1.092 (18)	N *
With visc.var. (Wilson's) .(no.)	1.33 1.494 (21)	* 2.65 1.785 (20)	2.39 1.975 (18)	** 3.67 2.544 (18)	N **

TABLE 14. - Skeletal examination (p. 1)
(no. of cases, %)

Malformation	Gr# 1	Gr# 2	Gr# 3	Gr# 4
	0	100	300	1000
Dose (mg/kg/day)				
no. of examined fetuses	156	144	129	123
General observation				
scoliosis	1 .64%	0	0	0
Ribs				
8th, bifurcated	1 .64%	0	0	0
fused	0	0	0	2 1.63%
Vertebrae				
8th thoracic centrum, hemivertebra	1 .64%	0	0	0

TABLE 14. - Skeletal examination (p. 7)
(no. of cases, %)

Variants	Gr# 1	Gr# 2	Gr# 3	Gr# 4
Dose (mg/kg/day)	0	100	300	1000
no. of examined fetuses	156	144	129	123
Head				
unossified hyoid bone	24 15.38%	12 8.33%	14 10.85%	36 29.27%
hyoid body, incomplete ossification	4 2.56%	2 1.39%	8 6.20%	20 16.26%
Ribs				
12/13	1 .64%	3 2.08%	1 .78%	14 11.38%
13/14	3 1.92%	1 .69%	0	0
13th, punctate, unilateral	1 .64%	3 2.08%	0	18 14.63%
13th, punctate, bilateral	2 1.28%	2 1.39%	3 2.33%	8 6.50%
14th, punctate, unilateral	3 1.92%	1 .69%	0	0
13th, reduced, unilateral	0	0	2 1.55%	5 4.07%

TABLE 14. - Skeletal examination (p. 8)
(no. of cases, %)

Variants	Gr# 1	Gr# 2	Gr# 3	Gr# 4
Dose (mg/kg/day)	0	100	300	1000
no. of examined fetuses	156	144	129	123
Ribs				
13th, reduced, bilateral	1 .64%	0	2 1.55%	6 4.88%
Sternum				
5th sternebra, butterfly	1 .64%	0	0	0
1st sternebra, asymmetric	0	0	0	4 3.25%
2nd sternebra, asymmetric	0	1 .69%	3 2.33%	9 7.32%
3rd sternebra, asymmetric	0	3 2.08%	3 2.33%	10 8.13%
4th sternebra, asymmetric	5 3.21%	10 6.94%	7 5.43%	2 1.63%
5th sternebra, asymmetric	2 1.28%	2 1.39%	2 1.55%	0
2nd sternebra, bipartite	0	0	0	3 2.44%

TABLE 14. - Skeletal examination (p. 9)
 (no. of cases, %)

Variants				
Dose (mg/kg/day)	Gr# 1	Gr# 2	Gr# 3	Gr# 4
-----	0	100	300	1000
-----	-----	-----	-----	-----
no. of examined fetuses	156	144	129	123
.....
Sternum				
3rd sternebra, bipartite	1 .64%	0	0	0
4th sternebra, hemisternebra	1 .64%	0	0	0
5th sternebra, hemisternebra	15 9.62%	8 5.56%	9 6.98%	0
6th sternebra, hemisternebra	0	0	1 .78%	0
1st sternebra, unossified	0	0	1 .78%	14 11.38%
2nd sternebra, unossified	2 1.28%	0	1 .78%	15 12.20%
3rd sternebra, unossified	0	0	0	8 6.50%
4th sternebra, unossified	0	0	0	46 37.40%

TABLE 14. - Skeletal examination (p. 10)
(no. of cases, %)

Variants	Gr# 1	Gr# 2	Gr# 3	Gr# 4
Dose (mg/kg/day)	0	100	300	1000
no. of examined fetuses	156	144	129	123
Sternum				
5th sternebra, unossified	54 34.62%	87 60.42%	91 70.54%	123 100.00%
6th sternebra, unossified	40 25.64%	49 34.03%	70 54.26%	111 90.24%
1st sternebra, incomplete ossification	5 3.21%	2 1.39%	5 3.88%	59 47.97%
2nd sternebra, incomplete ossification	12 7.69%	14 9.72%	17 13.18%	61 49.59%
3rd sternebra, incomplete ossification	3 1.92%	1 .69%	4 3.10%	64 52.03%
4th sternebra, incomplete ossification	11 7.05%	16 11.11%	20 15.50%	60 48.78%
5th sternebra, incomplete ossification	79 50.64%	45 31.25%	27 20.93%	0
6th sternebra, incomplete ossification	63 40.38%	50 34.72%	43 33.33%	9 7.32%

TABLE 15. - Visceral examination (p. 1)
(no. of cases, %)

Malformation	Gr# 1	Gr# 2	Gr# 3	Gr# 4
Dose (mg/kg/day)	0	100	300	1000
no. of examined fetuses	155	145	127	119
General observation				
vascular ring	0	0	0	2 1.68%
anophthalmia, bilateral	0	0	0	1 .84%
microphthalmia, right	0	0	0	2 1.68%
microphthalmia, left	0	0	0	1 .84%
aortic arch, displaced, right	0	0	0	2 1.68%
botallus duct, displaced, right	0	0	0	2 1.68%
double aortic arch	0	0	0	1 .84%
Kidney				
hydronephrosis, bilateral	0	0	0	1 .84%

TABLE 15. - Visceral examination (p. 1)
(no. of cases, %)

Malformation	Gr# 1 0	Gr# 2 100	Gr# 3 300	Gr# 4 1000
Dose (mg/kg/day)				

no. of examined fetuses	155	146	127	119
.....				
General observation				
vascular ring	0	0	0	2 1.68%
anophthalmia, bilateral	0	0	0	1 .84%
microphthalmia, right	0	0	0	2 1.68%
microphthalmia, left	0	0	0	1 .84%
aortic arch, displaced, right	0	0	0	2 1.68%
botallus duct, displaced, right	0	0	0	2 1.68%
double aortic arch	0	0	0	1 .84%
Kidney				
hydronephrosis, bilateral	0	0	0	1 .84%
Kidney				
hypoplasia, left	0	0	0	1 .84%

TABLE 15. - Visceral examination (p. 3)
(no. of cases, %)

Anomalies	Gr# 1	Gr# 2	Gr# 3	Gr# 4
Dose (mg/kg/day)	0	100	300	1000
no. of examined fetuses	155	145	127	119
Brain				
lateral cerebral ventricles, dilated	0	0	0	2 1.68%
General observation				
neck, subcutaneous hematoma	0	1 .69%	0	0
Kidney				
absence of renal papilla, right	1 .65%	1 .69%	1 .79%	1 .84%
absence of renal papilla, left	0	0	0	2 1.68%
absence of renal papilla, bilateral	0	0	0	5 4.20%
hemorrhagic, left	0	0	0	1 .84%

TABLE 15. - Visceral examination (p. 4)
(no. of cases, %)

Anomalies	Gr# 1	Gr# 2	Gr# 3	Gr# 4
Dose (mg/kg/day)	0	100	300	1000
no. of examined fetuses	155	145	127	119
Trunk				
subcutaneous, hemorrhage	0	0	1 .79%	0

TABLE 15. - Visceral examination (p. 5)
(no. of cases, %)

Variants

	Gr# 1	Gr# 2	Gr# 3	Gr# 4
Dose (mg/kg/day)	0	100	300	1000
no. of examined fetuses	155	145	127	119

Kidney

renal pelvis dilated, right	2 1.29%	7 4.83%	5 3.94%	13 10.92%
renal pelvis dilated, left	0	6 4.14%	3 2.36%	3 2.52%
renal pelvis dilated, bilateral	5 3.23%	12 8.28%	6 4.72%	30 25.21%

Ureter

convoluted, right	2 1.29%	5 3.45%	2 1.57%	2 1.68%
convoluted, left	8 5.16%	12 8.28%	13 10.24%	2 1.68%
convoluted, bilateral	18 11.61%	34 23.45%	23 18.11%	53 44.54%
dilated, right	2 1.29%	2 1.38%	0	4 3.36%
dilated, left	2 1.29%	2 1.38%	5 3.94%	3 2.52%

Variants

	Gr# 1	Gr# 2	Gr# 3	Gr# 4
Dose (mg/kg/day)	0	100	300	1000
no. of examined fetuses	155	145	127	119

Ureter

dilated, bilateral	12 7.74%	10 6.90%	10 7.87%	30 25.21%
--------------------	-------------	-------------	-------------	--------------

2.10.2 Human data

2.10.2.1 Adverse effects on sexual function and fertility

2.10.2.1.1 [Study 1] Investigation of environmental boron exposure on Y:X sperm ratio

Study reference:

Yalçın, C. Ö., Üstündağ, A., & Duydu, Y. (2019). Is There an Association Between Extreme Levels of Boron Exposure and Decrease in Y: X Sperm Ratio in Men? Results of an Epidemiological Study. Turkish Journal of Pharmaceutical Sciences, 16(1), 96

2.10.2.1.2 [Study 2] Investigation of environmental boron exposure on Y:X sperm ratio and sex ratio of offspring

Study reference:

Duydu, Y., Başaran, N., Yalçın, C. Ö., Üstündağ, A., Aydın, S., Anlar, H. G., Bacanlı, M., Aydos, K., Atabekoglu, C.S., Golka, K., Ickstadt, K., Scwerdtle, T., Werner, M., Meyer, S. and Bolt, H. M. (2019). Boron-exposed male workers in Turkey: no change in sperm Y: X chromosome ratio and in offspring's sex ratio. Archives of toxicology, 93(3), 743-751.

2.10.2.1.3 [Study 3] Investigation of environmental boron exposure on human reproduction

Study reference:

Bolt, H. M., Başaran, N., & Duydu, Y. (2020). Effects of boron compounds on human reproduction. Archives of toxicology, 94(3), 717-724.

2.10.2.2 Adverse effects on the development of the offspring

2.10.2.2.1 [Study 1] Pre- and postnatal environmental boron exposure and infant growth (prospective study, mother-child cohort)

Study reference:

Hjelm, C., Harari, F., & Vahter, M. (2019). Pre-and postnatal environmental boron exposure and infant growth: Results from a mother-child cohort in northern Argentina. Environmental research, 171, 60-68.

2.11 Specific target organ toxicity – single exposure

Not assessed in this CLH-proposal.

2.12 Specific target organ toxicity – repeated exposure

Not assessed in this CLH-proposal.

2.13 Aspiration hazard

Not assessed in this CLH-proposal.

3 ENVIRONMENTAL HAZARDS

Not assessed in this CLH-proposal.